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GENERAL INTRODUCTION 
Pure dysgermlnoma of the ovary is a rare malignant tumor arising 
from the germ cells of the ovary· Only recently it has been apprecia-
ted to differentiate pure dysgermlnoma from mixed germ cell tumors 
containing dysgermlnoma (Asadourian and Taylor, 1969; Gordon et al, 
1981t De Palo et al, 1982). In addition, a widely accepted clinical 
staging system for gynecological malignancies including ovarian malig-
nancies has also recently been introduced (Kottmeier and Kolstad, 
1973, 1976, Federation of Gynecologists and Obstetricians = FIGO) 
offering the opportunity to compare treatment results of aeries of 
patients according to stage. As a result of these developments little 
is known which patients with pure dysgermlnoma of the ovary are at 
risk for an unfavourable outcome. For this reason, there Is little 
agreement on the treatment of notably early stage dysgermlnoma of the 
ovary. As the majority of cases occurs in adolescence and early adult 
live, preservation of fertility is very often desired. 
The main dilemma in this respect is: Should the patient with early 
stage dysgermlnoma of the ovary undergo conservative treatment i.e. 
unilateral salpingo-oophorectomy (USO) as to preserve reproductive 
capacity, but with an increased risk of recurrent disease? Or should 
she be treated by a non-conservative approach i.e. total abdominal 
hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) either with 
or without following adjuvant therapy with probably less risk of 
recurrent disease but without the possibility of future childbearlng? 
It is the objective of this study to identify risk factors both 
clinical and histopathologic, in patienta with pure dysgermlnoma of 
the ovary, to obtain more insight Into the way of proper treatment of 
these patients. For this purpose patiente with the diagnosis of pure 
dysgermlnoma of the ovary occurring in the Netherlands during the 
period 1970 to 1981 were reviewed. 
This period of time was chosen mainly because of a number of merely 
practical reasons. As has been mentioned previously, during the seven-
ties the clinical staging system of the FIGO was widely accepted. This 
made it possible to compare treatment results of patients with ovarian 
cancer and In this respect dysgermlnoma of the ovary treated in diffe-
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rent centres. Patients before 1970 were disregarded because in quite a 
number of those patients either clinical or pathology data were inade­
quate which would Invalidate a comparison between these data and the 
survival of these patients. To get a reasonable follow-up period 
patients diagnosed after 1980 had to be excluded, as the period of 
follow up was closed in 19Θ3. 
When elaborating on risk factors in patients with pure dysgerminoma 
of the ovary it seems appropriate to direct special attention to the 
histopathology of this tumor. This includes a semiquantitative survey 
of the histology of pure dysgerminoma of the ovary, and in view of the 
recent increasing appreciation of computerized histology in other 
malignancies (Baak and Oort, 1983), correlating guantitative morpho-
metric studies with the clinical course. 
The results of this study might render a better understanding of 
risk factors in patients with pure dysgerminoma of the ovary. 
Pail I REVIEW OF THE LITERATURE OF PURE DYSGERMINOMA OF THE OVARY. 

Chapter 1 . 
EffiRYDNIC DEVELOPHENT OF GERH C a i S AND OVARY. 
1.1. Introduction. 
For an understanding of the morphogenesis, the morphological fea­
tures and the pathofysiology of dysgerminoma of the ovary, a study of 
the embryonic development of germ cells and the ovaries is necessary. 
1.2. Embryonic development of germ cell and ovary. 
The ovaries are composed of tissue derived from the proliferating 
coelomic epithelium of the dorsal genital ridge, the mesenchyme and 
the primordial germ cells. 
In the 4th week of development the primordial germ cells can be 
recognized between the endodermal cells of the dorsal wall of the yolk 
sac close to the allantoic diverticulum (Witschl, 1948) (fig. 1.1). 
HEART 
— HINDGUT 
— ALLANTOIS 
PRIMORDIAL 
GERM CELLS 
YOLK SAC 
Figure 1.1. Location of primordial germ cells In the young embryo 
(After Witschl, 194Θ). 
The sex of the embryo is determined at the time of fertilization. 
However, only around the seventh week of development the gonads demon­
strate their male or female morphological features. Until that time 
the development of the genital tract and the primitive gonads is simi­
lar for both sexes (Teilum, 1952; Hamilton, 1972). 
From the yolk sac area the germ cells migrate through the dorsal 
mesentery towards the genital ridges. These come to existence in the 
4th week of embryonic development along the middle of the dorsal wall 
of the coelomlc cavity (Fig. 1.2). 
PRIMORDIAL 
GCRM CtLLS 
COELOMIC 
CAVITY 
MESONEPHROS 
GENITAL 
RIDQE 
Figure 1.2. Migration of primordial germ cells into the genital ridge. 
The migration of the germ cells occurs probably by an active amoe-
boid movement (Witsch!, 1948). It is also possible that this movement 
occurs along lymph vessels (Witschi, 1948; Pinkerton, 1961). The pri-
mordial germ cells reach the genital ridges during the 6th week of 
development. 
The migration of primordial germ cells could be the explanation for 
the fact that along the route of the primordial germ cells extra gona-
dal germ cell tumors can be found. Thus, benign and malignant germ 
cell tumors can be found in the mediastinum, retroperitoneally and in 
the sacral region (Gillman, 1948; Friedman, 1951). 
Through mitotic cleavages the germ cells increase in number in the 
genital ridges. Here the germ cells come into relation with the two 
other components of the gonad: the coelomlc epithelium and the mesen-
chym which are both of mesodermal origin. 
In the mean time in the indifferent gonad a strong proliferation of 
MESENTERIUM-
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the coelomic epithelium has taken place. Cells of the coelomic epithe-
lium invade the underlying mesenchyme forming primitive "sexcords", 
which in the female embryo, are divided around the 12th embryonic week 
into irregular cell groups containing clusters of primordial germ 
cells. After degeneration, these clusters at a later stage (5th 
embryonic month) will be replaced by stroma. The stroma contains nune-
rous blood vessels and developes eventually into the medullary part of 
the ovary which is devoid of oogenia. 
The cortex of the ovary is formed in the 7th week by active proli-
ferating surface epithelium, superficially infiltrating the underlying 
mesenchyme. In this manner a second generation of "sexcords" i.e. the 
cortical sexcords is formed· These remain situated close to the 
surface epithelium to differentiate into pregranulosa cells eventually 
surrounding primordial germ cells. 
During this time the germ cells have developed into oogonia. Some 
of the latter cella develop Into primordial oocytes. 
In the following months the number of oogonia increases to reach 
its' zenith around the 7th month. Hereafter a degeneration of most 
ooqonla and primordial oocytes takes place, and some surviving super-
ficially located oocytes enter the first stages of meiotlc cleavage· 
During this last cleavage the pregranulosa cells come to surround 
Individual oocytes to form primordial follicles. 
At birth the oocytes are in the dlctyotene stage of melosis. In 
this way the first stage (prophase) of meiotlc cleavage has been 
finished. 
1.3. Conclusion. 
Possible causative factors, which may play a role in the develop-
ment of germ cell tumors are not known. Data from literature are limi-
ted to theoretical considerations. It has been put forward, that the 
absence of a surrounding layer of pre-granulosa cells could be causa-
tive to the development of either benign or malignant germ cell 
tumors, considering the occurrence of germ cell tumors along the 
embryonic route of migration of primordial germ cells (Emmen, 1981). 
In chapter 3 it will be demonstrated, that primordial germ cells 
and pure dysgerminoma of the ovary show morphological and histochemi-
cal resemblances illustrating their cloae relationship. 
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Chapter 2. CLASSIFICATION OF GERH CELL TUMORS ΟΓ THE OVARY. 
2.1. Introduction. 
A panel of pathologists under auspices of the World Health Organi­
sation (WHO) in 1972 proposed a classification for ovarian tumors, 
based on the recognition of identifiable histology and patterns of 
growth: 
A. Epithelial tumors. 
B. Sexoovd strornal tumore. 
C. Germ oeil tumors. 
D. Lipoid cell timore. 
E. Secondary (metastatio) tumore. 
F. Unolaseified tumors. 
According to this classification pure dysgerminoma of the ovary 
belongs to the group of germ cell tumors, which show a number of 
striking resemblances (Talerman, 1977): 
1. The tumore have a common histogenesis. 
2. Relatively frequent hietologiaally different tumor elements, but 
all of germ cell origin, are present within the same tumor. 
3. In extra gonadal locations histologically similar tumors are pre­
sent. These locations are along the line of migration of the pri­
mordial germ cells from the mil of the yolk sac to the genital 
ridges. 
4. There is a remarkable homology between the various tumor types in 
the male and the female. 
Teilum (1965) studied the histogenesis and the relationship between 
the various types of germ cell tumors (Fig. 2.1). 
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Figure 2.1. Histogenesis and interrelationship of germ cell tumors 
(Teilum, 1977). 
2.2. Classification of germ cell tumors of the ovary. 
A classification of germ cell tumors including tumors derived from 
sex cord stroma has been recently by the WHO (1973): 
T. Germ cell tumors. 
1. Dysgerminoma. 
2. Endodermal sinustumor. 
3. Embryonal carcinoma. 
4. Polyembryoma. 
5. Choriocarcinoma. 
6. Teratomas. 
A. Immature 
B. Mature 
- Solid. 
- Cystic with or without malignant transformation. 
C. Monodermal or highly specialized tumors. 
- Struma ovarii. 
- Carcinoid. 
- Struma ovarii and carcinoid. 
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7. Mixed germ cell tumors (tumors composed of types one through six in 
any possible combination). 
II. Tumors composed of germ cells and sex cord stroma derivatives. 
1. Gonadoblastoma. 
2. Unclassified germ cell-sex cord stroma tumor. 
2.3. Morphology of germ cell tumors of the ovary. 
It must be kept in mind, that although germ cell tumors may occur 
in a pure form, it could also be possible that each of them may be ad-
mixed with other neoplastic germ cell elements. Especially dysgermi-
noma is notorious to be one of the elements of a mixed germ cell 
tumor. These tumors of which dysgerminoma may be one of the elements 
are generally considered to have a less favourable outcome compared to 
pure dysgerminoma of the ovary. Therefore it seems appropiate to ren-
der a summary of the most distinctive morphologic features of the germ 
cell tumors and their respective epidemiologic notations. 
I. Germ cell tumors. 
1. Dysgerminoma 
The morphology of this tumor will be extensively reviewed in 
chapter 3. 
2. Endodermal sinustumor 
Together with dysgerminoma this tumor can be considered one of the 
more common malignant germ cell tumors (Kurman and Morris, 1977). The 
tumor mainly occurs in the 2nd and 3rd decades of live. On histologi-
cal examination of the tumor five different subtypes can be recog-
nized, which may be found in the same tumor (Teilum, 1971)! 
- Microcystic and myxomatous type. The tumor is composed of a loose 
network with small cystic spaces or microcysts containing hyaline, 
periodic acid-Schiff (PAS) positive globules. 
- Endodermal sinus type. This type shows capillary bloodvessels sur-
rounded by connective tissue, which is lined by a layer of flattened 
hobnail-shaped cells. These structures are known as Schiller-Duval 
bodies. 
12 
- Solid cellulary type. This type is composed of cellnests with poly-
gonal cells. The mitotic activity may be brisk. 
- Alveolar or cystic type. This type is composed of cells lying in al-
veolar aggregates and large cystic spaces and cavities lined by flat 
cells or cells resembling cuboidal epithelial cells. 
- Polyvesicular type. This type is composed of numerous cysts lined by 
columnar or cuboidal epithelial cells. The cysts are surrounded by 
connective tissue stroma. 
Using immunoperoxidase techniques alpha-fetoprotein (AFP) has been 
identified in endodermal sinus tumor cells demonstrating the associa-
tion with AFP synthesis resulting in elevated AFP serum levels in 
these patients. 
J. Embryonal carcinoma. 
Microscopically this tumor is characterized by large undifferen-
tiated pleomorfic cells in solid aggregates but could also show a 
glandular aspect. Mitotic activity is usually brisk. 
Syncytiotrophoblast giant cells (SGC) are scattered throughout and 
can be demonstrated by anti-B-subunit of human choriogonadotropin 
(B-hCG) immunoperoxidase. Hyaline bodies resembling those in endoder-
mal sinus tumor may be present which can be shown by anti-AFP Immuno-
peroxidase. Both B-hCG and AFP serum levels are elevated in patients 
with embryonal carcinoma (Kurman and Norris, 1978; Kurman et al., 
1979). 
Embryonal carcinoma is a rather uncommon tumor and like most of the 
other malignant germ cell tumor mainly occurs in the first three 
decades of live. 
4. Polyembryoma. 
Microscopically the tumor features a large component of structures 
called "embryoid bodies", because of their resemblence with early nor-
mal embryos. 
Some authors considered this tumor and notably the embryoid bodies 
to be a differentiation of embryonal carcinoma (Pierce and Dixon, 
1959; Stevens, 1960). 
The tumor is exceedingly rare, occurring in the 2nd and 3rd decade 
and most commonly found in combination with another germ cell tumors 
notably mature and immature teratoma (Beck et al., 1969). 
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5. Choriocarcinoma. 
Microscopically the tumor shows two distinctive cells types: cyto-
trophoblast cells which are large cells with clear cytoplasm and a 
centrally located nuclei conversely to the syncytiotrophoblast giant 
cells (SGC), which contain multiple nuclei. B-hCG can be demonstrated 
in SGC using anti-B-hCG immunoperoxidase. 
Differentiation between the two cell types may be very difficult 
when these are poorly differentiated and in case of extensive hemor-
rhages and necroses. In patients with choriocarcinoma serum levels of 
hCG are always Increased. 
Choriocarcinoma is a very rare tumor and seldomly occurs in a pure 
form. The tumor is admixed most commonly with teratomatous elements 
and dysgerminoma (Fox and Langley, 1976). 
A germ cell origin can only be established with certainty if the 
tumor occurs prepubertally as in patients in the reproductive age 
choriocarcinoma may have a much more common gestational origin 
(Scully, 1979). A differentiation between gestational choriocarcinoma 
and choriocarcinoma of germ cell origin is important as the prognosis 
of the later type is much more worse as compared to the gestational 
type. 
6. Teratoma. 
These tumors are composed of tissues derived from the three germ 
layers in variable amounts. 
The tumor can be classified as follows: 
A. Immature teratoma. 
On gross examination, the tumor is usually solid but may also 
contain cystic structures (Kurman and Morris, 1978). 
Microscopically, the tumor predominantly shows neural tissue of-
ectodermal origin such as neuroepithelium, glial cells and areas 
resembling neuroblastoma. Mesodermal and endodermal dérivâtes are 
present in various amounts. 
Immature and embryonal epithelium are commonly encountered. The 
degree of immaturity reflects the ability to metastasize. A histo-
logical grading based on the presence of malignant embryonal tissue 
and the degree of mitotic activity has been suggested for prognos-
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tic purposes (Thürlbeck and Scully, 1960). 
Metastases of this tumor sometimes shows arrangements seen in 
benign mature teratoma. 
Immature teratoma is the 3rd ranking malignant germ cell tumor, 
after dysgerminoma and endodermal эіпиэ tumor (Abell et al., 1965; 
Norris, 1972; Li, 1973). Age wise, the peak incidence is in the 
second decade (Scully, 1978). 
B. Mature teratoma. 
- Solid teratoma. 
This is a solid benign timor, which features rudimentary organ 
formations arising from the three germ layers. Neurogenic elments 
may predominate. Mitotic activity is very low. 
- Cystic teratoma. 
Mature cystic teratoma (synonym: dermoid cyst) is composed of 
well differentiated derivatives of the three germ layers. 
The cyst is lined by keratinized epidermis with sebacious and 
sweat glands, and hair follicles. The most common (+ 60S) struc­
tures are fat and smooth muscle (Blackwell et al., 1946). 
Mature cystic teratomas are usually benign. Malignant dediffe-
rentiation is uncommonly (2-4%) found arising mainly from the squa­
mous component of the tumor leading to the formation of squamous 
cell carcinoma (Malkasian et al., 1967; Pantoja et al., 1972). 
Mature cystic teratoma is the most common germ cell tumor and 
ovarian teratoma (Abell et al., 1965; Ein et al., 1970; Norris, 
1972; Li et al, 1973). The age distribution reveals a much larger 
interval as compared to the other germ cell tumors illustrated by a 
substantiate proportion of occurrence in post-menopausal patients 
(Fox and Langley, 1976). 
С Monodermal tumors. 
These tumors are rare and are generally considered as one-sided 
highly specialized derivatives of teratomas, since most of them are 
associated with teratomatous elements. 
- Struma ovarii. 
This tumor shows mature thyroid tissue with numerous acini of 
various sizes lined by columnar, flattened or cuboidal epitheliun. 
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The acini contain colloid which is eosinophilic and PAS positive. 
To classify a teratoma as a struma ovarii the major proportion 
of the tumor should consist of mature thyroid tissue. 
Contrary to most of the germ cell tumors, this tumor occurs in 
higher age with a peak freguency in the 5th decade (Robboy and 
Scully, 1972). 
- Carcinoid. 
This tumor is composed of numerous small acini and solid nests 
of polygonal cells. In the periphery of these nests enterochromatin 
cells which may be both argyrophilic and argentaphylic of which the 
later can produce 5-hydroxytryptamin (Fox and Langley, 1976). 
This tumor usually arise from gastro-intestinal epithelium 
present in mature cystic teratoma. 
- Struma ovarii and carcinoid. 
This rare tumor shows a morphological resemblance to the medul­
lary carcinoma of the thyroid. The para-follicular cells are simi­
lar to enterochromatin cells. The tumor has been shown to contain 
both iodine and 5-hydroxytryptamin. 
7. Mixed germ cell tumors. 
By definition these are composed of two or more neoplastic germ 
cell elements. 
The most frequent elements found are dysgerminoma and endoderma1 
sinustumor (Kurman and Morris, 197Θ). The prognosis in patients with 
mixed germ cell tumors is by and large dependent on the size of the 
tumor and the histological composition i.e. the most malignant germ 
cell element (Kurman and Norria, 1978). 
II. Mixed germ cell-atroma cell tumors. 
1. Gonadoblastoma. 
Scully (1953) was the first to recognize the existence of this 
tumor. Gonadoblastoma usually occurs in patients with pure or mixed 
gonadal dysgenesis. The karyotype of these patients Is very often 
46,XY (Teter and Bocskowski, 1972; Scully, 1979). In some isolated 
cases gonadoblastoma have been reported to develop in an otherwise 
normal ovary (Scully, 1972). 
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Microscopically, the tumor is composed of groups of cellular nests 
which contain a mixture of germ cells and sexcord stroma cells, resem-
bling Immature Sertoli and granulosa cells. Most often the cell nests 
contain hyaline bodies, which are frequently calcified. Furthermore 
the cell nests contain lymphocytes and occasionally qranulomas. 
Between the nests In a majority of the cases cells resembling 
Leydig and lutein cells can be found. 
Gonadoblastoma have been commonly found to produce androgens and 
estrogens leading to a variety of manifestations such as primary ame-
norrhoea, virilization and precocious puberty. 
Gonadoblastoma is a benign tumor, but can be considered as a prema-
lignant laesion. Up to 50S of the tumors is overgrown by a germ cell 
tumor, most frequently dysgerminoma (Scully, 1970). In such a dysger-
mlnoma remnants of gonadoblastoma may be found as calcified bodies. 
2. Unclassified mixed germ cell-stroma cell tumors. 
This category contains all tumors composed of germ cell and sex 
cord elements excluding gonadoblastoma in view of its distinctive his-
tologic appearance. 
Microscopically, the tumor is composed of two patterns each contai-
ning the aforementioned elements. One pattern is characterized by 
trabecular structures. The other one features small solid tubules 
devoid of a lumen and surrounded by loose connective tissue (Talerman, 
1977). The germ cells may resemble those in dysgerminoma, whereas the 
sex cord elements resemble those in gonadoblastoma but in some cases 
they may be less mature (Scully, 1979). 
The few reported tumors of this kind had occured in patients, who 
generally were below the age of ten and did not show chromosomal ab-
normalities or gonadal dysgenesis (Talerman, 1977; Scully, 1979). 
2.4. Conclusion. 
It has been widely accepted, that germ cell tumors originate from 
primitive germ cells (Teilum, 1944, 1968; Friedman and Moore, 1946; 
Dixon and Moore, 1952; Friedman, 1952; Witsch!, 1948). 
In view of the histogenesis of germ cell tumors, namely its deriva-
tion from the primitive germ cell, these tumors could be regarded as 
the "earliest" tumors in man. 
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The totipotency of germ cells Is illustrated by the wide variety of 
its derivative tumors. 
As mixed germ cell tumors should contain at least two different 
germ cell elements, the term "mixed dysgerminoma" is a faultive one 
and does injustice to the presence of other germ cell elements than 
dysgerminoma. The term dysgerminoma of the ovary should only be 
reserved for pure dysgerminoma of the ovary. 
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Chapter 3. MORPHOLOCY OF PURE DYSCERHINOHA OF THE OVARY AND 
HISTOLOGICAL RISK FACTORS. 
3.1. Introduction. 
Chevassu (1906) was the first to describe seminoma of the testis. 
Chenot (1911) percieved the histological resemblance between seminoma 
of the testis and a tumor occurring in the ovary. Because of the ana-
logy with seminoma of the testis the ovarian counterpart was named by 
Masson (1912) "seminoma of the ovary" as quoted by Talerman (1977). 
This term is still in use in French literature. 
The term dysgerminoma has been delineated From the term disqermi-
noma (dis = two; germinoma = germ cell), which was First introduced by 
Robert Meyer (1931). This term is more or less self explanatory for 
the embryogenesis of the tumor. In Meyer's view this tumor arises from 
so called "neuter" or disgerminal cells, to indicate their inability 
For sexual differentiation and therefore their indifferent state. 
Notably in Anglosaxon literature nowadays the term dysgerminoma is 
widely used. However, previously several synonyms have been used, 
which are partly a reflection of embryoqenesis, partly of morphology. 
Widely used synonyms are: germinóme, carcinoma puellarum, embryonal 
carcinoma, large cell carcinoma, small CPII carcinoma, seminoma, gono-
cytoma, gonocytoma I and round cell carcinoma (Scully, 1979). 
In this thesis the term dysgerminoma is used to indicate pure 
dysgerminoma of the ovary. 
3.2. Macroscopical appearances. 
Dysgerminoma occurs commonly unilateral (Table ή.6). Some authors 
found a predominately occurrence of dysgprminoma in the right ovary 
(Seeqar, 1935; Sailer, 1953). According to Sailer (1953) this predi­
lection for the light ovary reflects a slow differentiation and matu­
ration of this gonad as compared to the left gonad so that more undif­
ferentiated germ cells could he present in the right gonad enhancing 
the possibility of tumor development. 
Figures for bilateral involvement range between З.ВЖ and slightly 
more than 2ПЖ (De Palo et al., 1982; Boyes et al., 1977). 
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Linton (1981) noted in a series of 136 patients only 4 patients 
(330 with a tumor less than 3 cm across. In 64 (47%) patients the size 
of the tumor varied between 5 and 15 cm. No less than 68 patients 
(50Ж) had a tumor size more than 15 cm. Large tumors with a diameter 
up to 50 centimeters have been reported (Asadourian and Taylor, 1969). 
The tumor generally has a smooth grey-white firm fibrous capsule 
and a gyriform surface, which gives the tumor a cerebriform aspect. In 
most oases the capsule is intact. In case of large tumors the capsule 
may be ruptured (Talerman, 1977). 
On cut surface dysgerminomas form solid tumors, which may be firm 
and rubbery and are often lobulated, whilst the colour has been 
described as white, yellow, pink. The latter may be caused by hemor­
rhages and necrosis, which are commonly found (Fig. 3.1). 
Figure 3.1. Pure dysgerminoma of the ovary. (N=Necrosis). 
(Courtesy of G.A.Hoogendoorn and F.J. van Bodegom) 
21 
Hemorrhages and necrosis generally are the initial cause for the 
formation of small cavities. However, cavities and even more cystic 
areas in pure dysgerminoma should alert the observer to the possible 
presence of other germ cell elements (Talerman, 1977) such as immature 
teratoma and endodermal sinus tumor. 
3.3. Microscopic appearances. 
Novak (1938) observed that; "There are few tumors of the ovary, 
which present such distinctive histologic characteristics as does dys-
germinoma". 
The microscopic appearance of pure dysgerminoma is remarkable 
indeed. The cells are arranged in clusters, strands or can display a 
medullary pattern and are separated by fibrous connective tissue 
stroma (Fig. 3.2). 
Figure 3.2. Pure dysgerminoma of the ovary.(T=Tumor; S=Stroma) 
(Magnification 10X, Hematoxylin-Eosin stained) 
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Areas with a large number of tumor cells are found, while in the 
same tumor other areas are found with a small number of tumor cells. 
Dysgerminoma cells are round, oval or polygonal in shape. The dia-
meter of the cells can vary between 12 and 25 microns, but within the 
same tumor varies only a little. 
The cell borders are generally sharply defined. The cytoplasm of 
the cells Is often clear but can also be pale granular eosinophilic. 
The nucleus of the tumor cell is located centrally and may occupy 
nearly half of the cell (Fig. 3.3). 
Much the same as the tumor cell the vesicular nucleus has a round 
or oval shape. The nucleus is surrounded by a distinctive membrane. 
The nucleus contains an ample amount of unevenly dispersed finely 
reticular chromatin (Fig. 3.3). 
Figure 3.3. Pure dysgerminoma of the ovary (NzNuclei; C=Chromatin; 
NLL=Nucleolei). 
(Magnification 63X, Hematoxylin-Eosin stained) 
The nucleus contains 1 and sometimes 2 distinctive eosinophilic 
nucleolei (Fig 3.3). 
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The amount of DNA in the nuclei is twice the amount of DNA present 
compared to nuclei of lympohocytes and therefore equal to that of the 
primary oocytes arrested in prophase (Asadourian and Taylor, 1969). 
The dysqerminoma cells contain cytoplastic glycoqen, which can be 
demonstrated with the Periodic Acid Schiff (PAS) reaction. Lipid 
stains can demonstrate the presence of lipid in the cytoplasm of the 
tumor cells. The cells of dysqerminoma show a positive alkaline phos-
phatase reaction. 
Mitotic fiqures are usually present and may vary from sparse to 
numerous in different areas of the tumor. 
The connective tissue stroma surroundinq the tumor cells shows a 
tremendous variety within the same tumor varyinq from a delicate 
fibro-vesicular network to larqe fibrous strands, which are often 
hyalinized. 
The stroma often shows inflammatory signs, and lymphocytic infil-
tration. The number of lymphocytes may vary from small to larqe col-
lections. Plasma cells and eosinophilic granulocytes are also commonly 
present in the septa. Granulomata are frequently seen in the septa and 
usually consists of epitheloid histocytes, lymphocytes, plasma cells 
and multi-nucleated giant cells, both of the Lanqhans and foreiqn body 
type (Fig 3.4.). 
Figure 3.4. Pure dysqerminoma of the ovary (GzGranuloma; L=Lymphocy-
tes; MzMultinucleated qiant cell of the Lanqhans type; 
T=Tumor cells). 
(Maqnification 25X, Hematoxylin-Eosin stained) 
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Hemorrhages and necrosis ere frequently found in large tumors and 
in case of torsion of the tumor. Sometimes microcalcifications occur 
in these sites. 
Occasionally round calcified bodies are found in pure dysgerminoma 
which may indicate the one time presence of gonadoblastoma overgrown 
by dysgerminoma (Scully, 1970). 
Calcification of large parts of the tumor itself is very rare and 
has been described only twice (Asadourian and Taylor, 1969; Nelken et 
a b , 1978) 
In a small number of cases cells may be found resembling syncytio-
trophoblast giant cells (SGC). These cells are either present in clus-
ters or are distributed diffusely. Dysgerminoma containing syncytio-
trophoblast giant cells represented 3S of the number of dysgerminomas 
of the Armed Forces Institute of Pathology files (Zaloudek et al., 
1981). 
Using peroxidase labelled antibodies Ueda et al. (1972) could show 
these cells to contain hCG. Kaplan and Hawley (1981) demonstrated with 
the aid of immunoperoxidase that syncytiotrophoblast cells contain the 
beta subunit of hCG. In "normal" pure dysgerminoma cells no indica-
tions were found for the presence of B-hCG. 
SGC in pure dysgerminoma, are thought to be responsible for an 
increase of hCG serum levels (Kurman and Norria, 1978; Castlemán, 
1972; Ueda et al., 1972). In these cases, however extensive histologic 
examination is mandatory in order to exclude other neoplastic germ 
cell elements such as choriocarcinoma and embryonal carcinoma which 
can also produce hCG (Perlinet al., 1976; Kurman and N o m s , 1979). 
3.4. Electronmicroscopical findings. 
Electronmlcroscopy of cells of pure dysgerminoma shows a rather 
compact cytoplasm. The cells are connected by desmosomes and can be 
found in high numbers adjacent to each other. 
The cells have round, oval or polygonal nuclei with one or two 
nucleoli containing vilamentous nucleonemata. 
Mitochondria are numerous, mostly rounded and contain tubular and 
vesicular cristae. Endoplasmatic reticulum is sparse, of the rough 
type and is often found to have a striking linear arrangement. In the 
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cytoplasm partieels often are to be found which were thought to be 
glycogen deposits (Kay et al., 1971). 
It has been demonstrated that some dysgerminomas are associated 
with hormone production. Indications to this feature were found by the 
presence of granula of the secretory-type. It Is not gulte clear what 
the origin is of these granula. It seems, as if these granula are more 
often present in stroma cells rather than in the germ cells illustra­
ted by the feet that stroma cells more often contain a distinctive 
Golgi-apparatus and an endoplasmatic reticulum of the rough type 
(Lynn, 1967; Kay et al., 1971; Garrido et al., 1976). 
Lipid vacuoles have also been demonstrated In dysgermlnoma of the 
ovary by electronmicroscopical studies (Lynn, 1967; Kay et al., 1971). 
from Lynn's publication it appeared that lipid secretion is mainly 
taking place in the stroma cells. However, Kay et al. demonstrated 
that lipid vecuols could also be found in germ cells. The meaning of 
the lipid secretion is not clear. 
3.5. Hlatologlcal risk factors 
As has been mentioned earlier the prognosis of patients with a 
mixed germ cell tumor, of which dysgermlnoma may be one of the ele­
ments, is generally considered less than that of patients with pure 
dysgermlnoma, and dependent on the presence of other more malignant 
germ cell elements (Talerman, 1977; Kurman and Norria, 1979; Gordon et 
al., 1981). Therefore this review of histologic risk factors is limi­
ted to cases with the pure form of dysgermlnoma. 
Data from literature indicates that histological factors affecting 
prognosis of patients with pure dysgermlnoma of the ovary were mainly 
semi-quantitatively determined. 
Fauvet (1936) suggested, that the amount of tumor in relation to 
the amount of stroma present affects prognosis. Others concurred in 
this respect. This correlation however, was not in all cases present. 
Also their series of patients (22) was rather small (Talerman et al. 
(1973) 
Seegar (1937) concluded from her survey that the number of mitosis 
did not influence the prognosis. Others held a different view in this 
respect. The number of mitosis per 5 high power fields (HPF) in Θ0 pa-
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tients was counted. In 30 patients with more than 8 mitoses the morta­
lity rate was 235, whereas in 50 patients with less than 8 mitoses 
this percentage was only 10$ (Asadourian and Taylor, 1969). 
The presence of syncytlotrophoblastic giant cells does not affect 
the prognosis. Zaloudek et al.(1981) reported on 6 patients with pure 
dysgerminoma containing such cells. All patients had clinical stage la 
and were well 1-14 years after treatment. 
Cell atypia appears to have an adverse effect on prognosis, illu­
strated by a mortality rate in 153! of patients with a distinctive cell 
atypia wheras in patients with minimal atypia the death rate amounted 
to only 9Й (Asadourian and Taylor, 1969). 
The degree of lymphocytic infiltration into the stroma Is related 
to prognosis as a marked Infiltration is associated with a favourable 
outcome conversely to a minimal infiltration (Asadourian and Taylor, 
1969; Talerman, 1973; Gillespie et al., 1978; Steffen and Genton, 
1980). Most of these studies had a semi-quantitative nature (Asadou­
rian and Taylor, 1969; Talerman et al., 1973; Gillespie et al., 1978). 
Steffen and Genton (1980) performed a quantitative study of the lym­
phocytic Infiltration into stroma. They studied a series of 17 
patients. In 16 patients a pure dysgerminoma was found. In 1 patient a 
mixed germ cell tumor (dysgerminoma-maliqnant teratoma) was found. All 
12 patients with pure dysgerminoma with more than 10 lymphocytes per 
high power field (HPF 500 x) were still alive. Conversely, 75Ä of the 
patients (3/4) with less than 10 lymphocytes per high power field 
died. 
3.6. Conclusion. 
Pure dysgerminoma of the ovary is a malignant germ cell tumor which 
can reach a considerable size in spite of an usually short duration of 
symptoms. According to some authors this phenomenon is indicative to 
the fact that dysgerminoma is a fast growing tumor (Santesson, 1947; 
Talerman et al., 1973). However, Hain (1949) reported on a patient 
with 2 years symptoms of precocious puberty in association with dys-
germinoma of the ovary. 
Microscopically, dysgerminoma is a distinctive tumor characterized 
by round, oval or polygonal cells which are grouped together in cell 
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nests. These cell nests are surrounded by stroma, showing lymphocytic 
infiltration. 
The relationship of dysgsrminoma cell with primordial germ cells Is 
emphasized by a couple of similarities. Both primordial germ cells and 
dysgerminoma cells contain twice the amount of DNA present in diploid 
cells (Asadourian and Taylor, 1969). Furthermore, the alkaline phos-
phatase reaction both in primordial germ cells and dysgerminoma cells 
is positive (McKay et el., 1953) 
The presence of syncytiotrophoblastic giant cells only in pure dys-
germinoma does not necessarily mean the admixture with a choriocarci-
noma. In the latter case a biphasic population of syncytio- and cyto-
trophoblast cells should be present (Kurman and Morris, 197B). The 
presence of syncytiotrophoblast giant cells does not affect the prog-
nosis (Zaloudek et el. (1981). 
There is general agreement to the fact that the presence of other 
neoplastic germ cell elements has an adverse effect on prognosis, as 
pure dysgerminoma compared with most other malignant germ cell tumors 
has a favourable prognosis (Talerman, 1977; Kurman and Morris, 1979; 
Gordon et al., 1981). 
There is less agreement to the effect of stroma-tumor rate, mitotic 
activity, cell-atypia and architecture of the tumor on prognosis. 
Although most authors consider a large lymphocytic infiltration into 
the stroma to be associated with a favourable prognosis, others 
question, in view of the histologic variation within the same tumor, 
that the behaviour of an individual tumor can be assessed from its 
histologic appearance (Santesson, 1947; Talerman, 1977). 
Each histologic risk factor may not indicate by Itself an unfavou-
rable outcome, but could all be present within the same tumor, This 
has led to the designation anaplastic dyagerminoma, which is associa-
ted with an aggressive clinical course (Gillespie and Arnold, 1978). 
It should be noted that in view of the fact that most studies had a 
retrospective nature concerning small series of patients conclusive 
statistical evidence concerning histological risk factors is not avai-
lable. In this respect an thorough quantitative morphometrical analy-
sis of the histology of patients with pure dysgerminoma of the ovary 
might shed some light upon its significance to the prognosis of these 
patients. 
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Chapter 4. CLINICAL ASPECTS OF PATIENTS WITH PURE DYSGERHINOHA OF THE 
OVARY. 
4.1. Introduction. 
The low incidence of pure dysgerminoma of the ovary makes it rather 
tedious to study its clinical aspects. Moreover, as has ben mentioned 
earlier, only recently it had been widely recognized to differentiate 
pure dysgerminoma from mixed germ cell tumors of which dysgerminoma is 
one of the elements (Asadourian and Taylor, 1969, Gordon et al., 1981, 
De Palo et al., 1982), although already in 1947 the first data on pure 
dysgerminoma were published (Santesson, 1947). 
The malignant nature of the tumor has been doubted for a long 
period of time. It was not until the fifties that dysgerminoma was 
established as a malignant tumor. (Mueller et al., 1950; Pedowitz et 
al., 1955). Ironically both publications were surveys of literature, 
probably containing mixed germ cell tumors as well. 
As in other ovarian neoplasia diagnosis and treatment are ultima-
tely dependent on surgical exploration. As in patients with an adnexal 
tumor, dysgerminoma is preoperatively often unexpected, evaluation of 
metastases in a number of occasions is performed only after surgical 
exploration (Krepart et al., 1978) 
Diagnostic evaluation and treatment of pure dysgerminoma of the 
ovary also depends on stage of the disease and knowledge of biological 
behaviour. 
This chapter serves the purpose to appreciate the possible agree-
ments and controversies in literature in order to compare these with 
the results of the analysis of clinical aspects of the patients from 
the Dutch survey. 
4.2. Epidemiologic aspects of pure dysgerminoma of the ovary. 
Until 1938 119 patients with dysgerminoma of the ovary had been 
described (Seegar, 1938). Until 1950 the number of described patients 
was 426 (Mueller et al., 1950). After 1969 the number of reported 
patients increased rapidly because of some studies reporting on large 
series of patients (Asadourian and Taylor, 1969; Gordon et al., 1981; 
De Palo et al., 1982). 
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The incidence of dysgerminomas is unknown. Usually only the percen­
tage of dysgerminomas compared to other ovarian tumors and other germ 
cell tumors is known. These figures emanated from pathology institu­
tions and hospitals and not from any population based on registry and 
it is therefore only possible to get a impression of the frequency of 
dysgerminoma. The tumor accounts for 0.1Ж to 3S of all ovarian 
neoplasms and 35 to 5Й of all ovarian malignancies (Sjovall et el., 
1943; Santesson, 1947; Mueller et al., 1950; Asadourian and Taylor, 
1969; Kurman and Morris, 1977). 
These data are from publications from Europe and the United States. 
Elsewhere, the frequency of dysgerminomas among all ovarian malignan­
cies may be higher. For example, in Japan dysgerminoma accounts for 5 
to 138 of all ovarian tumors (Scully, 1978) and in India dysgerminoma 
of the ovary may account for up to 173. of all ovarian malignancies 
(Jatoi, 1959). 
Only 3 articles give an impression of the distribution of some 
malignant germ cell tumors (Table 4.1). 
Tabi· 4.1. Dietributum of gem cell tuners conpared to total nutter of gem 
cell tunara in patienta under the age of 20 yeare, 
Author 
Abell et «1. (1965) 
Horris et ed. (19T2) 
Li et e l . (1973) 
Total DO of patients 
Но of 
Batiente 
Iti 
13І4 
227 
1.02 
Gera 
Dyegerminoma 
11(26.8) 
l»8(35.8) 
78(31·.2) 
137(3U.1) 
c e l l ttoora 
Embryonal 
Сагеіпаша'
17 
9(22.0) 
32(23.9) 
1.6(20.2) 
87(21.6) 
(О 
Malignant 
Teretcma» 
21(51.2) 
51·(Ί0.3) 
103(li5. h) 
1Тв{Ыі.Э) 
Endodeimal sinus tumors included. 
vMixed gena cell tuaors included. 
The authors in this table assigned mixed germ cell timors to the 
group of teratomas. The authors also added together patients with 
embryonal carcinomas and endodermal sinustumors. Taking these data 
into account it becomes obvious that dysgerminoma is the most common 
form of pure malignant ovarian germ cell tumor for patients under the 
age of 20 years. 
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Pure dysgerminoma of the ovary most freguently occurs in patients 
between 11 tot 20 years. It also appears that 60% of dysgerminomas 
occur in patients below the age of 30 years (Fig. 4.1). 
The youngest patient ever reported in literature was 7 months of 
age (Breen, 1967), whereas the oldest patient with dysgerminoma was 76 
years of age (Mueller et al., 1950). 
Ίο 
ΙΟΟη 
40-
30 
20 
0-10 11-20 21-30 31-40 >40 uNKNOWNyrs 
Figure 4.1 Age distribution (n=1329) 
(Data accumulated from articles by Santesson 1947; Mueller et al., 
1950; Pedowitz et al., 1955; Brody, 1961; Koller and Gjrfnnœs, 1964; 
Jackson, 1967; Asadourlan and Taylor, 1969; Talerman et al, 1973; 
Boyes et al., 1978; Krepart et al., 1978; Freel et al., 1979; Lucraft, 
1979; Steffen and Genton, 1980; Linton, 1981; De Palo et al., 1982) 
In 15.000 to 25.000 pregnancies 1 malignant tumor occurs (Karlen, 
1979). Furthermore, it has been reported dysgerminoma to account for 
20 to ЗОй of malignant ovarian tumors diagnosed during pregnancy 
(Scully, 1979). 
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Recently a survey was performed on a group of 100 patients in which 
an ovarian tumor was found during pregnancy. In 37 patients the timor 
appeared to be benign. In the remaining 63 patients a malignant ova­
rian tumor was present. In 19 patients (Э0Ж) of the latter group dys-
germinoma was diagnosed. Unfortunately in this study clinical stage is 
not mentioned. The overall 5 year survival rate of pregnant patients 
with pure dysgerminoma of the ovary was B4ÌS (Novak, 1975). 
In series of patients with a pure dysgerminoma of the ovary 12 to 
17% of the patients were pregnant or less than 6 weeks post-partum at 
the time of diagnosis (Table 4.2). 
Table 4.2. Nimber of pregnant patients with pure dysgerminoma of the 
ovary compared to the total number of patients with pure 
dysgerminoma of the ovary. 
Author Total no No of pregnant 
of patients patients'7 
η п_(Я 
Brody (1961) 60 7 (12) 
Jackson (1967) 20 3 05) 
Asadounan and 
Taylor (1969) 105 5 Ο Ό 
Boyes et al. (1978) 25 Ί (16) 
Krepart et al. (1978) 36 6 (17) 
Total no of patients 2U6 35 (i1*) 
Includes patients less than 6 weeks postpartum. 
4.3. Patterns of spread. 
Dysgerminoma when confined to the ovary or ovaries, is surrounded 
by a firm fibrous capsule. According to some authors this capsule is 
causative to the fact that spread occurs in a relatively late stage 
(Asadourian and Taylor, 1969; Talerman, 1977). Microscopic infiltra­
tion of the capsule has been recorded in 10S of the patients with uni­
lateral disease (Asadourian and Taylor, 1969). Rupture of the capsule 
by reactive processes can cause adhaesions with adjacent organs which 
can later on be Infiltrated by tumor, leading to intraperitoneal 
spread (Talerman, 1977). 
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Retroperitoneal location by lymphatic spread ia more frequently 
found (Sarrazin et al., 1974; Markovitz et al., 1977; Musumeci et al., 
197Θ; De Palo et al., 1982). 
For a better understanding of lymphatic spread a description of the 
lymphatic drainage system is necessary. 
The main lymphatic drainage of the ovaries passes through aix to 
eight lymph vessels following the gonadal vessels (Fig. 4.2). 
A AORTA 
ІС INFERIOR CAVAL VEIN 
RV . RENAL VEIN 
OV OVARIAN VEIN 
EIA EXTERNAL ILIAC ARTERY 
LYMPH VESSELS 
Figure 4.2. Illustration of lymph node draining system of the ovaries. 
On the right side these lymph vessels empty into lymph nodes, which 
stretch out from the cavai veins bifurcation to the level of the dex­
trous renal vein and are situated ventrally and laterally of the 
aorta. 
The lymph vessels draining the left ovary also empty in a group of 
lymph nodes, which are situated ventrally and laterally of the aorta, 
but in contrast to the right side are only situated on the level of 
the sinistrous renal vein (Fig. 4.2). 
Above the level of the renal blood vessels the next lymph node 
stations are in the mediastinal and supraclavicular lymph node 
chains.A secondary lymphatic trunk drains via the broad ligament to 
the middle lymph node chain of the external iliac. 
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The differences in spread patterns between epithelial ovarian 
cancer and dysgerminoma of the ovary are emphasized by the findings 
that in 8S of the patients with stage I epithelial ovarian cancer 
tumor deposits were found in the retroperitoneal lymph nodes, whereas 
in patients with stage I dysgerminoma 30S had metastases to these 
lymph nodes (Musumeci et el., 1977, 1978). Moreover, in report on 
lymphogenic spread in 14 patients with clinical stage III dysgerminoma 
of the ovary only 2 patienta had intraperitoneal spread, whereas in 
the remaining 12 cases retroperitoneal metastases solely could be 
found (De Palo et al., 1982). 
The main lymphatic drainage is to the para-aortic lymph nodes which 
is illustrated by the fact that these lymph nodes could be involved in 
up to lOOtS of the patients with lymph node metastases. Conversely, in 
approximately 458 of these patients metastatic disease had been found 
in the iliac lymph node chain (Sarrazin, 1974; Markovitz et al.,1977). 
Hematogenic spread is generally found in a later stage or in wide-
spread recurrent disease (Talerman et al. 1977; Gordon et al., 1981). 
Hematogenic metastases are most frequently found in liver, lungs and 
bone (Santesson, 1947; Mueller et al., 1950; De Lima, 1966; Asadourian 
and Taylor, 1969; Gordon et al., 1981). 
4.4.1. Clinical findings. 
The clinical findings of pure dysgerminoma of the ovary are quite 
insidious. Only whenever the tumor reaches a certain size or in case 
complications occur caused by tumor growth, symptoms will become evi-
dent. The most frequent signa and symptoms are a distended abdomen, a 
palpable tumor and abdominal pain (Table 4.3). 
Table 4.3. Signs and symptoms in patients with pure dysgerminoma of 
the ovary.4 
Signs and symptoms 
Abdominal mass and pain 
Abdominal mass 
Abdominal pain 
Vaginal bleeding 
At time of cesarían section 
Unknown 
Number of 
patients 
6 
13 
13 
1 
1 
2 
Percentage 
17 
36 
36 
3 
3 
Ь 
''Krepart et al. (1978) 
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Rotation of the tumor might cause complaints of sudden severe abdo­
minal pain (Santesson, 1947; Brody, 1961; Koller, 1964; Jackson, 1967; 
Asadourian and Taylor, 1969; Talerman et al., 1973; Boyes et al., 
1978; Krepert et al., 1978; De Palo et al., 1982). In these cases the 
differential diagnosis should include an extra-uterine pregnancy and 
in case of right sided sudden peln an acute appendicitis should be 
considered as well. 
In view of the sparse case reports ascites appears to be an uncom­
mon finding in patients with dyagermlnoma of the ovary (Brody, 1961; 
Burkons and Hart, 1977; К repart et al., 1978; Boyes et al., 1978; 
Freel et al., 1979; Gordon et al., 1981). 
Loss of weight and menstrual disorders are also less frequently 
found (Santesson, 1947; Asadourian and Taylor, 1969; Boyes et al., 
1978). 
The duration of symptoms is usually short. De Palo et al. (1982) 
found that more than 50% of the patients in a group of 56 patients had 
symptoms less than 1 month, whereas only 53 of the patients had symp­
toms longer than 6 months. Because of the age distribution a number of 
symptomless dysgerminomas are found at routine check-ups like contra­
ception follow-up and during pregnancy. This is highlighted by the ob­
servation that in one report in 17 patienta (30S) out of 56 patients, 
dysgerminoma was an incidental finding (De Palo et al., 1982). 
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4.4.2. Associated endocrine aspects. 
The greater proportion of pure dysgerminoma of the ovary is not 
associated with endocrine manifestations. 
However, some cases have been described in which hCG production was 
found in patients with dysgerminoma of the ovary (Hain, 1949; Hobson 
and Balrd, 1966; Castleman, 1972; Ueda et al., 1972; Zaloudek et al, 
1981). It has now been established that syncytiothroblast giant cells 
(SGC) are responsible for hCG production (Ueda et al., 1972; Kaplan 
and Hawley, 1981). 
Using anti B-hCG immunoperoxidase SGC can be demonstrated because 
of the presence of B-hCG. No reaction has been observed either in dys­
germinoma cells or in inflammitory or stromal components (Kaplan and 
Hawley (19Θ1) 
In some cases hCG production has been associated with endocrino­
logie symptoms due to production of androgens or estrogens (Hain, 
1949; Castleman et al., 1972). These symptoms have disappeared follo­
wing the removal of the tumor. Hain (1949) described a patient with 
dysgerminoma of the ovary with precocious puberty and a positive 
Ascheim-Zondek test. The signs of precocious puberty typically disap­
peared after removal of the dysgerminoma. 
The production of steroid hormones in patients with elevated hCG 
levels could be explained by the fact that circulating hCG stimulates 
the ovarian stroma to synthesize these hormones (Scully, 1979). It 
could also be possible that the action of hCG evokes stimulation of 
the contralateral ovary to synthesize steroid hormones (Zaloudek et 
al., 1981). Furthermore, a focus of gonadoblastoma, which is capable 
of synthesizing steroid hormones could be present within the tumor. In 
a few cases elevated hCG levels and endocrine manifestations has been 
found without an acceptable explanation, possibly due to Inadequate 
sampling (Talerman, 1977; Scully, 1979). 
At present, there is no conclusive evidence that dysgerminoma cells 
are capable of hormone production. This is substantiated by the fin­
dings of Lynn (1967) end Kay and el. (1972), who demonstrated produc­
tion of notably estrogenic steroids by stromal cells only. Dysgermi­
noma cells did not show any signs of steroid production. 
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4.4.3. Associated genetic aspects. 
Although Meyer (1931) suggested a very close association between 
dysgermlnoma of the ovary and developmental and sexual abnormalities, 
later reports did not substantiate this contention (Santesson, 1947; 
Brody, 1961; Asadourlan and Taylor, 1969; Talerman et al., 1973; 
Gordon et al., 1981). In fact, these authors stated, that mostly dys-
germlnoma occur in normally developed females. 
The association between dysgermlnoma and genetic abnormalities are 
mainly limited to patients with gonadal dysgenesis with 46,XY karyo-
type. Teter and Bocskowski (1972) reported on 26 patients with either 
pure or mixed gonadal dysgenesis without somatic malformations. In 4 
cases a dysgermlnoma occured in patients with a 46,XY karyotype. In 3 
other patients, 2 patients with gonadal dysgenesis (46,XY karyotype) 
and 1 patient with Turner's syndrome (45,X0/46,XY karyotype), a gona-
doblastoma was found. 
According to these authors, the presence of the Y chromosome 
suggests that malformed dysgenetic gonads were supposed to develop 
Into testis.All patients showed signs of masculinization and had a 
negative sex chromâtine pattern. The authors pointed out the high 
proballty of the existence of a germ cell neoplasm in patients with 
the following features: 
1. An adnexal tumor. 
2. Signs of masculinization in women ьп-tk ртітаіу amenorrhea. 
3. A negative sex chromatine pattern and the presence most 
usually in the fom of normal male 46,XÏ karyotype. 
4. Calcification of the tumoT, shown by radiologic examination, 
caused by the presence of calcifications in a gonadoblaotoma, 
In up to 50% of the patients with ganadoblastoma malignant changes, 
mainly dysgermlnoma, occur (Scully, 1979). Because of the frequent 
occurrence of bilateral tumors and the absence of gonadal function a 
radical therapeutic approach i.e. bilateral salplngo-oophorectomy, has 
been recommended in patients with gonadoblastoma and the presence of 
an Y chromosome (Talerman, 1977; Scully, 1977). 
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In this respect investigations of the genotype and the karyotype of 
patients with dysgerminoma, especially those with evidence of masculi-
nizatlon or developmental and menstrual abnormalities and of course 
premenarchal patients is important. 
4.5. Diagnosis and pre- and post operative evaluation. 
4.5.1. Tumor markers. 
Tumormarkers play an important part in the diagnosis of germ cell 
tumors (Perlin et al., 1976). Recently a set of conditions to define 
the ideal tumormarker has been stipulated (Lokich, 197Θ): 
- The tumormarker should only be produced in timor tissue. 
- Serum levels should only be increased in case of a malignant 
turrar. 
- There should be a direct correlation between serum levels and the 
amount of tumor burden. 
Contrary to most other types of germ cell tumors dysgerminoma of 
the ovary does not produce a specific tumormerker. 
In some cases serum lactic dehydrogenase (LDH) and LDH iso-enzyms 
are increased (Bloemers et al., 1963; Sheiko and Hart, 1982; Awais, 
1978, 1983; Friedman et al., 1984). 
LDH and LDH iso-enzyms are glycolytic enzyms present in a number of 
tissues and neoplasms. Serum LDH and LDH iso-enzyms are not to be 
considered specific tumor markers for pure dysgerminoma of the ovary 
according to the set of conditions for the ideal tumormarker (Lokich, 
1978). 
Serum levels of LDH have been demonstrated to be increased preope-
ratively in patients with pure dysgerminoma of the ovary and decreased 
after removal of the tumor (Awais, 1983). In this study no levels of 
LDH iso-enzyms had been reported. Dysgerminoma cells might be the 
source of increased LDH and LDH iso-enzym activity in such cases 
(Sheiko and Hart, 19B2). 
In some cases serum levels of human chorionic gonadotropin (hCG) 
are elevated. This specific set of dysgerminomas contain isolated syn-
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cytlotrophoblast giant cells in which hCG can be demonstrated (Kurman 
and Morris, 1978; Ueda et al., 1972; Kaplan and Hawley, 1981; Zaloudek 
et al., 19B1). 
4.5.2. Radiological examination. 
For β sufficient preoperative evaluation of dysgerminoma of the 
ovary radiological examination is usefull to determine metastases of 
all sorts. 
The following types of radiological examination are to be discussed: 
1 . Conventional r a d i o l o g i c a l techniques. 
2. Lyirphography. 
3. Computed tomography scan (CT-scan). 
4. Ultra-sound sonography. 
4.5.2.1. Conventional radiological techniques. 
A chest X-ray provides information about state of the heart and 
lungs and also detects clinically silent metastases and pleural 
spread. A large bowel contrast study provides information if it does 
show an impression of the large bowel In case of a large tumormess. 
Also this type of X-ray could render information for the differential 
diagnosis of a large bowel tumor. 
Intravenous urography would provide information about renal func­
tion and ureteral obstruction. The latter Is of importance when retro­
peritoneal resection is necessary. 
A plain film of the abdomen could provide clues to the fact whether 
calcification of the tumor is present. However calcification of dys­
germinoma is very rare (Asadourian and Taylor, 1969; Nelken et al., 
1978) 
4.3.2.2. Lymphography 
The spread of dysgerminoma of the ovary frequently occurs by lym­
phatic route (Chapter 4.3). Lymphography is therefore of utmost impor­
tance to assess the presence of metastases. 
Kinmonth (1952) was the first to describe the technique of lympho­
graphy by way of injection of patent-blue in the dorsum of the foot. 
Nowadays oily contrast medium is used instead of patent-blue (Wallace, 
1963). 
Knowledge of the main lymphatic drainage of the ovaries is impor­
tant for an understanding of lymphography (Chapter 4.3). 
By means of lymphography the most caudal lymph vessels and lymph 
nodes shown are the external Iliac and communal iliac chains. The 
lymph nodes of the obturator fossa are mainly seen as part of the 
middle external iliac chain. The lymph nodes of the hypogastrical 
chain are rarely seen. On the level of the lumbal spine three main 
lymph vessels are visible: lateral to the vena cava, lateral to the 
aorta and in between the aorta and the vena cava (Fiq. 4.2). Lymph 
nodes above the level of the cyaterna chyll are not made visible by 
lymphography. 
There are only a few reports in literature concerning the lympho-
graphlc aspects of dysgermlnoma of the ovary. Suspicious lymph nodes 
on the lymphanglogram in patients with pure dysgermlnoma of the ovary 
range from 33!8 to 43S (Markovitz et al., 196Θ, 1977; Musumeci et al., 
1978; Sarrazin et al., 1974). Only Musumeci et al. (197B) by means of 
histological examination determined the diagnostic accuracy of lympho­
graphy. The sensitivity was 908, the specificity was 845! and the over­
all accuracy for lymphography was BBS (Addendum 1). 
4.5.2.3. Computed Tomography scan (CT-scan). 
Concerning the application of CT-scan in dysgermlnoma of the ova­
ries no data are known. Recently the results concerning the applica­
tion of CT-scan in non-seminomatous testicular tumors were reported 
(Dunnick and 3avadpour, 1981; Thomas et al., 1981). In both studies 
the accuracy of CT-scan was 89Й. The sensitivity was respectively 83 
and 90Ж, whereas the specificity amounted to 100 and 838, respec­
tively. 
The combined use of lymphography followed by CT-scan appears to be 
preferable. Lymphography may be the most accurate single method of 
radiological examination, although CT-scan does provide better defini­
tion of the extend of the tumormass. The accuracy of CT-scan in their 
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study has been reported to be 89%, whereas a combination of CT-scan 
with lymphography renders a overall accuracy of 94S (Dunnick and 
Javadpour, 1981). 
4.5.2.4. Ultrasound examination. 
Till now one case report on ultrasound application in patients with 
dysgerminoma of the ovary has been published (Schaffer et al., 1982). 
The authors observed that dysgerminoma of the ovary is characterized 
by ultrasound examination by a solid ovarian mass and scattered, echo-
free zones, which are probably caused by necrosis. This description is 
by and large not a specific feature of dysgerminoma only, as in other 
ovarian neoplasms these features also have been found (Goswamy et al., 
1983). 
4.5.3. Laparoscopy. 
There ere no reports in literature on the use of laparoscopy in pa­
tients with dysgerminoma of the ovary. However, laparoscopy is widely 
used in gynaecological oncology. It is an important alternative to 
laparotomy in distinguishing benign pelvic tumors from ovarian cancer 
and in this respect dysgerminoma of the ovary. 
Laparoscopy might also be useful in the follow up of patients with 
encapsulated disease confined to one ovary (stage Ιβχ) and who did not 
receive adjuvant therapy. If the patient is receiving chemotherapy the 
efficiency of treatment can be evaluated by laparoscopy (Berek and 
Hacker, 1983). 
4.7. Stage. 
The routes of spread of dysgerminoma of the ovary are reflected in 
the staging classification proposed by the Cancer Committee of the 
International Federation of Gynecology and Obstetrics (FIGO, 1973), 
which is accepted for all malignancies of the ovary and for cancer of 
the Fallopian tube. More recently β revised version has been accepted 
(Kottmeier, 1976) (Table 4.4). 
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Table 4.4 FIGO etage grouping for primary сагогпота of the 
ovary (1976). 
Stage I Growth limited to the ovaries. 
la Growth limited to one ovary, no ascites? 
1 No tumor on the external surface, capsule intact. 
2 Tumor on the external surface or/and capsule ruptured. 
ІЪ Growth limited to both ovaries; no ascites0 
1 No tumor on the external surface; capsule intact. 
2 Tumor on the external surface or/and capsule(s) ruptured. 
Ic Tumor either Stage la or Stage lb, but with ascites0 pre­
sent or positive peritoneal washings. 
Stage II Growth involving one or both ovaries with pelvic 
extension. 
IIa Extension and/or metastases to uterus and/or tubes. 
IIb Extension to other pelvic tissues. 
H e 
or positive peritoneal washings. 
Stage 111 Growth involving one or both ovaries with intraperito­
neal metastases outside the pelvis and/or positive re­
troperitoneal nodes. Tumor limited to the true pelvis 
with histoloRically proven malignant extension to 
small bowel or omentum. 
Stage IV Growth involving one or both ovaries with distant me­
tastases. If pleural effusion iq present there must be 
positive cytology to allot a case to Stage IV. Paren­
chymal liver metastases equals Stage IV 
Special category. Unexplored cases thought to be ovarian carci­
noma. 
0Ascites is peritoneal effusion which m the opinion of the 
surgeon is pathological or/and clearly exceeds normal amounts 
Dysgerminoma of the ovary is commonly found in earlier stages. 
Especially stage I is most frequently found (Table 4.5). 
Articles published after 197} when the FIGO staging classification 
was internationally accepted, are mainly used in this table. Three 
articles published before 1973 were extensively studied (Koller et 
al, 1964; Asadourian and Taylor, 1969; Talerman et al., 1972). In 
these articles for obvious reasons FIGO-stage I has not been mentioned 
as such, but the number of unilateral tumors with unruptured capsules 
(i.e. FIGO-stage lay) was described. 
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Tabi· 4.5. Stage diatribution dyagenrinoma of the ovary, 
Author No of 
pat ients 
Koller and Gjonnaee* ( 1 9 6 4 
Asadourian and Taylor* 
Taleman e t a l . (19Τβ) 
Boyes e t a l . (19ΤΘ) 
Burkons and Hart (19ΤΘ) 
Krepart e t a l . (1978) 
Freel e t a l . (1979) 
Lucraft (1979) 
Gordon e t a l . (19β1) 
De Palo e t a l . (19β2) 
Total no of pat ients 
(1969) 
Π 
105 
17 
20 
13 
36 
21 
33 
136 
1Λ 
Ul)2 
I 
11.(82.3) 
78(71·. 2) 
13(76.5) 
1U(70.0) 
10(77.0) 
22(61.0) 
11(52.14) 
щиз.о) 
107(78.7) 
26(59-0) 
309(69.9) 
Stage (J) 
II - IV 
3(17.7) 
18(17.1) 
M23.5) 
6 ( 3 0 . 0 ) 
3(23.0 ) 
1 4 3 9 . 0 ) 
8(38.1) 
19(57.0) 
21(15.1») 
18(1.1.0) 
11U(25.8) 
Unknown 
_ 
9(8.5) 
_ 
_ 
_ 
_ 
2 ( 9 . 5 ) 
8 ( 5 . 9 ) 
19(1..3) 
Retrospectively staeed. 
The stage diatribution in stage I revéales that stage la has by far 
the highest incidence (Table 4 .6 ) . 
Tabi· 4 . · . Caiparative incidence of etage la, lb. Io pure dyegeminoma of 
the ovary. 
Author 
Koller and Gjonnaes* (1961.) 
Talerman et al .•(1972) 
Boyes et a l . (1977) 
Burkons and Hart (1977) 
Kurman and Rorris (1978) 
Gordon et a l . (I981) 
De Palo et a l . (1982) 
Total no of patiente 
Яо of patients 
Stage I 
U 
13 
111 
10 
78 
107 
56 
262 
la 
13(92.3) 
10(76.9) 
10(71.1.) 
9(90.0) 
71(91.0) 
91.(87.9) 
21.(92.U) 
231(88.2) 
Stags I 
lb 
К 7.1) 
2(15.1.) 
3(21.1.) 
-7( 9.0) 
7( 6-5) 
К 3.8) 
21( 8.0) 
(() 
l e 
. 
1(10.0) 
К 7.2) 
1(10.0) 
. 6( 5.6) 
К 3.8) 
10( 3.8) 
Retrospectively staged. 
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4.7. Therapy. 
The treatment of pure dysgerminoma of the ovary can be classified 
as follows: 
1. Initial treatment of pure dysgerminoma of the ovary. 
2. Treatment of recurrent disease (4.8.2.) 
The treatment modalities of pure dysgerminoma of the ovary are: 
A. Surgical therapy. 
B. Radio therapy. 
C. Chemotherapy. 
Because of the low incidence of the tumor a prospective study is 
not feasable which conseguently makes it rather difficult to be con-
clusive comparing these treatment modalities. 
4.7.1. Initial treatment of pure dysgerminoma of the ovary. 
A. Surgical treatment. 
Surgical treatment is the cornerstone of therapy of pure dysgermi-
noma of the ovary. However, the form of surgical treatment of patients 
with early stage disease (stage la) remains a matter of disagreement. 
As far as these patients are concerned three forms of therapy have 
been advocated: 
-Conservative surgical treatment i.e. unilateral selpingo-oopho-
rectomy (USO). 
-Conservative surgical treatment followed by radiotherapy 
-Non-conservative surgical treatment i.e. total abdominal hyste-
rectomy with bilateral salpingo-oophorectomy (TAH-BSO), which is 
usually followed by adjuvant radiotherapy. 
Most authors recommend conservative surgical treatment in patients 
with unilateral encapsulated (stage laj) as to preserve future child-
bearing capacity (Malkasian and Symmonds, 1964; Asadourian and Taylor, 
1969; Papillon et al., 1976; Kurman and Norris, 1977; BurUons and 
Hart, 1978; Lucraft, 1979; Gordon et al., 1981; De Palo et al., 1982). 
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Some authors favour non-conservative surgical treatment in any case 
followed by adjuvant radiotherapy as to minimize the risk of recurrent 
disease and mortality (Mueller et al., 1950; Pedowitz et al., 1955; 
Thoeny et al., 1961). It should be noted that these arguments are 
based on earlier report series including a large nunber of cases with 
widespread disease because of late discovery and moreover Including 
cases with mixed germ cell tumors, adversely affecting prognosis 
(Asadourian and Taylor, 1969; Talerman, 1977). 
Some other authors advocate a conservative approach with some 
restrictions (Boyes et al., 1978; Krepart et al., 1978; Freel et al., 
1979). Krepart et al. (1978) advised conservative treatment in pa­
tients with unilateral disease unless the tumor is greater than 10 cm 
across, in case of evidently enlarged or abnormal lymph nodes and/or 
when ascites is present at surgery. These last 2 restrictions point at 
a higher stage than laj and should therefore disregarded discussing 
the treatment of patients with stage lal disease. This leaves tumor 
size to be the only factor determining treatment in patients with 
stage Ιβχ disease, wich has also been supported by others as well 
(Boyes et al., 1978; Freel et al., 1979; Piver, 1981; Morrow and 
Townsend, 1981). 
Conversely, other authors did not find a correlation between tumor 
size end survival, and therefore these authors supported the concept 
of individualized treatment for patients with dysgerminomas of the 
ovary (Malkasian and Symmonds, 1964; Burkons and Hart, 1978; Asadou­
rian and Taylor, 1969; Gordon et al., 1981) 
Asadourian and Taylor (1969) noted a recurrence rate of 225 in 46 
conservatively (USO) treated patients with clinical stage lAj. In 25 
non-conservatively (TAH-BSO) treated patients with stage la the recur­
rence rate only amounted to 122. However, the recurrences of the first 
group could be treated succesfully in 50S of the cases. The 5 year 
survival rates for both groups were equal (90%). The 10 year survival 
rate for the conservatively treated group was also in agreement with 
that of the non-conservatively group (88S and 848, respectively). 
Gordon et al. (1981) reported an actuarial survival rate at 5 and 
10 years of 94.4S and 92.IS, respectively in 72 conservatively treated 
patients with clinical stage la. In their study 14 patients with 
clinical stage la underwent non-conservative treatment. The actuarial 
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survival rate at 5 and 10 years in this small group of patients was 
78.5 and 63.6%, respectively. 
Because of the high rate of bilateral disease (4Й to 21%) and the 
risk of occult involvement of the contralateral ovary, a biopsy speci­
men of the contralateral ovary is recommended in case of conservative 
treatment (Boyes et al., 1978; Krepart et al., 1978; Freel et al., 
1979; Gordon et al., 1981). 
Occult involvement of the contralateral ovary is most probably the 
cause of recurrence in the contralateral ovary after conservative 
treatment (Santesson, 1947). The author reported a recurrence rate of 
2955 (7/24) in 24 conservatively treated patients. All recurrences were 
found in the remaining ovary. In 18 other patients, who were conserva­
tively treated followed by radiotherapy, none developed a recurrence 
in the remaining ovary which had been irradiated as well (Santesson, 
1947). 
The third therapeutic approach in patients with stage Ιβχ dysgermi-
noma consists of conservative surgical treatment and in order to de­
crease the risk of recurrent disease adjuvant low dose (less than 1.5 
Grey skindose) radiotherapy to the abdominal lymph nodes and the tumor 
bed, while the the contralateral ovary is shielded (Brody, 1961). With 
this kind of combination therapy a 5 years survival rate has been 
reported of 94Й in 17 patients with stage lal disease (Brody, 1961). 
Some authors recommend non-conservative surgical treatment in cli­
nical stage la if the patient is over the age of 30 and/or does not 
have the wish for future fertility (Boyes et al., 1978; Freel et al., 
1979). 
Non-conservative surgical treatment (total abdominal hysterectomy 
and bilateral salpingo-oophorectomy) is considered to be the treatment 
of choice in clinical stage lb and higher (Boyes et al., 1978; Burkons 
and Hart, 1978; Krepart et al., 1978; Freel et al., 1979; Gordon et 
al., 1981). 
The surgical technique of non-conservative treatment in dysgermi-
noma of the ovary does not differ from the technique as used in 
epithelial ovarian malignancies (Freel et al., 1979). 
В. Radiotherapy. 
Compared to most other ovarian malignancies radiotherapy has an 
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unique place in the treatment of pure dysgerminoma of the ovary 
(Lucraft, 1979). 
Beclfere in 1921 was the first to report a case in which dysgermino-
ma appeared to be radiosensitive. Already in 1917 in the Mayo-clinics 
radiotherapy had been used in the treatment of patients with dysgermi-
noma (Thoeny et al., 1961) 
With radiotherapy long term survival have been achieved even in 
patients with widespread disease (Boyes et al., 1978). 
In literature the recommendations concerning the technique and dose 
levels of radiotherapy in patients with dysgerminoma vary. Moving 
strip technique has been recommended with a dose level between 2000 
and 2200 rad and a pelvic boost with a dose level between 1300 and 
2000 rad (Delcos et al., 1961; Krepart et al., 1978). 
Others also advocated this technique but in addition recommended 
prophylactic Irradiation to the mediastinum in patients with extra-
pelvic disease. No mediastinal recurrence developed in 5 such pa-
tients, whereas, 2 patients out of 6 with extrapelvic stage III 
disease developed recurrent disease in mediastinal lymph nodes, which 
had not been irradiated (Pirtoll and Cionini, 1980). 
In another report the effects of radiotherapy have been analyzed in 
5 deaths (1 patient stage II and 4 patients stage III) among a series 
of 33 patients with dysgerminoma· With 1 exception either the dose or 
the extent of radiotherapy given was less than the author would now 
recommend. In 1 patient the pelvis was only treated and the 3 other 
patients had 2000 rad in 21 days, 2000 rad in 28 days and 2300 rad in 
28 days. The remaining patient was treated with a kilovoltage trunk-
bridge which gives a less homogeneous distribution than megavoltage 
techniques used nowadays. Of these patients 3 had widespread disease, 
which was only biopsied. It has been recommended to use megavoltage 
irradiation with parallel opposed pairs of fields covering the whole 
abdomen with appropiate shielding in a total dose of 3000 rad in 20 
fractions in 4 weeks (Lucraft, 1979). 
Some authors recommended in stage I and II cases megavolt irradia-
tion to the whole pelvis, and, in view of the high frequency of lym-
phatic spread, additional irradiation to the para-aortic lymph nodes 
(Boyes et al., 197B). The authors believed dose levels of 3000 - 4000 
rad to be sufficient for curative treatment. 
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The benefits of additional radiotherapy may be best illustrated by 
the findings of some authors, who noted that none of the patients in 
their series who developed recurrent disease after receiving high 
doses radiotherapy had a recurrence in the previously treated field 
(Krepart et al., 197Θ). 
Furthermore, in another report patients, who received postoperative 
irradiation to the pelvis, only developed recurrent disease above the 
pelvis, whereas other patients, who did not receive adjuvant radio­
therapy, developed recurrent disease both in the pelvis and above the 
pelvis (Afridi et al., 1976). 
In case of spread to the para-aortic nodes irradiation of the 
mediastinal and supra-clavicular regions, as to cure silent spread to 
these regions, is not questioned (Papillon et al., 1976; Boyes et al., 
1978; Krepart et al., 1978; Freel et al., 1979; Lucraft, 1979; Pirtoli 
and Cionini, 19B0). 
C. Chemotherapy. 
The first results of chemotherapy use (nitrogen mustard) in a 
patient with pure dysgerminoma of the ovary were published in 1952 
(Anderman et al., 1952) 
However, because of the remarkable results of radiotherapy in pure 
dysgerminoma of the ovary adjuvant chemotherapy in pure dysgerminoma 
of the ovary did not receive much attention in literature (Boyes et 
al., 1978). 
These few reports concern patients with either metastatic or recur­
rent disease or when the tumor did not respond to radiotherapy. Still, 
encouraging results, meaning complete remissions were achieved with 
chemotherapy in these patients. Chemotherapeutics used were vincris­
tine, bleomycine, cyclophosphamide, myeleran, actinomycine-D, 5-F.U., 
adriamycine and cis-platinum (Smith et al., 1973; Cohen and Goldsmith, 
1976, Boyes et al., 1978; Krepart et al., 1978; De Palo et al., 1982; 
Van Lindert, 19B2). 
At the present moment combination chemotherapy appears to be promi­
sing. In this regard combinations either including vincristine, acti-
nomycin-0 and cyclophosphamide (VAC) or vinblastine, bleomycine and 
cis-platinum (VBP) have been used with considerable succes (Schwartz 
et al., 1983; Einhorn and Donohue, 1977; Van Lindert, 1982). As yet, 
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the chemotherepeutic combination of choice is not well established. 
Regarding the similar way of action with radiotherapy alkylating 
chemotherapeutics should render good results (Cohen and Goldsmith, 
1977; Newlands et al., 19Θ2). 
4.8.1. Recurrent disease. 
The overall recurrence rate in patients with dysgerminoma of the 
ovary varies between 15 to 52% (Brody, 1961; Malkasian and Symmonds, 
1964; Gordon et el., 1981). 
Approximately 75S of the recurrences are detected within two years 
after treatment. Five yeara after treatment 80 to 955 of the recurren­
ces have occurred (Asadourlan and Taylor, 1969; Krepart et al., 1978; 
Gordon et al., 1981; De Palo et al., 1982), although in some rare 
cases disease can recur after still β longer period of time (Freel et 
al., 1979; Gordon et., 1981). 
Recurrent disease is often found intraperltoneally, in contrast to 
primary tumor growth (Brody, 1961; Freel et al., 1979; Krepart et al., 
1978; Gordon et el., 1981). In a series of 12 patients with recurrent 
diaease, 8 (66%) had intraabdominal tumor deposits. Recurrences are 
often found at multiple sites (Krepart et el., 1978) (Table 4.7). 
Table 4.7. Locations of recurrent disease in 12 patients, 
Locations Number of patients 
Abdomen θ 
Pelvis 5 
Para-aortic lymph nodes 5 
Supraclavicular lymph nodes k 
Vertebral column 2 
Lung 1 
Liver 1 
* Krepart et al. (1978) 
According to some authors the development of recurrent disease is 
releted to size of the primary tumor, clinical stage and treatment 
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(Asadourian and Taylor, 1969; Krepart et al., 1978; Gordon et al., 
1981; De Palo et al., 1982) 
Krepart et al. (1978) reported on 5 patients with stage la dysger-
minoma measuring less than 10 cm across, who were all alive and well 
36 to 212 months after unilateral salping-oophorectomy. Conversely, 9 
other patients with stage la dysgerminoma measuring 12,5 to 20 cm 
across all developed recurrent disease. 
Gordon et al. (1981) reported that in only 3 out of 9 patients with 
recurrent disease the initial tumor was less than 15 cm and none was 
less than 10 cm. All patients had clinical stage la, were treated by 
unilateral salpingo-oophorectomy and developed recurrent disease in 
the remaining ovary. 
De Palo et al. (1982) reported on 31 patients with FIGO-stage I. 
Only 1 patient developed a recurrence. However, in 12 patients with 
stage III dysgerminoma 5 developed recurrent disease. 
Asadourian and Taylor (1969) reported a recurrence rate of 225! in 
46 patients with stage la, treated by unilateral salpingo-oophorec-
tomy. However in 25 other patients with the stage la treated by total 
abdominal hysterectomy and bilateral salpingo-oophorectomy the recur-
rence rate only accounted for 9%. 
Data in literature suggest that recurrent disease seldomly develops 
in previously irradiated areas using megavoltage techniques (Afridi et 
al., 1976; Krepart et al., 1978; Pirtoli and Cionini, 1980) 
4.8.2. Treatment of recurrent disease. 
As in primary disease, surgical intervention is also very important 
in recurrent disease, enhancing prognosis with a removal of as much 
tumor tissue as possible (Afridi et al., 1976; Krepart et al., 1978). 
Radiotherapy in patients with recurrent disease could also be of 
vital importance if during initial treatment radiotherapy was used in 
low doses or not used at all (Krepart et al., 1978). Radiotherapy in 
recurrent disease is often aimed at the precise location of the recur-
rence, which makes it mandatory to perform a very precise intra-opera-
tive evaluation of the metastases in patients with recurrent disease 
(Freel et al., 1979). 
Chemotherapy has rendered encouraging results in patients with 
recurrent disease (Chapter 4.7.1.C). 
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Α.9. Ovarian function and pregnancy after treatment. 
No extensive studies are known concerning this subject in patients 
treated for dysgerminoma of the ovary. Most reports are limited to the 
effects after radiation therapy (Santesson, 1947; Brody, 1961). 
Santesson (1947) analysed in 16 patients the effects of adjuvant 
radiation therapy Including the remaining ovary after conservative 
surgical therapys. Of these, 8 patients (44%) still had a menstrual 
cycle and 3 patients got pregnant after treatment. It should be kept 
in mind that these patients were treated with less powerfull orthovol-
tage radiotherapy compared to the present megavoltage radiotherapy. 
Brody (1961) reported on 22 patients who underwent conservative 
surgical therapy i.e. unilateral salpingo-oophorectomy followed by 
abdominal megavoltage radiotherapy, while the remaining ovary was 
shielded. Of these, 10 patients (45%) became pregnant 18 times. There 
was 1 miscarriage, 1 patients underwent a termination of pregnancy, 15 
normal offspring and 1 child with congenital deformaties were 
delivered. 
Other reports in literature concerning this subject are limited to 
case reports (Ayerst and Johnson. 1959; Gans et al·, 1963; McCarthy 
and Milton, 1975). 
In order to elaborate on the effect of treatment on ovarian func­
tion it is necessary to consult data on patients with other malignan­
cies than dysgerminoma of the ovary. 
At present there appears no adverse effects of unilateral salpingo-
oophorectomy on ovarian function (Stillman et al., 1981). Others noted 
no adverse effect of oophoropexy on ovarian function in patients with 
Hodgkin's lymphoma (Thomas et al., 1976). 
The incidence of ovarian failure increases with increased ovarian 
exposure. The authors found no ovarian failure in 122 patients in 
which the ovaries were not Included in the field of irradiation, 
whereas 5/35 (24S) had ovarian failure when the ovary of least expo­
sure was determined to be at the edge of the radiation field (290 rad 
at the edge of the field) and 68% (17/25) developed ovarian failure 
after an average 3200 rad to the ovaries (Stillman et al., 1981). 
Concerning the Influence of chemotherapy little is known. Prelimi-
nery data suggest that high dose alkylating agents used in patients of 
older age adversely affect ovarian function (Koyama et al., 1977). 
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Less ia known of the effects of other single chemotherapeutic 
agents. The reproductive performances after chemotherapeutic treatment 
of patients with gestational trophoblastic disease have been the sub-
ject of a number of studies (Pastorfide and Goldstein, 1973; Ross, 
1976; Walden and Bagshawe, 1976). The treatment however, consisted 
either of multiagent chemotherapy, which precludes an insight into 
which agent might be damaging to future offspring or of single chemo-
therapy, like methotrexate, which is not commonly, if ever used in 
patients with pure dysgerminoma of the ovary. 
4.10. Survival. 
The overall survival rate for patients with pure dysgerminoma of 
the ovary is summarized in Table 4.8. As can be noticed the survival 
rate reported by Brody (1961) is somewhat lower as compared to the 
other reports. This is caused by the fact that Brody used crude survi-
val rates whereas in the other publications actuarial survival rates 
were used, as was earlier on discussed some authors (Asadourian and 
Taylor, 1969). Moreover, in the early sixties orthovoltage radiothe-
rapy was used, which is less effective than the present megavoltage 
radiotherapy. 
The overall actuarial 5 years survival rate varies between 83% and 
93SÍ (Table 4.8). 
Table 4 8 5 years overall survbval rate pure dysgerminoma of the 
ovary. 
Author Number of 5 years survi-
patients vai rate (%) 
Brody (1961) 60 75 
Asadourian and Taylor (I969) 105 86 
Boyes et al (197В) 25 91 
Iiicraft (1979) 33 85 
Gordon et al (1981) 116 83 
In Table 4.Θ only those publications were taken into account in 
which a review of the histolgic material was performed, a rather large 
series reported on and finally a 5 years survival rate was noted. 
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4.11. Clinical factors affecting survival. 
4.11.1. Age at the time of diagnosis. 
There are only a few publications in literature which examined the 
relationship between age and prognosis and also reported on large 
series. It had been reported that the survival rate was decreased for 
patients below the age of 20 and for patients above the age of 40 
years (Brody, 1961; De Lima, 1966) (Table 4.9). 
Table 4.9. Correlation between age and eitrvival. 
Age 
10 -
21 -
30 -
1+0 -
g r o u p i n g 
• 19 
• 29 
• 39 
- h9 
y r . 
y r . 
y r . 
y r . 
НшпЪег of 
p a t i e n t s 
16 
30 
θ 
6 
5--year sur­
v iva i r a t e 
g i 
Θ3 
87 
50 
{%) 
*Brody (1981). 
Others reported a lower survival rate for patients above the age of 
40 years as compared to that of younger patients (Boyes et al., 1978; 
Lucraft, 1979). 
Some other authors could not detect a correlation between age and 
survival (Koller and Gjonnaes, 1964; Asadourian and Taylor, 1969; 
Talerman et al., 1972; Papillon et al., 1976; Freel et al., 1979). 
4.11.2. Pregnancy at the time of diagnosis. 
Reports on the correlation between pregnancy at the time of diag­
nosis and prognosis are limited to case histories with one notable ex­
ception. Novak et al. (1975) reported on 19 patients with pure dysger-
minoma of the ovary diagnosed during pregnancy or immediately (6 
weeks) postpartum. Although stage was not mentioned the over all 5 
year survival rate amounted to 8458 which is equal to that of non-preg­
nant with dysgerminoma of the ovary. 
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4 . 1 1 . 3 . Size of the tumor. 
Some authors reported an adverse effect of size of the primary tu-
mor on recurrent disease (Krepart et al., 1978; Gordon et al. (1981). 
However, there appears to be no correlation between size of the prima-
ry tumor and survival. In a large series of 94 patients with stage la, 
no one died with a tumor size less than 10 cm, and only 1 patient with 
a tumor larger than 15 cm died (Gordon et al., 1981). 
4.11.4. Stage 
Long before the international acceptance of a clinical staging 
system it was reported that the prognosis of patients with a dysgerml-
noma was related to rupture of the capsule, infiltration of adjacent 
organs and distant spread (Novak and Gray, 1938). 
For the description of spread at the present time the FIGO staging 
system is used (Table 4.4) 
The FIGO-staging classification was introduced in 1973, making it 
hard to evaluate results based on earlier reported series. However, 
the distinctive description of tumor growth in 3 articles, published 
before 1973, made it possible to use these articles as well to corre-
late stage and survival (Brody, 1961; Melkasian and Symmonds, 1964; 
Asadourian and Taylor, 1969). 
Stage I. Growth limited to the ovaries. 
Stage la. Growth limited to one ovary; no ascites. 
Data from literature concerning the effect of stage la^ on survival 
are summarized in Table 4.10. 
Table 4.10. 5 year survival rate stage la}. 
Author No of 5 year sur-
patients vivaJ. rate {%) 
Brody (19ñl) 
Malkasian and Symmonds ( Ι96Ό 
Asadourian and Taylor (1969) 
Boyes e t a l . (19ΤΘ) 
Gordon et a l . (19S1) 
22 
Ili 
TI 
11* 
86 
91* 
83 
88 
86 
91* 
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Table 4.10 emphasizes the excellent survival rate in patients with 
stage lai· However in cases with a frank rupture of the tumor (Stage 
Ιβ2) the survival rate may drop to only 60% (Brody, 1961). 
However, if only microscopic capsular penetration (stage Іаг) has 
occured the prognosis does not seem to seriously affected, illustrated 
by an 83% (5 out 6 patients) survival rate in such patients (Asadou-
rian and Taylor, 1969). 
lb. Growth limited to both ovaries; no ascites. 
The number of patients with stage lb recorded in literature is 
rather small. The 5 year survival rates range from 50% (7 patients) to 
100% (7 patients) (Asadourian and Taylor, 1969; Gordon et al., 1981). 
Ic. Tumor either stage la of lb, but with ascites present or positive 
peritoneal washInga. 
According to literature ascites has an adverse effect on survival. 
However, because of the low incidence of stage Ic (Table 4.3) these 
data are all based on case reports. (Burkons and Hart, 1977; Krepart 
et al., 1978; Boyes et al., 1978; Freel et al., 1979; Gordon et al., 
1981). Only in one report 5 patients with stage Ic had a 5 year 
survival rate of 100% (Brody, 1961). 
Stage II. Growth involving one or both ovaries with pelvic extension. 
The 5 year survival rates In patients with clinical stage II 
disease range from 60% to 100% (Boyes et al., 1978; Lucraft, 1979; 
Gordon et al., 1981). However, the largest series of patients with 
stage II disease contained only 11 patients (Lucraft, 1979; Gordon et 
al., 1981). 
Stage III. Growth involving one or both ovaries with peritoneal metas­
tases outside the pelvis and/or positive retroperitoneal 
nodes. Tumor limited to the true pelvis with histologically 
proven malignant extension to the small bowel or omentum. 
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Regarding the definition of stage III patients with this stage can 
be divided into two groups with: 
A. Intraperitoneal metastases outside the pelvis. 
Θ. Metastases to the retroperitoneal lymph nodes. 
Till now only one publication has classified patients with stage 
III disease accordingly and compared survival in both groups (De Palo 
et al., 1982). From these data it appears that the actuarial survival 
rate at 4 years in group A was only slightly more than 20%, whereas 
the actuarial survival rate at 4 years for group В amounted to 75%. 
The authors could not supplement a conclusive explanation for this 
observation. 
Others, who did not classify the patients accordingly reported a 
survival rate varying from 55S> to 778 (Lucraft, 1979; Krepart et al., 
197Θ). 
Stage IV. Growth involving one or both ovaries with distant metas­
tases. If pleural effusion is present there must be positive 
cytology to allot а сазе to stage IV. Parenchymal liver 
metastases equals stage IV. 
Stage IV dysgerminoma is seldomly encountered. Incidence and 
survival in this stage have been summarized in Table 4.11. 
Table 4.11. Frequeney and survival of patients with stage TV. 
Author Total No of No of patients Survi-
patients stage IV (?) val 
Taleman et al. (1972) 1? 1 (б) 1 
Boyes et al. (1978) 25 1 (U) 1 
Burkons and Hart (197θ) 13 1 (θ) 1 
Krepart et al. (1978) Зб 2 (6) 
Gordon et al. (1981) 136 1 (1) 
Three patients were considered to be clinical stage IV based on 
positive mediastinal or supraclavicular lymph nodes (Talerman et al., 
1973; Boyes et al., 1978; Burkons and Hart, 1978). 
Krepart et al. (1978) reported a case with parenchymal liver metas 
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tases, while no further information was provided on the remaining 
patient. One patient died after β tranfusion reaction, whereas the 
second patient died with metastases 16 months after diagnosis. 
Gordon et al (1981) did not supply information on their patient in 
regard to location of spread and cause of death. 
4.11.5. Recurrent disease. 
A review of the literature does not disclose conclusive data on the 
risk factors affecting patients with recurrent disease. This is mainly 
due to the small numbers of cases studied. However, to a certain 
extent initial radiotherapy might influence the prognosis of patients 
with recurrent disease (Brody, 1961). In patients with recurrent 
disease in areas treated primarely by low dose radiotherapy a full 
dose of radiotherapy can not be given to those areas. Furthermore, 
radiotherapy will decrease the blood flow in those areas so that 
chemotherapy might be less effective. 
As far as known no data is available whether the time interval 
between primary treatment and occurrence and the location of recurrent 
disease have any effect on the prognosis. 
The 5 year survival rate of recurrent disease varies between 50 and 
75% (Brody, 1961; Malkasisn and Symnonds, 1964; Asadourlan end Taylor, 
1969; Krepart et al., 1978; Freel et al., 1979; Gordon et al., 1981). 
The prognosis of a recurrence after recurrent disease is not very 
good. In one report 4 patients out of 5 died with such a history 
(Krepart et al., 1978). 
4.12. Conclusion. 
The incidence of pure dysgerminoma of the ovary remains unknown. 
This mainly due to the absence of a central cancer registry. 
Most patients (70S) with dysgerminoma of the ovary are in their 
second or third decede, which might partly explain the fact that 
around 14" of these patients are pregnant at the time of diagnosis 
(Talerman, 1977). However, patients with other germ cell tumors with 
the same age distribution do not show this epidemiologic feature 
(Krepart et al., 1978). 
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The signs and symptoms of dysgerminoma of the ovary itself ere not 
indicative to this tumor. However, one should always be suspicious of 
a germ cell tumor in a young patient with a palpable adnexal tumor. In 
these patients a ultrasound examination could confirm the diagnosis of 
an adnexal mass and could probably point into the direction of a 
malignant tumor (Schaffer et al. 1981). Furthermore, if the serum LDH 
levels is increased the differential diagnosis should include dysger­
minoma of the ovary (Awais, 1978, 1983; Friedman et al., 1984). 
An adequate preoperative workup should also include routine labora­
tory procedures and a chest X ray. Furthermore, blood levels of hCG 
and AFP should be determined as to exclude the existence of other qerm 
cell elements producing these tumor markers. 
It is questionable whether a pre-operative lymphangiogram, because 
of its infiltrative nature, is indicated in patients with a suspected 
dysgerminoma of the ovary. However, if the diagnosis dysgerminoma of 
the ovary has been histologically confirmed, a postoperative study, 
especially after conservative surgical treatment, is mandatory. 
The relatively high incidence of early etage disease might reflect 
the less malignant nature of pure dysgerminoma of the ovary (De Lima, 
1966; Kurman and Norris, 1977; Gordon et al, 1981). 
Bilateral disease (stage lb) in dysgerminoma of the ovary is found 
in approximately in lOSS of the cases in contrast to the other malig­
nant germ cell tumors in which bilaterallty is exceedingly rare 
(Kurman and Norris, 1978). The true frequency of bilateral involvement 
in patients with dysgerminoma of the ovary is most likely to be higher 
because of unrecognized microscopic involvement of the contralateral 
ovary. Kurman and Norris (1978) found in 67SS of the patients with 
stage lb the contralateral ovary macroscopically to be affected. 
However, the remaining ЗЗЙ of the patients with stage lb had only 
occult involvement of one of the ovaries detected after histological 
examination. 
The optimal treatment for young patients with unilateral stage lai 
disease remains controversial. One group advocates unilateral sal-
pingo-oophorectomy in these patients to be sufficient, whereas the se­
cond group advocates a more radical approach i.e. total abdominal hys­
terectomy and bilateral salpingo-oophorectomy followed by adjuvant ra­
diotherapy, regardless of extension of disease and age of the patient. 
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In l i terature there i s only one report comparing the treatment 
results of patients with unilateral stage la disease (Asadourian and 
Taylor, 1969). In t h i s report the recurrence rate in the conservati­
vely treated group was s igni f icant ly higher than the radically treated 
group of patients (22S and 12S, respect ively) . However, the survival 
rate in both groups were identical (90й). 
Conservative treatment, as to preserve reproductive capacity, 
should only be carried out i f the prognosis i s not effected in an 
adverse way by th is mode of treatment. Therefore recommendations for 
conservative treatment for patients with pure dysgerminoma might be as 
follows: 
Tabi· 4.IS. Reeamandatiena for oonservative treatment of patiente 
vitíi pure ауедегтіпота of the ovary, 
- Young patient vith the vieh to retain the capacity for future child-
bearing 
- Stage la . dyegerminana (Crcrvth limited to one ovary; no tumor on the 
external surface; capsula intact; no ascites) 
- negative peritoneal vaahings 
- Regative biopsy of the contralateral ovary 
- Begative retroperitoneal lynph node biopsies and/or negative lym-
phangiograa 
- Histologic exanination should only reveal pure dysgerminaaa of the 
ovary and no other aalignant'gens ce l l elenents 
- Extensive and reliable follow up 
There is full agreement on the treatment of patients with clinical 
stage laj dysgerminoma or higher. These patients should be treated by 
a non-conservative therapy i.e. total abdominal hysterectomy and bila­
teral salpingo-oophorectomy followed by radiotherapy. 
The treatment results with chemotherapy are most promising but 
still needs further study. 
The actuarial survival rate of patients with pure dysgerminoma of 
the ovary varies between B3 and 93S stressing the lower malignant 
nature of the tumor (Asadourian and Taylor, 1969; Boyes et al, 1978; 
Lucraft, 1979) Gordon et al, 1981). 
There are conflicting data in literature concerning the effect of 
age and size of the primary tumor on prognosis. Survival appears to be 
adversely affected by initial stage as demonstrated in Table ¿.13 
(Gordon et al., 1981). 
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Table 4.13. Five- and 10 year survival rates for pure dysgerminoma 
of the minyvj * 
  ovary 
Stage 
I 
I I 
I I I 
IV 
*Gordon 
No of 
pa t i en t s 
9U 
11 
7 
1 
et al. (1981) 
Survival 
5 years 
82 (90) 
7 (6U) 
It (57) 
0 ( 0) 
(%) Mo of 
p a t i e n t s 
69 
9 
6 
0 
Survival {%) 
10 years 
55 (82) 
1* (1*5) 
3 (50) 
0 ( 0) 
The causative factors of recurrences are probably related to 
inadequate staging in view of the short interval between primary 
treatment and the development of recurrent disease. However, it could 
also be possible that a recurrence develops by new tumor growth in the 
remaining ovary· 
Frequent and precise follow-up procedures will detect the develop-
ment of recurrent disease, even if there are no complaints of the 
patient whatsoever (Lucraft, 1979). 
Most of the recurrences develop within 2 years after primary treat-
ment, however, in exceptional cases a recurrence develops far beyond 
this period of time, stressing the need for a long term follow up 
(Freel et al, 1979; Gordon et al., 1981). 
The survival rate of recurrent disease varies between 50 - 75S 
(Asadourian and Taylor, 1969; Krepart et al., 1978; Freel et al., 
1979; Gordon et al., 1981). Recurrences are mainly treated by surgical 
intervention and radiotherapy. As the knowledge on chemotherapeutic 
use is gaining, in the near future this mode of adjuvant treatment 
will be probably applied more in patients with recurrent dysgerminoma. 
This survey of the literature on clinical aspects of patients with 
pure dysgerminoma of the ovary renders the possibility to compare 
published data with the findings of the Dutch survey. Moreover, 
possible clinical risk factor in these patients could be studied in 
analogy of those In literature. 
Part II AN ANALYSIS OF CLINICAL AND HISTOPATHOLOGICAL ASPECTS OF 54 
PATIENTS WITH PURE DYSGEHMINOMA OF THE OVARY. 
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Chapter 5. 
CLINICAL ASPECTS OF 5» PATIENTS WITH PURE PYSCERHINOHA ОТ THE OVARY. 
5.1. Introduction. 
In the previous chapters it became obvious that a clinical apprai­
sal of patients with pure dysgerminoma of the ovary renders a number 
of problems mainly due to the retrospective nature of the data because 
of the low incidence of the tumor. However, in cases of rare diseases 
these types of reports are the only data available and could therefore 
be valualable. 
Gordon et al. (1981) reported on 25% of his patients in his series 
(n=136) who needed additional therapy after the development of 
recurrent disease, but it remained unclear how to differentiate these 
patients at the time of primary diagnosia from patients who did not 
develop recurrent disease. This is in agreement with the findings of 
others (Brody, 1961; Asadourian and Taylor, 1969; Talerman et al., 
1973; Krepart et al., 1978; De Palo et al., 1982). 
As yet, the main objective in reporting on patients with pure dys­
germinoma of the ovary should be to Identify which patients are at 
risk for an unfavourable outcome, for this reason clinical aspects of 
patients with pure dysgerminoma of the ovary diagnosed in the Nether­
lands between 1970 and 1981 were subjected to analysis. 
5.2. Materials and methods. 
All patients with pure dysgerminoma of ovary in the aforementioned 
period of time have been registered by the C.B.S.l and the S.M.R.2. 
Ic.B.S.: Centraal Bureau voor de Statistiek. 
Dutch Central Bureau of Statistics. 
2S.M.R.: Stichting Medische Registratie. 
Dutch Bureau for Registration of Medical Data from Hospitals. 
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However, in case of patients with pure dysgerminoma registration by 
these institutions patients appeared to be insufficient as 
these patients were classified as patients with an ovarian 
malignancy. Thus only by an elaborate manner it appeared to be 
possible to obtain data on patients with pure dysgerminoma of the 
ovary. 
A questionnaire on pathology data of patients with pure dysgermi­
noma of the ovary, was distributed among the (60) pathology institu­
tions in the Netherlands. In all, 57 (98Я) of these responded sup­
plying data on 46 patients with supposedly pure dysgerminoma of the 
ovary. 
The Ovarium Tumoren Commissie, which is an advisery board in the 
Netherlands for ovarian malignancies, provided information on another 
7 patients. 
Hereafter, the gynecologists of these patients were asked to co­
operate in supplying clinical information. Finally a questionnaire was 
send to ell the remaining gynecologists in the Netherlands, who sup­
plied clinical and pathology data on 3 more patients. 
As a result of this survey information on 56 patients, with suppo­
sedly pure dysgerminoma of the ovary and diagnosed between 1970 and 
1961, was accumulated. 
After review of the histologic material (Prof. Dr. G.P.Vooys, 
pathologist St. Radboud University Hospital and J.W.R. Meyer, resi­
dent-pathologist St. Radboud University Hospital) of the 56 patients 2 
patients were excluded (undifferentiated ovarian adenocarcinoma in 1 
patient and rhabdomyosarcoma of the ovary in the other patient). At 
the review of the histological material, in all the remaining 54 
patients other neoplastic germ cell elements could be excluded. 
Extensive clinical information and follow-up data were abstracted 
from patient's charts of all 54 patients. 
Clinical stage was based on the revised version of the Cancer Com­
mittee of the FIGO (Kottmeier, 1976) (Chapter 4.6). 
The follow-up varied between 28 months and 156 months. The median 
duration of follow-up was 71.5 months. Three patients (5.6!8) out of a 
total group of 54 patients were lost to follow-up. 
Histological material of these 54 patients was also subjected to 
semi-quantitative and quantitative morphometric studies. The results 
of the latter studies will be dealt with in chapter 6. 
65 
5.3. Epidemiological aspects. 
5.3.1. Age distribution. 
The youngest patient was 5 years of age, the oldest patient 40 
years of age. The median age was 20.5 years. At the time of diagnosis, 
48 patients (895) were less than 30 years of age. 
The age distribution is shown in Figure 5.1. 
Figure 5.1. Age distribution dysgerminoma of the ovary (n=54) 
Number 
18η 
16-
14-
12-
10-
Θ-
6 -
4 -
2-
r 
5-9 | 15-19 
10-14 20-24 30:34 40-44 
Age 
5.3.2. Incidence. 
The total number of patients with pure dysgerminoma of the ovary in 
the Netherlands between 1970 and 1981 amounted to 54. Because of the 
small number of patients the incidence was calculated per 1,000,000 
women instead of the customary 100,000 women. The incidence of pa­
tients with pure dysgerminoma of the ovary during this period of time 
per 1,000,000 women in the Netherlands was 0.72. If corrected for the 
age span of these 54 patients (5 - 40 years) the incidence was 1.18 
per 1,000,000 women. In addition, the incidence per 1,000,000 women 
according to age could be calculated (Fig. 5.2). 
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Figure 5.2. Incidence of patients with pure dysgerminoma of the ovary 
per 1.000.000 women in the Netherlands according to age 
and compared to the incidence of all ovarian malignancies* 
( t щ = logarithm of the incidence rate pure dysgermi-
noma/all ovarian malignancies) 
Rate per 
log scale 1000 000 
" » 2 8 n 
100-1 
10 
1 
01 
001 
0 001 -1 
* Before 1975 each time a patient with ovarian cancer was admitted as 
a new patient. As a result, most of the patients, because of multi­
ple admissions, were classified as many times as the were admitted 
to the hospital. After 1975 only first admissions were registered. 
For this reason in the Netherlands reliable incidence figures of 
ovarian cancer are only available after 1975. However, according to 
data from the CBS and SMR there seems to be no major difference of 
incidences of patients before and after 1975. Therefore the inci­
dence of patients with pure dysgerminoma of the ovary, diagnosed be­
tween 1970 and 1981, could be compared with the incidence of pa­
tients with ovarian cancer diagnosed after 1975. 
5.4. Analysis of clinical data. 
5.4.1. Menstrual history - parity - contraceptive use. 
Nine patients (175!) were premenarchal at the time of diagnosis. 
Forty four patients (81S) were menstruating regularly. One patient 
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(2S) only had monthly withdrawal bleedings due to oral contraceptives. 
She never had a spontaneous menstrual cycle. 
Two patients (4$) were nulliparous primigrávidas before diagnosis. 
Two patients (4S) were primlparous. Nine patients (17S) were multipa-
rous. The remaining 41 patienta (76%) never had been pregnant prior to 
diagnosis. 
Five patienta (93!) were pregnant at the time of diagnosis. In 1 pa-
tient (2%) the tumor was discovered 4 weeks after delivery. This means 
that 6 (US) patients in the present series were either pregnant or 
immediately postpartum at the time of diagnosis. 
5.4.2. Signs and symptoms. 
At the time of diagnosis malignant tumors of the ovary are seldomly 
asymptomatic. The symptoms, however, are often Insidious in onset. The 
same applies for the eigne and symptoms in patients with dysgermlnoma 
of the ovary, which are summarized In Table 5.1. 
Table 5.1. Signs and symptoms in patients with dysgeiminoma 
of the ovary. 
Signs and symptoms No of patients {%) 
Chronic abdominal pain θ (15) 
Acute abdominal pain 3 ( 6 ) 
Palpable abdominal tumor 1 б (30) 
Chronic abdominal pain with tumor 15 (28) 
Acute abdominal pain with tumor 5 ( 9 ) 
Miscellaneous 5 ( 9) 
Incidental finding 1 ( 2 ) 
Unknown 1 ( 2 ) 
A palpable abdominal tumor alone or together with abdominal pain, 
was the most common finding (67%). Abdominal pain, either chronic or 
with a sudden onset was found in 5B% of the patients. In 1 patient 
dysgermlnoma of the ovary was an incidental finding during a routine 
pelvic examination (Table 5.1.). 
In 45 patients the duration of the symptoms was known. Of these 
patients the median duration of the symptoms was 5 weeks. In 96% of 
6В 
the patients the duration was less than 6 months. One patient had 
vaque abdominal tenderness for 1 year before the dysqerminoma was 
detected. 
5.4.3. Diagnostic procedures. 
As the present series had a retrospective nature no uniformity can 
be expected in regard to diagnostic procedures. The analysis covers 
both pre- and postoperative diagnostic procedures. 
5.4.3.1. Laboratory findings. 
In 4 (72) patients no laboratory tests were performed. In 4 (75) 
additional patients the results of the test could not been traced. 
Routine laboratory procedures i.e. haematology tests, renal and 
liver function tests were performed in 46 patients (86$). 
Laboratory procedures gave normal values in 29 patients (638>). In 
16 cases (35Й) high levels were found for the erythrocytes sedimention 
rate (ESR). 
In 2 patients liver function tests were abnormal. In both cases 
alkaline phosphatase serum levels were unexplicably elevated. In 1 
patient serum Creatinin levels were elevated. On preoperative intra­
venous urography no abnormalities could be found. Subsequently this 
biochemical abberration cannot easily be explained. 
The laboratory tests in the present series did not reveal gross ab­
normalities apart from an elevated ESR in 35% of the patients. 
5.4.3.2. Tumor markers. 
In 6 patients human chorionic-gonadotropin (hCG) levels were deter­
mined before operation. Of these, 2 patients had increased levels. 
However, by light microscopic examination and using anti-hCG peroxi­
dase techniques trophoblastic elements and particularly syncytiotro-
phoblast cells could not be demonstrated in the histologic material of 
these patients. 
In 1 of these 2 patients serum levels of hCG were not determined 
after operation. In the second patient serum levels were normal after 
operation. 
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Serum levels of lactic dehydrogenase (LDH) were determined pre- and 
postoperatively in 24 patienta (Table 5.2). 
In 8 patients (33%) serum levels of LDH were found to be normal 
before and after operation (Table 5.2.). 
In 16 patients (67%) elevated serum levels of LDH were found before 
operation. Of these, 14 patients had normal levels after operation and 
the remaining 2 patients had persistlngly high levels after operation 
(Table 5.2.). Both patients had clinical stage IV dysgermlnoma and 
residual tumor after operation. 
Table 5.2. Pre- and postoperative LDH аетгіт levels in 
patients uith dysgerminoma of the ovary. 
No of patients LDH serum levels 
( 11=21. ) 
Preoperative Postoperative 
θ 
lit t 
2 t t 
(= normal value; + elevated level) 
These findings suggest, that, although by no means specific for 
pure dysgerminoma of the ovary, LDH determination might be an usefull 
tool for pre- and postoperative evaluation of such patients. 
Serum levels of LDH iso-enzymes 1 to 5 were only determined in a 
few cases. No specific pattern could be recognized in the present 
series of patients. However, persistlngly high levels of iso-enzyme 1 
through 5 were found in 2 patients who had residual disease after 
operation. Both patients had clinical stage IV. 
5.4.3.3. Radiological examination. 
5.4.3.3.A. Chest X-ray. 
In 41 patients a chest X-ray was made pre-operatively. Of these, 
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chest X-rays of 38 patients (93S) showed no abnormal changes. The re­
maining 3 patients (7%) had pathologic findings. 0Γ these, 2 patients 
were thought to have distant spread to mediastinal lymph nodes. One 
patient had an abnormal chest X-ray due to préexistent tuberculosis. 
5.4.3.3.B. Lymphanqioqraphy. 
Lymphangiography was performed in 2Θ patients. All but one were 
post-laparotomy studies. 
Negative lymphangiograms were found in 21 patients (75Й). 
In the remaining 7 patients (25*) suspicious lymph nodes were found 
either along the iliac and/or para-aortal vessels. Of these, 4 pa­
tients had stage I, 1 patient had stage II and the remaining 2 pa­
tients had stage III at operation. 
One patient underwent a lymphangiogram 4 weeks after her first ope­
ration (Unilateral salplngo-oophorectomy). This lymphangiogram showed 
suspicious lymph nodes along the iliac vessels. She then underwent a 
second laparotomy (Total abdominal hysterectomy with removal of the 
remaining adnex, omentectomy and sampling of retroperitoneal lymph 
nodes). Histologic examination of the lymphangiographic suspicious 
lymph nodes however, did not show metastatic disease. 
In the remaining 6 patients no attempt was made to obtain a histo­
logic confirmation of the abnormal findings on postoperative lymphan­
giography. However, treatment design was consequently adapted to the 
abnormal lymphangiogram in these 6 patients (adjuvant therapy). 
5.4.3.3.C. Miscellaneous radiologic studies. 
Intravenous urography (IUG) was done in 16 patients. In 2 of these 
patients (138) IUG showed replacement of one of the ureters by tumor-
growth without hydronephrosis. In the remaining 14 cases {67%) no 
abnormalities were found. 
In 4 cases a plain film of the abdomen was taken. None of these 
showed abnormalities and subsequently added no information to the 
clinical findings. 
Ultrasonography was performed in 11 patients. In all cases the 
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clinical finding of a pelvic tumor of apparently adnexal origin could 
be confirmed. In 2 patients their echoscopist suggested the existence 
of a malignancy based on a large solid adnexal tumor with localized 
small echofree zones. 
A large bowel contrast study was performed in 6 patients. Intesti­
nal tract was replaced by the tumor mass in all patients· In all cases 
It seemed unlikely that the existing tumor did arise from the 
intestinal tract. 
Other postoperative radiologic studies included liver scan (6 pa­
tienta), computed tomography (CT) scan of the abdomen (2 patients), a 
scan of the spleen (1 patient) and a bone scan (1 patient). None of 
these procedures revealed abnormalities. 
5.4.4. Pre-existing abnormalities. 
In 2 patients a congenital deformation of the uterus was found at 
operation. Both patient had a bicornal uterus. 
In 4 patients chromosomal studies were performed. Of these, 3 pa­
tients had a normal chromosomal configuration. The chromosomal study 
in 1 patient revealed a 46,XY-conflguration. Histologic examination of 
the gonads did not reveal signs of the existence of gonadoblastoma. 
One other patient, who was 37 years of age at the time of diagno­
sis, never had a spontaneous menstrual bleeding prior to diagnosis. 
She only had monthly withdrawal bleedings due to oral contraceptives. 
No further investigations were done in this patient аз to detect the 
cause of this abnormal finding. 
5.4.5. Clinical stage. 
In 31 patients (578) the diagnosis was made before 1976, for which 
reason these patients had to be staged retrospectively by the author 
according to the revised version (1976) of the FIGO staging classifi­
cation (Chapter 4.7), using the operation notes and charts available. 
In 9 patients (.17%) diagnosed after 1976 the clinical stage had not 
been recorded in their charts. These patients were also staged retro-
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spectively. In the 14 remaining patients (26%), in which the tumor was 
diagnosed after 1976, clinical stage was recorded in their charts. On 
review, the original staging in these patients could be confirmed. 
At the time of diagnosis, stage I disease was found in 34 patients 
(63S). Stage II was found in 9 patients (17$). Stage III was found in 
9 patients (17Й), whereas, the remaining 2 patients (4Ж) had clinical 
stage IV (Table 5.3). 
Table 5.3. Clinical stage (FIGO) in 54 patients with pure 
dysgerminoma of the ovary 
Clinical stage (FIGO) 
I 
II 
III 
IV 
Total No of pati ents 
No of patients (%) 
3k (63) 
9 (17) 
9 (17) 
2 ( 1*) 
SU 
Of 34 patients with stage I disease 29 patienta (85SS) had stage la. 
In the remaining 5 patients (15%) with stage I either ascites was pre­
sent or peritoneal washings during operation were positive so that 
these patients were staged as stage Ic. None of the patients had stage 
lb (Bilateral disease without ascites) (Table 5.4), although one of 
the patients with stage Ic did have bilateral involvement of the 
ovaries. 
Table 5.4. Distribution of stage Ia,Ib,Ic within the group 
of patients with stage I dysgerminoma of the 
ovary (N =34) 
Stage 
la 
ІЪ 
Ic 
Total no of patients 
No of patients (%) 
29 (85) 
0 (ou) 
5 di) 
31· 
Stage lai was found in 25 patients (BS30 of 29 oat-.enH with 
clinical stage la, whereas 4 patients (14$) had sta^e Ia2· 
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Nine patients had clinical stage II. Of these, 3 (33») had stage 
Ha, 1 patient (11%) had stage lib, whereas the remaining 5 patients 
(56%) with stage II had ascites and were subsequently stage H e . 
Patients with clinical stage III were classified either with only 
positive retroperitoneal lymph nodes (4 patients) or with intraperito­
neal spread Irrespective whether positive retroperitoneal lymph nodes 
were present or not (5 patients). 
Two patients of the present series had stage IV, based on wide­
spread intraperitoneal and retroperitoneal disease together with his­
tologically confirmed mediastinal and supraclavicular lymph node meta­
stases. 
In 28 of the patients (52Й) disease was confined to the right ova­
ry. In 14 patients (26%) dysgerminoma was found only in the left ova­
ry. In the remaining 12 patients (24Ï) both ovaries were involved. One 
of these patients had stage Ic disease, whereas the remaining 11 pa-
tients all had metastatic disease. 
5.4.6. Treatment. 
5.4.6.1. Primary surgical treatment. 
All patients were treated primarily by surgery (Table 5.5). 
Table 5.5. Primary surgical treatment of dysgerminoma of 
the ovary related to clinical stage. 
Operation 
USO 
TAH-USO 
ΤΑΗ-ΒΞΟ 
TAH-BSO-0 
TAH-BSO-D 
Total 
I 
32 
1 
1 
31* 
II 
It 
1 
2 
2 
9 
Stage 
III 
5 
3 
1 
9 
IV 
2 
2 
Overall (%) 
Щ (76) 
1 ( 2) 
θ (15) 
3 ( 5) 
1 ( 2) 
su 
USO: unilateral salpingo-oophorectoniy; TAH-BSO: total abdo­
minal. hysterectomy with bilateral salpingo-oophorectomy; 
0: omentectomy; D: debulking procedure. 
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The most common (32 patients) treatment in patients with clinical 
stage I was unilateral salpingo-oophorectomy (USO). USO as a primary 
procedure was used in stage II in 4 patients while in stage III 5 pa­
tients were treated by USO (Table 5.5). 
The high percentage of unilateral salpingo-oophorectomy indicates a 
tendency to a more conservative approach notably in patients with ear­
ly stage disease. 
In 7 stage I patients who underwent USO also biopsies were taken 
from the contralateral ovary revealing bilateral disease in 1 patient. 
This patient also had ascites and was subsequently staged as stage Ic. 
In none of the remaining 6 patients the biopsies revealed evidence of 
disease. 
In 4 patients with unilateral disease who underwent USO samples 
were taken from retroperitoneal lymph nodes, revealing metastatic 
disease in 3 patients. 
Total abdominal hysterectomy with bilateral salpingo-oophorectomy 
(TAH-BSO) was used once in stage I, twice in stage II and IV and three 
times in stage III. In 3 of these patients samples were taken from re­
troperitoneal lymph nodes, revealing metastatic disease in 2 patients 
with clinical stage III. 
TAH-BSO and omentectomy were once performed in stage I and twice in 
stage II. TAH-BSO and a debulking procedure were performed in 1 pa­
tient with stage III with intraperitoneal spread. 
A ТАН-USO was performed in 1 patient with stage II. 
In 3 patients a second laparotomy was done shortly after primary 
surgical treatment (USO). In 1 of these (stage Ic), postoperative lym­
phography revealed suspicious iliac lymph nodes and subsequently TAH-
USO and omentectomy were performed 4 weeks after the first operation. 
The 2 remaining patients with clinical stage III underwent a TAH-BSO 2 
and 3 weeks, respectively after the first operation (USO). To prevent 
double counting, all 3 patients were classified according to their 
last surgical treatment, because of the short interval between the 
first and second operation. 
5.4.6.2. Postoperative treatment. 
In all, 26 patients (48S) were treated postoperatively. Of these, 
20 patients (37Й) received radiotherapy only (Table 5.5). 
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Table 5.6. Postoperative therapy in dysgemànoma of the 
ovary related to stage and primary surgical 
treatment. 
O p e r a t i o n 
USO 
TAH-BSO 
TAH-BSO-0 
TAH-BSO-D 
T o t a l 
( n - 2 6 ) I 
Τ 
_ 
_ 
-
7 
XT 
P o s t o p e r a t : 
I I - I V 
6 
4 
1 
1 
13 
I 
2 
_ 
_ 
-
2 
ive t h e r a p y 
ста 
I I - I V 
: 
_ 
_ 
-
1 
XT. 
I 
_ 
_ 
_ 
-
-
-CTH 
I I - I V 
2 
1 
3 
XT = radiotherapy ι CTH = chemotherapy. 
Three patients (6S) received chemotherapy, while 3 other patients 
(6S) received combination adjuvant therapy (radiotherapy and chemo­
therapy). 
Of the 32 patients with stage I who underwent USO, 9 patients 
received additional therapy. Of these, 7 received radiation therapy 
and the remaining 2 patients received chemotherapy (Table 5.6). 
In stage II to IV 17 patients (85S) out of 20 patients received 
adjuvant therapy. In stage IV both patients received combined radio­
therapy and chemotherapy (Table 5.6) 
A. Radiotherapy. 
Postoperative abdominal radiotherapy was used in 15 patients. Of 
these, 3 were treated by moving strip technique, while the remaining 
12 patients were treated by open field technique. 
Of the patients treated by moving strip technique 1 recieved a sur­
dosage to the para-aortic lymph nodes. 
Of 12 patients treated by open field technique 9 received additio­
nal irradiation to the pelvis. Of the latter group in 2 patients 
(both stage III with spread to the retroperitoneal lymph nodes), the 
mediastinal and left supraclavicular lymph nodes were irradiated as 
well, and in 1 of these patients the para-aortic lymph nodes were also 
irradiated. 
Of the remaining 8 patients with radiation therapy 5 patients re­
ceived irradiation to the pelvis (1 patient also received radiotherapy 
to the higher iliac and para-aortlc lymph nodes), whereas the remai-
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ning 3 patients received irradiation to the iliac, para-aortic, 
mediastinal and left supraclavicular lymph nodes. 
B. Chemotherapy. 
In all, 6 patients received postoperative chemotherapy. Of these, 2 
patients (stage I) were succesfully treated by USO followed by single 
agent alkylating therapy (Melphalan, chlorambucil), whereas another 
patient (Stage III retroperitoneal disease) developed recurrent di­
sease after USO and adjuvant chemotherapy (Melphalan). 
In one patient (stage III intraperitoneal disease; TAH-BSO) a com­
plete remission was reached with combination chemotherapy (vinblas­
tine, bleomycin and cisplatinum) after developing progressive disease 
with radiotherapy. 
The remaining 2 patients (stage IV; TAH-BSO) with chemotherapy also 
had progressive disease with radiotherapy. Both patients had no res­
ponse with several several combinations of chemotherapy and sub-
seguently died of disease. 
5.4.6.3. Secondary treatment. 
Secondary treatment related to dysgerminoma of the ovary was per­
formed in 11 patients. Surgery was performed in 7 patients as a treat­
ment of recurrent disease. Surgical evaluation of adjuvant therapy in­
dicated secondary surgical treatment in the 4 remaining patients. 
In 3 patients USO was performed. One of these also underwent omen­
tectomy. 
Five patients underwent ТАН-USO. Of these, 2 patients also under­
went an omentectomy and 1 patient underwent a debulklng procedure 
together with a TAH-USO. 
All 7 patients who underwent secondary surgical treatment for 
recurrent disease also recieved additional therapy. Four of these 
recieved radiation therapy. The remaining 3 patienta received chemo­
therapy (vinblastine, bleomycin, cisplatinum in 2 patients and cyclo­
phosphamide in 1 patient). 
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5.4.7. Menstrual history and fertility after primary treatment. 
A. Menstrual history after primary treatment. 
At the time of diagnosis 44 patients (BIS) were postmenarchal. Of 
these, 12 underwent a TAH-BSO as primary surgical treatment, leading 
to an amenorrhoeic status in these patients. As a result the remaining 
32 patients are eligible for analysis of the menstrual status after 
treatment. 
Of this group of patients 18 underwent an USO without any adverse 
effect on the menstrual status. However, of the 11 patients who 
received additional radiotherapy only 2 (185) had a normal menstrual 
cycle after completion of therapy whereas the remaining 9 (B2S) were 
amenorrhoeic after treatment (Table 5.7). 
Only 3 patients received additional chemotherapy. Two patients 
(67Й) had regular periods after completion of therapy, whereas the 
remaining patient became amenorrhoeic after treatment (Table 5.7). 
Table 5.7. Menstrual status after therapy (n=32) . 
Treatment 
USO 
USO-XT 
USO-CTH 
No of 
patients 
18 
11 
3 
Menstrual 
cycle {%) 
18 (100) 
2 ( 18) 
2 ( 67) 
Amenorrhoea 
(*) 
9 (82) 
1 (33) 
USO: Unilateral salpingo-oophorectomy; XT: Postoperative ra­
diotherapy; CTH: Postoperative chemotherapy. 
B. Fertility after primary treatment. 
Of the aforementioned 32 patients 9 (28S) became pregnant 22 times. 
Twenty children (91S), all without congenital deformations were deli­
vered. In 2 occasions a miscarriage occured. 
One patient became pregnant after postoperative radiotherapy (Irra­
diation to the pelvis 2.4 Gy) and subsequently delivered a male infant 
at a gestational age of 32 weeks. The remaining 3 patients who had 
regular periods after postoperative therapy did not become pregnant. 
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5.4.8. Overall survival. 
In the present series 5 patients died from disease. These patients 
all died within 2 years after diagnosis. 
One patient died from intercurrent disease. The cause of death was 
a massive gastro-intestinal bleeding due to a severe thrombocytopenia 
as a complication of an acute lymphoblastic leukemia. This patient is 
not taken into account considering the overall survival rate. 
Figure 5.3. Overall actuarial survival rate dysgerminoma of the ovary 
(n=54) 
100 
90- ' 
80-
70-
Ο Ι ι 1 1 1 1 1 1 ι 1 Г 
1 2 3 4 5 6 7 Θ 9 10 
Years from diagnosis 
The corrected o v e r a l l a c t u a r i a l s u r v i v a l r a t e amounted to 90S at 5 
and 10 years a f t e r diagnosis ( F i g . 5 . 3 ) 
The corrected a c t u a r i a l 5 and 10-year survival r a t e for p a t i e n t s 
with stage I was 94S and for p a t i e n t s with stage l a i these were both 
96$. The a c t u a r i a l 5 and 10-year s u r v i v a l r a t e for p a t i e n t s with stage 
I I - I V was 86$. 
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5.Α.9. Recurrent disease. 
In all, 11 patients developed a recurrence. Ten patients developed 
recurrent disease between 2 months and 44 months after completion of 
treatment. One patient had a recurrence in the remaining ovary 77 
months after completion of treatment. The overall recurrence free 
interval rate was 76% (Fig. 5.5). 
Figure 5.5. Overall recurrence-free interval rate (n=54) 
7 8 9 10 
Years from diagnosis 
In 7 patients (64$) a recurrence was discovered following the com­
plaints of these patients, whereas in 4 patients 06%) recurrent di­
sease was discovered during routine follow up examination, without the 
patients having complaints whatsoever. 
In 9 patients recurrent disease was found in para-aortic lymph 
nodes (5 patients) and/or in supraclavicular lymph nodes (4 patients), 
and 3 of these 9 patients developed recurrent disease together with 
Intraperitoneal spread (Table 5.Θ). 
Two patients (both stage lai) bed a recurrence in the remaining 
ovary following USO. In 1 of these recurrent disease developed In the 
remaining ovary together with spread within the pelvis, while the 
во 
second patient had recurrent disease in the remaining ovary only 
(Table 5.8). 
Table 5.8. Location of recurrent disease in dysgernrinoma 
of the ovary (n=ll). 
Location No of patients 
Remaining ovaiy 2 
Pelvis 1 
Para-aortic nodes 5 
Supraclavicular nodes h 
Intraperitoneal 3 
Three patients with recurrent disease died after secondary treat­
ment. The 5 year survival rate of patients with recurrent disease was 
738. 
5.5. Prognostic factors. 
To provide a better understanding of the prognosis of patients with 
pure dysgermlnoma of the ovary clinical data were correlated with 
stage at the time of diagnosis, recurrent disease and survival. 
As has been mentioned previously 6 patients died in the present 
series. Of these 1 patient died of non-related intercurrent disease 
(leukemia), and had been disregarded concerning survival rate, which 
therefore represents the corrected survival rate. 
Clinical factors (Chapter 4) which might influence prognosis are: 
- Age at the time of diagnosis. 
- Duration of symptoms. 
- Pregnancy at time of diagnosis. 
- Clinical stage at the tine of diagnosis. 
- Size of the primary tumor. 
- Primary treatment. 
- Size of residual disease after primary surgery. 
The outcome of 54 patients In the present series has been summa­
rized in Table 5.9. 
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Tabi· б.В. Outcome of S4 patiente with pure аувдеттіпопа of the ovary, 
5b patients- -•Ίΐ alive without recurrent disease 
-• 2 persistent diseaae ^ 2 deaths 
-• 11 recurrent diseaae • 3 deaths 
5.5.1. Age at the time of diagnosis and prognosis. 
To determine the effect of age at the time of diagnosis on progno­
sis the patients were divided into two groups: patients below the me­
dian age (20.5 years) and those above the median age. 
To avoid small age groups other age classifications were not taken 
into consideration for analysis. 
When age is correlated to stage no differences are obvious. Also 
the recurrence rate is egual in both age groups (Table 5.10). 
Tabla S.10. Correlation of age0 with clinical etage, recurrent disease 
and mortality. 
Age Stage Recurrences 5 year aorta-
I II III IV (¡0 lity (Ï) 
«20.5 yrs (n-2T) 19 2 6 - 5 (JB.?) í ( 3.7) 
>20.5 yrs (n»27) 15 7 3 2 6(22.2) MlU.8) 
Above and below the median age (20.S yrs). 
The survival rate at 5 years in the younger age group (younger than 
20.5 years) is higher compared to the 5 year survival rate of the 
older age groep (Table 5.10; Fig. 5.4), which is partly caused by the 
fact, that both patients with persistant disease were above the median 
age. It should be noted that these small groups prevent any relialable 
statistical analysis. 
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Figure 5.4. Five year survival rate related to age. 
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5.5.2. Duration of symptoms and prognosis. 
In 45 patients the duration of symptoms was known. These patients 
were divided by the median duration which was 5 weeks into 2 groups: 
those patients with a duration of symptoms shorter (22 patients) and 
those with a duration longer than 5 weeks (23 patients). 
There appeared to be no difference for these 2 groups if related to 
stage, and recurrent disease. 
The survival was hard to compare as the duration of symptoms of the 
5 patients who died of disease was known in only 3 cases. 
5.5.3. Pregnancy at the time of diagnosis and prognosis. 
Six patients were either pregnant at the time of diagnosis (5 pa­
tients) or immediate post partum (1 patient) at the time of diagnosis. 
Stage, treatment and outcome of these patienta have been summarized in 
Table 5.11. 
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Table 5.11. Correlation between pregnancy at the time of 
diagnosis and clinical stage, treatment, re­
current disease and survival, 
Stage 
l a i 
l a , 
I c 
I c 
I I I 
I I I 
Treatment 
USO 
USO 
USO-XT 
USO 
TAH-BSO 
USO 
R.D. S u r v i v a l 
l o s t t o f o l l o w up 
+ + 
_* 
+ 
+ 
+ + 
4Includes 1 patient 4 weeks postpartum, 
Intercurrent death (leukemia). 
R.D. Recurrent disease¡ USO: unilateral salpingo-oopho-
rectomy; BSO: Bilateral salpingo-oophorectomy; XT: Radia 
tiontherapy. 
One patient with stage Ic underwent USO and had biopsies taken from 
the contralateral ovary, which showed disease. During operation this 
ovary did not show macroscopic disease. She then received irradiation 
to the pelvis and to the abdomen (open field technique). This patient 
died 20 months after completion of treatment following a massive 
gastro-intestlnal bleeding due to a severe thombocytopenia as a com-
plication of an acute lymphoblastic leukemia. An autopsy was not per-
mitted. However, at the time of her death the patient was without evi-
dence of clinical disease. 
Two patients had a recurrence after primary treatment. One patient 
(pregnant at the time of diagnosis) with stage III (retroperitoneal 
and intraperitoneal disease) had a recurrence 5 months after treatment 
(USO). She then underwent a TAH-USO and a debulking procedure followed 
by radiotherapy and is alive and well 45 months after diagnosis. 
Another patient with clinical stage lai at t h e t i m e o f diagnosis 
had recurrent disease 11 months after completion of primary treatment 
(USO). Metastatic disease was found in a left supraclavicular lymph 
node. She subsequently underwent a TAH-USO and omentectomy followed by 
irradiation to the pelvis, and the para-aortic, mediastinal and supra-
clavicular lymph nodes and is without evidence of disease 111 months 
after diagnosis. 
Tentativily, because of the small number of patients, it could be 
concluded that the recurrence rate (33S) in these 6 patients is high 
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compared to that (9/48=1951) of the group of non-pregnant patients but 
that the survival rate (100%) is excellent. 
5.5.4. Stage and prognosis. 
In the present series there appeared to be no correlation between 
clinical stage and prognosis although both patients with stage IV died 
from disease. Eight patients (24%) with stage I had a recurrence, and 
2 of these patients (6%) died of disease (Table 5.12). 
Table 5.12. Correlation of clinical stage with reaurrent 
disease and mortality. 
Stage No of patients R.D. (.%) Mortality (%) 
I 31* θ (2U) 3V( 9) 
II 9 1 (11) 1 ( 11) 
III 9 2 (22) - ( 0) 
IV 2 - ( 0) 2 (100) 
R.D.: Recurrent disease. 
^Includes 1 intercurrent death (Leukemia). 
Of the patients with stage I who had recurrent disease 7 had stage 
lai· The remaining patient had clinical stage Ic. 
In stage II one patient developed a recurrence (intraperitoneal and 
supraclavicular) after 9 months and died 17 months after completion of 
primary treatment (TAH-BS0-XT). 
In stage III 2 patients had recurrent disease 5 and 9 months, res­
pectively after completion of treatment. Both patients were alive and 
well without evidence of disease 45 and 54 months, respectively after 
completion of primary treatment. 
Both patients with clinical stage IV were never without disease and 
subsequently died 2 and 4 months after completion of treatment. 
5.5.5. Treatment and prognosis. 
In stage I 23 patients underwent USO. Of these, 8 (35%) developed 
recurrent disease. Of the latter group of patients, 2 (22 %) died 
(Table 5.13). 
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Table 5.13. Primare/ treatment correlated with stage, recur­
rent disease and mortality. 
Stage Treatment Ho of B.D. Morta l i ty 
p a t i e n t s (%) (І) 
8 ( 35) 2 ( 9 ) 
1V( lit) 
I I 
IV 
uso 
USO-XT 
USO-CTH 
TM-BSO±0 
USO 
USO-XT 
TAH-USO 
TAH-BSO-0-XT 
TAH-BSO-XT 
TAH-BSO-0-
XT-CTH 
uso 
TAH-BSO-XT 
TAH-BSO-D-XT 
USO-XT 
USO-CTH 
TAH-BSO-
XT-CTH 
23 
τ 
2 
2 
1 
3 
1 
1 
2 
1 
1 
3 
1 
3 
1 
2 
1 ( 50) 1 ( 50) 
I I I USO  1 (100) 
1 (100) 
2 (100) 
vIntercurrent death (leukemia); R.D.: recurrent disease; 
USO: unilateral salpingo-oophorectomjr; TAH: total abdominal 
hysterectony ; BS0: bilateral salpingo-oophorectomy; 0: omen-
tectomy; D: debuUcing procedure; XT: Radiation therapy; CTH: 
Chemotherapy. 
From the data from table 5.13 it appears to be difficult to draw 
conclusions concerning the effect of treatment of patients with dys-
germinoma of the ovary on prognosis as the number of patients in 
higher stages than stage I are rather low. 
In stage I nine patients underwent an USO followed by either radio­
therapy (7 patients) or chemotherapy (2 patients). In 2 additional pa­
tients a TAH-BS0 was performed. In 1 patient an omentectomy was per­
formed, while the other patient had a TAH-BS0 only. Both patients sur­
vived without recurrent disease (Table 5.13). 
In 18 patients with clinical stage II and III recurrent disease was 
found in 3 patients (8%). In 1 patient a recurrence developed after 
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TAH-B50 followed by radiotherapy. Another patient had recurrent di­
sease after USO only. The remaining patient developed recurrent disea­
se after USO and chemotherapy (Table 5.13). 
In stage IV two patients died with persistent disease. These pa­
tients died 2 and 4 months, respectively, after completion of treat­
ment, which consisted of a TAH-BSO followed by radiotherapy and chemo­
therapy (Table 5.13). 
In stage lai ^ 9 patients underwent USO. Of these, 7 patients (37S) 
developed recurrent disease. Six patients with stage lai disease had a 
more extensive treatment and none developed a recurrence. Of the re­
maining 9 patients with stage I five patients (2 stage Іаг; 3 stage 
Ic) underwent USO and 4 patients (2 stage Ia2> 2 stage Ic) underwent a 
more extensive treatment. One patient with stage Ic who underwent USO 
developed recurrent disease (Table 5.14). 
Table 5.14. Treatment results in stage I dysgerminoma, 
Treatment Stage No of patients R.D. (?) Mortality {%) 
USO la-, 19 
Ext.treatm. la-] 6 
USO laj 2 
Ext.treatm. Ia2 2 
USO Ic 2 
Ext.treatm. Ic 3 
Intercurrent death. Ext.treatm.: Extensive treatment includes USO 
followed by either radiotherapy or chemotherapy, or TAH-BSO ± Omen-
Lectoray. 
The overall mortality rate of patients treated with USO only was 9Ж 
(23/2), whereas in the group of patients with extended treatment no 
patient died of disease. 
USO only was compared with USO followed by either radiotherapy or 
chemotherapy (Table 5.15). 
7 (37) 1 ( 5) 
1 (50) 1 (50) 
1 V (33) 
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Table 5.15. Comparison of USO only and USO followed by additional 
therapy related to stage, recurrent disease and mor­
tality. 
T r e a t m e n t 
USO 
T o t a l 
USO-XT/CTH 
T o t a l 
S t a g e 
I 
I I - I I I 
I 
I I - I I I 
No of 
p a t i e n t s 
23 
2 
25 
9 
7 
16 
R.D. (%) 
8 (35) 
J (50) 
9 (36) 
1 ~ T 0 
1 ( 6) 
M o r t a l i t y ( ? ) 
2 ( 9) 
3 (12) 
Ли) 
1 ( 6 ) 
intercurrent death (Leukemia). R.D.: recurrent disease; USO: uni­
lateral salpingo-oophorectoiny; XT: Radiotherapy; CTH: Chemotherapy. 
From the data from Table 5.15 it appears that in the present series 
there exists a considerable difference in outcome between patients 
treated by USO and those treated by USO followed by additional 
therapy. This is even more evident, when the stage distribution of the 
2 treatment groups is taken into account. 
USO only was mainly (23 patienta) used in stage I. There were two 
exceptions: one patient with clinical stage Π was treated by USO and 
one patient, who was pregnant at the time of diagnosis, with stage III 
was treated by USO. 
USO followed by either irradiation or chemotherapy was used in 9 
patients with stage I and in 7 patients with stage II and III. 
5.5.6. Size of the primary tumor and prognosis. 
To determine the influence of the size of the primary tumor on 
prognosis the patienta were classified according to tumor size (Table 
5.16). 
Tumor size was recorded In the pathology reports of 51 patients. In 
3 cases tumor size was not recorded. The smallest tumor found was 6 cm 
in diameter in a patient with clinical stage lai· The largest solitary 
tumor found measured 29 cm in diameter in β patient with clinical 
stage Ic. 
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Table 5.16. Size of the timón· correlated uith stage, récur-
rent disease and mortality. 
No of p a t i e n t s 
+6-10 
6 
Tumor s ize (cm) 
11-15 16-20 21-25 
15 ^0 5 
>2b 
5 
UnXno-vm 
3 
Stage I 3 8 17 't 1 1 
I I 2 2 3 - - 2 
I I I 1 5 - 1 2 -
IV 2 
H.D. 
№ 
M o r t a l i t y 
(*) 
1 
( I T ) 
1 
(17) 
3 
(20) 
-
-
k 
(20) 
1 * 
( 5) 
1 
(20) 
1 
(20) 
1 
(20) 
3 
(60) 
1 
-
-
R.D. Recurrent disease; vIntercurrent death (leukemia); 
No tumor less than 6 cm had been found. 
There was no correlation between tumor size and clinical stage or 
recurrent disease. Both patients however, with clinical staqe IV had a 
tumor size larger than 25 cm (Table 5.16). 
One patient with a tumor size of 9 cm died, and two other patients 
with a tumor size of 17 and 24 cm, respectively died. In the group of 
patients with a tumor mass larger than 25 cm Э patients died (Table 
5.16). 
5.5.7. Residual tumor after initial operation and prognosis. 
In 44 patients no residual tumor remained after operation. Residual 
tumor less than 2 cm in diameter was present after initial operation 
in 3 patients, whereas in 2 other patients residual timor greater than 
2 cm in diameter was present after initial surgical treatment. In 2 
patients residual tumor was present after operation, however its size 
was not recorded. In 3 patient the possible presence of residual tumor 
after initial operation was not recorded at all. 
Of the 44 patients without residual timor after initial operation 4 
patients (10%) died. Of these 3 died of disease, whereas the 4th 
patient died of Intercurrent causes (leukemia). 
All 3 patients with residual tumor less than 2 cm In diameter sur-
vived after completion of adjuvant therapy. Conversely, both patients 
with residual disease greater than 2 cm in diameter died in spite of 
extensive adjuvant therapy. Both patients had clinical stage IV. After 
surgical treatment enlarged mediastinal lymph nodes with histological-
ly proven dysgermlnoma greater than 2 cm in diameter remained behind. 
Two patients with residual tumor without known size both survived. 
It could be tentativlly concluded that in patients with residual 
disease greater than 2 cm the prognosis is adversely affected. 
5.6. Discussion. 
The incidence of pure dysgermlnoma of the ovary has never been cal-
culated because of the lack of a central cancer registration in moat 
countries. However, based on the comparison with the incidence of 
other ovarian malignancies it has always been assumed that dysgerml-
noma is a rare tumor compared to the other ovarian malignancies (Asa-
dourian and Taylor, 1969). The age distribution of the present series 
is in agreement with previous publications (Brody, 1961; Asadourian 
and Taylor, 1969; Krepart et al., 1978). The Incidence of pure dyager-
minoma related to age increases with age. However, as could be expec-
ted, the age related incidence as a proportion of all ovarian malig-
nancies shows a downward trend with Increasing age. 
The age distribution illustrates, pure dysgermlnoma of the ovary to 
be a malignancy of the young. 
Dysgermlnoma was diagnosed in 6 patients (11.6%) who were either 
pregnant or shortly postpartum at the time of diagnosis. This figure 
is in agreement with previous reports (Brody, 1961; Jackson, 1969; 
Asadourian and Taylor, 1969). Notably, patients who are pregnant at 
the time of diagnosia represent a complex problem. Firstly, a staging 
laparotomy could be hampered by the enlarged pregnant uterus. Second-
ly, there Is the ethical problem whether to terminate the existing 
pregnancy or not in case the surgeon is contemplating nonconservative 
treatment. 
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The relatively short median duration (5 weeks) of the signs and 
symptoms is similar to the findings of De Palo et al. (1982). The 
short duration of the signs and symptoms correlated with the relati­
vely large tumor size found does not necessarily mean that dysgermi-
noma is a fast growing ovarian tumor. It might be possible, that a 
slow growing tunoг could Invoke a habituation leading to the detection 
of an already relatively large tumor at the time of diagnosis. As has 
been mentioned earlier Hain (1947) reported endocrine manifestations 
(pubertas precox) lasting 2 years in a patient with dysgerminoma of 
the ovary. 
Abdominal pain (58.5S) and a palpable abdominal timor (67.95) were 
the most common clinical findings In the present series which concur 
with the findings in previous reports (Asadourian and Taylor, 1969; 
Krepart et al., 1978; Gordon et al., 1981). These clinical findings do 
not lead to the diagnosis of pure dysgerminoma of the ovary. However, 
age, short duration of symptoms, findings of ultrasound examination 
and possibly elevated LOH serum levels together with an adnexal tumor 
of considerable size give some clues to the diagnosis and necessitate 
an exploratory laparatomy. 
A pre-operative evaluation should Include determination of hCG and 
AFP serum levels to exclude other malignant germ cell tumors (chorio­
carcinoma, endodermal sinus tumor), which could produce these markers 
and could also be found in young patients. 
Furthermore, a preoperative chest X-rsy should be made to detect 
the presence of silent metastases, notably in the mediastinum, as had 
been demonstrated in this series in 2 patients with stage IV disease. 
The distribution of clinical stage is similar to that of previous 
reports (Table 5.3). The fact that only once bilateral disease was 
found in stage I is not really surprising as in only 7 patients (21%) 
of 34 patients with stage I, biopsies were taken from the contrala­
teral ovary. Moreover, 2 patients (9%) of 23 patients with stage I di­
sease who underwent unilateral salpingo-oophorectomy (USO) developed 
recurrent disease in the remaining ovary. 
On laparatomy, proper staging as in all ovarian malignancies is 
mandatory. This includes peritoneal washings and retroperitoneal lymph 
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node biopsies (iliac and para-aortic). The usefulness of the latter 
procedure is stressed by the fact, that in the present series 3 pa­
tients with unilateral disease had retroperitoneal metastases to iliac 
and para-aortic lymph nodes. 
In unilateral disease it is also recommendeble to take biopsies for 
frozen section from the macroscopically non-affected ovary to exclude 
bilateral disease. 
It should be the aim to remove the tumor without rupture of the 
capsula to prevent tumor spill. 
In case of bilateral disease and/or intraperitoneal and/or retrope­
ritoneal disease a total abdominal hysterectomy with lymphadenectomy 
and a debulking procedure should be performed. The value of 
omentectomy is dubious as in none of the patients with intraperitoneal 
stage III disease metastases were found in the omentum, nor were tumor 
deposits found in patients with recurrent intraperitoneal disease. 
Tumor implants which can not be removed should be marked with metal 
clips since this procedure enables the surgeon and radiotherapist to 
ascertain the efficiency of adjuvant radiotherapy or chemotherapy. It 
will also enable the surgeon to explore more easily these locations 
during a possible second-look operation (Freel et al.,1979). 
In view of the propensity for lymphatic spread in dysgerminoma of 
the ovary preferably a preoperative lymphangiogram or otherwise a 
postoperative lymphography is of great value. But in case of a 
"positive" postoperative lymphography these findings should be con­
firmed by obtaining histologic material by laparotomy or by fine 
needle aspiration as the diagnostic inaccuracy of lymphography is 
known to be in the range of IOS (Musumeci et al., 1978). 
The usefulness of lymphography might be illustrated by the finding 
that 7 patients out of β who did not have a lymphangiogram, developed 
a recurrence in para-aortic or supraclavicular lymph nodes. Three pa­
tients who developed recurrent disease after primary treatment did 
have a postoperative lymphangiogram. Of these, in 1 patient recurrent 
disease was found in the para-aortic nodes. 
The overall 5 and 10 year survival rate (90S) is in agreement with 
those reported by Asdourian and Taylor in 1969 (90S and 83.5S, respec­
tively) and compares favourably with the data reported by Gordon et 
al. in 1981 (82.6S and 73.8S, respectively) 
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In the present study a number of clinical factors have been correlated 
with the outcome to identify the patient at risk for an unfavourable 
outcome. 
Age did not correlate with stage and recurrent disease. However, 
there was a trend towards a higher survival rate for patients younger 
than 20.5 years as compared with patients older than this age, which 
is not in concurrence with earlier reports (Brody, 1961; De Lima, 
1966). 
Patients who were pregnant at the time of diagnosis appeared to 
have a less favourable prognosis as compared to non-pregnant patients. 
Two of the pregnant patients (30%) had recurrent disease, whereas in 
the non-pregnant group 9 patients (16.6%) had a recurrence. However, 
none of the pregnant patients died from disease. 
Concerning the prognostic influence of stage it is noteworthy that 
there was a high recurence rate in stage lai (? patients (24%) out of 
29 patients with stage lai). Thl3 I3 certainly related to the con-
servative mode of treatment applied in patients with stage lai but 
might also be correlated with Inadequate staging. 
The corrected actuarial survival rates at 5 and 10 years of pa-
tients with clinical stage I were both 94%. This figure is in agree-
ment with those of 94 and 92% reported by Gordon et al. (1981). For 
patients with stage lai disease the actuarial 5 and 10-year survival 
rate was 96%. The actuarial survival rate for patients with stage II 
-IV disease was 86%, which is considerably better than previous re-
ports (Asadourian and Taylor, 1969; Krepart et al., 1978; Gordon et 
al., 1981; De Palo et al., 1982) 
Although, notably in stage II-IV, it concerns a small nunber of 
patients, in the present series no drsmatic effect could be found of 
stage on prognosis, with the exception of 2 patients with stage IV, 
who both died of disease. In previous reports on larger series a more 
pronounced adverse effect of stage on survival had been demonstrated 
(Gordon et al., 1981). 
There was no correlation of tumor size with stage and recurrent 
disease, but it is noteworthy that both patients with clinical stage 
IV had a tumor larger than 25 cm in its greatest diameter. These fin-
dings are in agreement with those of Gordon et al. (1981). Conversely, 
Krepart et al. (1978) noted that recurrence rate and survival are ad-
versely affected by tumor size. 
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Treatment does influence to a certain extent the recurrence rate. 
It should be noted that the relatively small groups does not allow for 
any reliable statistical analysis, which has for this very reason been 
ommitted. Patients who were treated by USO alone did worse than pa­
tients who were treated by USO followed by either radiotherapy or che­
motherapy. These findings might indicate inadequate staging which of 
course applies for both treatment groups. However, additional therapy 
might eradicate unnoticed metastatic disease leading to a lower recur­
rence rate. 
The controversy which treatment to apply in stage I disease is 
stressed by table 5.П. 
Tabi· 5.17. Сопратівап of menstrual hietory, fertility and ртодповів 
after reepeative treatment in atage I dieeoee. 
Treatment 
No of patients 
Menstruation after 
treataent 
•o of patients pregnant 
after treataent 
No of pregnancies 
No of children alive 
Recurrences 
Mortality 
USO 
18 
18 (100) 
8 ( W) 
21 
19 
6 ( 33) 
1 ( 5) 
USO + additional 
therapy (Í) 
1U 
U (29) 
1 ( 7) 
1 
1 
1 ( 7) 
- ( - ) 
Of IB patients who underwent USO, all had regular periods after-
wards, but 6 patients (33S) had a recurrence, of whom 1 patient died. 
On the other hand of 14 patients who underwent USO followed by addi-
tional therapy (radiotherapy or chemotherapy) 10 patients (71%) became 
amenorrhoeic and 4 (29Ж) had regular periods afterwards. However, only 
1 patient (7%) had a recurrence and none died of disease. In the group 
of patients who underwent USO 8 patients (44S) became pregnant 21 
times, resulting in the delivery of 19 children, all without congeni­
tal deformities. Two times a miscarriage occured. In the group of pa­
tients who underwent USO followed by additional therapy only 1 patient 
(7%) became pregnant and subsequently gave birth to a premature male 
infant. 
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In this light, provided adequate staging, it appears to be impossible 
to render guidelines which patient with stage lal disease should re­
ceive which treatment, as it is unknown what is more Important to the 
individual patient: either to retain future fertility or a decreased 
risk on the development of recurrent disease. 
In 4 patients (36%) out of 11 patients who had recurrent disease no 
symptoms were present at the time of diagnosis of recurrence, stres­
sing the need of thorough follow up procedures in patients treated for 
dysgermlnoma of the ovary. 
The 5 year actuarial survival rate after recurrent disease amounted 
to 73S and compares favourably with literature. (Brody, 1961; Malka-
sian and Symmonds, 1964; Asadourian and Taylor, 1969; Freel et al., 
1979; Gordon et el., 19Θ1). However, the 5 year survival rate of 11 
patients with recurrent disease as compared to the remaining patients 
in the present series without recurrent disease is considerably less 
(73Й vs 95SS). Therefore, adequate staging procedures, from a clinical 
point of view, are of the utmost Importance, to know which patients 
are at risk for recurrent disease and a less favourable prognosis, to 
adjust proper treatment in these patients. 
from a histological point of view it might also be possible to 
forecast which patients are at risk for an unfavourable prognoais. The 
method of Investigation in this respect has mostly been along semi­
quantitative lines. Therefore a quantitative morphologic examination 
of tumor sections of patients with pure dysgermlnoma of the ovary 
might be valualable. 
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Chapter 6. 
HISTOPATHOLOGICAL ASPECTS OF PURE DYSGERHINOMA OF THE OVARY IN 5Д 
PATIENTS. 
6.1. Introduction. 
Histo-pathological aspects of pure dysgerminoma of the ovary have been 
extensively described in literature (Chapter 5). However, assessment 
of the clinical behaviour of pure dysgerminoma of the ovary from its 
histologic appearance has been the subject of only a few studies 
(Fauvet, 1936; Seegar, 1937; De Lima, 1966; Asadourian and Taylor, 
1969; Talerman et al., 1973; Morimoto, 1979; Steffen and Genton, 
19B1). 
In 1936 Fauvet rendered a statement that tumor volume compared to 
the surrounding stroma volume could be of prognostic significance. 
The prognosis might also be adversely affected by a slight lympho­
cytic stromal infiltration (Asadourian and Taylor, 1969; Steffen and 
Genton, 1981). 
There is less agreement on the prognostic effect of the number of 
mitoses in this type of tumor. Seegar (1937) did not find any prognos­
tic value of the number of mitoses, whereas, more recently it has been 
suggested that tumors with a high mitotic activity and moreover, with 
cellular atypia tended to be more aggressive (Asadourian and Taylor, 
1969 and Morimoto, 1979). 
Other authors expressed the opinion that due to the marked histolo­
gic variation within the same tumor histologic parameters are of du­
bious value as to asses which patients are at risk for an unfavourable 
prognosis (Santesson, 1947; Talerman et al., 1973). 
In view of the inconsistency of the findings in literature the use 
of objective quantitative techniques might enhance the significance of 
histological examination and its predictive value. 
To asses the histologic variation of pure dysgerminoma of the ovary 
in the present series tumor sections of a number of patients were 
reviewed semi-quantitatively. 
Furthermore, quantitative microscopic methods were applied includ­
ing determination of stroma/volume ratio, nuclear measurements, mito­
tic index, lymphocytic infiltration and nunerical quantitation of 
eosinophilic granulocytes and plasma cells. 
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These data were correlated with a number of clinical items in order 
to assess the prognostic value of histological findings· 
6.2. Material and methods. 
According to the selection criteria described in the preceding 
chapter (Chapter 5) 54 patients with pure dysgermlnoma of the ovary 
were eligible for clinical analysis. From these patients microscopic 
sections of tumor tissue were available. 
The tumor sections from all 54 patients, described in Chapter 5, 
were reviewed to exclude other tumor types and notably the admixture 
of dysgermlnoma with other germ cell elements. However, sections from 
Э patients were of poor quality and were not suitable for semi-quanti­
tative and quantitative morphometric examination. 
The microscopic sections from each patient were coded in order to 
prevent knowledge of the respective clinical data. 
Semi-quantitative histological examination. 
The microscopic slides from 51 patients that were of satisfactory 
to good quality were semi-quantitetively reviewed (G.P. Vooys, patho­
logist and 3. Meyer, resident-pathologist) and coded for a number of 
items. These items were all substracted from the literature where they 
were used as descriptors for the histology of pure dysgermlnoma of the 
ovary. 
Quantitative morphometry. 
The sections from 51 patients were used for morphometric analysis. 
The results of the analysis were correlated with a number of clinical 
items. 
From 47 patients (47/51 = 92%), apart from the microscopic slides 
also one or more (range 1 - 19) paraffin blocks were available from 
the primary tumor. To guarrantee standardized tumor sections of high 
quality the following preparatory procedure was carried out: 
- Each paraffin block was melted down and the thus remaining tissue 
was re-embedded in paraplast to enhance the firmness of the tis­
sue block. 
97 
- Each block was well fixed with vasalin to the operational unit of 
a Leitz cooling system at a constant temperature of -20"C. 
- A constant cutting speed was reached using a Jung motordnven mi­
crotome (Type 1140). Furthermore, the microtome was set to pre­
pare sections with a constant thickness of 5 micron using only 
disposable knives. 
- Two such prepared and hematoxylin-eosin stained sections were 
used for morphometric analysis. 
In the present series 3 types of morphometric studies were per­
formed: 
1 Measurement of stroma/volume ratto. 
2. Nuclear measurements. 
3 Ifumemcal quantitatbon of еозгпаркъіга granulocytes, plasma 
cells, mitotic actiVbty and lymphocytic activity. 
1. Measurement of stroma/volume ratio. 
Microphotographs were made of the tumor section(s) from each pa­
tient. In this manner 30 slides from each patient were available and 
these were projected (over all magnification 350x) on a graphic tablet 
(Bitpad Summagraphics) connected to a PDP 11/40 computer and stored on 
disk (Fig. 6.1). 
Figure 6.1. Illustration of the measuring system. 
4 
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Using a 450 point test grid (interpoint distance at specimen level 
32 micron) superimposed on the graphic tablet, all projected "stroma 
points" were counted and stored on disk. Also the points in projected 
areas not containing stroma or tumor, thought to be caused by shrin­
kage due to fixation and paraffin preparation, were counted and stored 
on disk. The letter number of points was subtracted from 450 leading 
to an accurate stroma/volume ratio. 
Reproducibility tests were better than 95Я>. 
The 450 point test grid was chosen out of practical purposes as a 
compromise between accuracy and tedious counting. The semi-quantita­
tive study of the tumor sections of the present series indicated, that 
roughly 50Й of the tumor sections consisted of stroma. With a 450 
point test grid this would lead to a relative error of 6.7Ï (\/225/225 
χ 100), whereas, for example, a 1000 point test grid would decrease 
the relative error only to 4.5S (ν/500/500 χ 100). 
2. Nuclear measurements. 
for this purpose microphotographie slides were made of random areas 
of the tumor section(s) from each patient and projected on the graphic 
tablet (over all magnification of 2650x) connected to a PDP 11/40 com­
puter. Of each tunoг section 50 randomly chosen nuclei were measured. 
From each nucleus the following features were assessed: 
A. Size dependent nuclear factors: B, Nuclear shape factors: 
- Area (AREA) - Axis ratio (AXRAT) 
- Perimeter (PERIM) - Circularity (CIRC) 
- Maximal diameter (MD) - Asymmetry (ASYM) 
- Axial momentum (AXMOM) 
Reproducibility tests for nuclear measurements exceeded 95%. 
A description of these nuclear features has been summarized in 
Addendum 4. 
3. Numerical quantitation of eosinophilic granulocytes, plasma cells, 
mitotic activity and lymphocytic infiltration. 
With a Leitz orthoplan light microscope at 787.5x magnification 
using a superimposed grid, areas (4.5 mm2 at specimen level) of every 
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section from all 51 patients (¿ 30 areas per patient) were chosen ran-
domly for counting. In each area the number of eosinophilic granulo-
cytes, plasma cells, the number of mitoses and lymphocytes were coun-
ted. All countings were performed by focussing throughout the thick-
ness of the section. 
Again, reproducibility tests were better than 954!. 
Table 6.1. Quani-Ltative morphometric parameters. 
Stroma/volume ratio 
Nuclear measurements 
Area 
Perimeter 
Maximal diameter 
Axial moment 
Axial ratio 
Circularity 
Asymmetry 
AHEA 
PERIM 
MD 
AXMOM 
AXRAT 
CIRC 
ASYM 
Numerical quantitation of 
Eosinophilic granulocytes 
Plasma cells 
Mitotic activity 
Lymphocytic infiltration 
Correlation of morphometric data with clinical data. 
The summarizing statistics included the mean values of 12 quantita-
tive morphometric data (Table 6.1) which were correlated with the cli-
nical data from the patients. Furthermore, standard deviations of 
these 12 quantitative morphometric mean values were calculated. To de-
crease the wide range of the standard deviations the square root of 
the standard deviation was calculated. The mean values of these varia-
bility coefficients (VC) were also used for statistical analysis. So, 
in all, the mean values of 24 quantitative morphometric parameters 
were correlated with clinical data from the patients. 
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Another way of stabilizing such a wide range of values would have 
been to calculate the logarithm of the standard deviation. This method 
was not used, however, as for some combinations of patients and para-
meters the standard deviation was close to zero· The logarithm of zero 
is infinitive. 
In order to investigate whether the results of the analysis could 
be influenced by an alternative choice of the summarizing statistics 
rather than using mean values and variability coefficients of the 
morphometric data, the following alternative values could be proposed: 
- The 90th percentile of the values of the morphometric parameters as 
an alternative for the mean values. 
Other percentiles were not used for various reasons (Addendum 7). 
- The interguartile range. This is the range between the 25th and 75th 
percentile and in statistics is sometimes used as an alternative for 
the standard deviation. Because of its wide range, the square root 
of the interquartile range was used for analysis of the morphometric 
data. 
A variable number of tumor sections was unsuitable for each of the 
above mentioned morphometric studies. The main reason for unsuitabili-
ty was an unacceptable amount of necrosis and/or hemorrhages present 
in the available tumor tissue and subsequently in the respective sec-
tions. 
Another reason was the low quality of microscopic sections from 
some patients, while the respective paraffin tumor blocks from these 
patients were not available, so that standardized tumor sections could 
not be prepared. 
The number of patients of which respective morphometric data were 
available for correlation with clinical data is given in Table 6.2 
subdivided by: 
1. stvoma/volime ratio 
2. nuclear measurements 
3 . numerical quantitation of eosinophilic granulocytes, plasma 
cells, mitotic activity and lymphocytic infiltration 
101 
Table 6 .2 . Patients of which the respective tumor sections were avai-
lable for morphometric studies (l-stroma/volume ratio; 
2=nuclear measurements i ¡^numerical quantitation of eosi-
nophilic granulocytes, plasma cells, mitotic activity and 
lymphocytic infiltration) 
(USO = unilateral salpmgo-oophorectomy) 
No of p a t i e n t s with a short duration of symptoms ( <: 5 weeks) with 
long duration ( > 5 weeks): 
short durat ion long duration Total no of p a t i e n t s 
1. 17 20 37 
2. 19 20 39 
3. 20 22 U2 
No of pregnant patients versus non-pregnant patients 
Pregnant Non-pregnant Total no of patients 
1. 1* Ή U5 
2. 5 1(2 1(6 
3. 1( 1(6 50 
No of patients with a small primary tumor ( ^  15 cm) versus those 
with a large primary tumor ( > 15 cm) 
Small tumor large tumor 
1. 16 27 
2. 18 27 
3. 18 30 
Total no of patients 
42 
1(5 
Ii8 
No of patients with stage lai versus all other stages. 
Stage lai all other stages Total no of patients 
1. 22 23 1(5 
2. 23 2k 1(7 
3. 2h 27 51 
No of patients with USO versus USO + adjuvant therapy. 
USO USO + adjuvant therapy Total no of patients 
1. 23 13 36 
2. 23 1U 37 
3. 23 16 39 
No of p a t i e n t s with r e c u r r e n t disease versus non-recurrent d i s e a s e . 
Recurrence Non-recurrence Total no of p a t i e n t s 
1. 9 3U 1(3 
2. 10 35 1(5 
3. 9 39 1*8 
No of non-survivors versus survivors . 
Survival Non-survival 
1. U 39 
2. k 1(1 
3. k hh 
Total no of patients 
1(3 
1(5 
1(8 
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Clinical data. 
Three of the selected 51 patients (median age 19 years), subjected 
to morphometric evaluation, were lost to follow-up. 
The following clinical data from the 51 patients were recorded: 
- Duration of symptoms. The patients were divided into 2 groups by 
the median duration of symptoms (5 weeks). Of 42 patients (81S) the 
duration of symptoms was recorded in their charts as such. In all, of 
20 patients the duration was less than or equal to 5 weeks whereas the 
remaining 22 patients had a duration of symptoms longer than 5 weeks. 
- Pregnancy at the time of diagnosis. Five patients (10S) were 
pregnant or shortly postpartum at the time of diagnosis. The morpho-
metric data of these patients were compared to those of 46 patients 
(90S) who were not pregnant at the time of diagnosis. 
- Size of the primary tumor. In 3 patients the size of the primary 
tumor was not known. The distribution by size of the primary tumor of 
the remaining 48 patients has been summarized in Table 6.3. The pa-
tients were, somewhat arbitrarily, further subdivided by the size of 
the primary tumor so that patients with a primary tumor smaller than 
or equal to 15 cm (18/48=38S) could be compared with patients with a 
primary tumor larger than 15 cm (30/48=628). 
Table 6.3. Distribution of tumor size (n=48J 
{%) 
6-10 
6 
(13) 
Tumor 
11-15 
12 
(25) 
s ize 
16-20 
20 
(42) 
(cm) 
21-25 
5 
(10) 
>25 
5 
(10) 
- Stage. The stage distribution of these patients has been summari-
zed in Table 6.4. 
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2h (ТЗГ 
It ( 1 2 ) V 
5 ( 1 5 ) V 
8 (16) 
9 ( I T ) 
1 ( 2) 
Table 6.4. Stage distribution (n-51) 
Stage No of patients 
I 33 (65) 
la, 
Ic 
II 
III 
IV 
( vPercentage of number of stage I patients) 
The morphometric data from patients with stage Іа^ were compared 
with those from patients with other stages, as patients with clinical 
stage lai should be the only patients to be considered for conserva­
tive therapy (USO). 
- Treatment. From the analysis of clinical data (Chapter 5) it ap­
peared that there was a trend toward a better outcome for patients who 
were treated by unilateral salpingo-oophorectomy (USO) followed by 
postoperative therapy (n=16) compared to those patients who were trea­
ted by USO only (n=24) (Chapter 5). For this reason, for morphometric 
purposes 40 suitable patients were subdivided by these treatment moda­
lities. 
- Recurrent disease. Forty eight patients could be analyzed for the 
development of recurrent disease. Of these, 10 patients (21Й) deve­
loped recurrent disease-
To avoid a biased comparison (non-recurrence vs recurrence) of sur­
gical therapy, only patients who underwent unilateral removal of the 
affected ovary (USO or unilateral oophorectomy, either combined or not 
with a biopsy of the contralateral ovary) were considered for statis­
tical analysis of the respective morphometric data. 
Following this set of conditions the morphometric data from 2B pa­
tients, who did not develop recurrent disease were compared to those 
from patients who did develop recurrent disease (n=9). 
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- Survival. In the present series 4 patients (IOS) died from disea­
se. These patients were compared with those 44 patients who survived. 
Because of the small number of patients the relation between mor-
phometrlc parameters and prognosis could only be determined for clini­
cal stage at the time of diagnosis and for recurrent disease. Because 
of a lack of homogeneous treatment regimens in those four who died of 
disease, a reliable statistical analysis of morphometric parameters 
from survivors and nonsurvivors was not possible. 
6.3. Results. 
6.3.1. Semi-quantitative analysis. 
Of the 51 tumors entered in this study an average of 4.5 slides 
(range 1-19 slides) were available for microscopic semi-quantitative 
evaluation. 
In 69% of the cases both tumorous tissue and normal ovarian struc­
tures were present. In 11% of the cases cystic structures were seen 
within tumorous areas. 
The tumors generally contained β considerable amount of fibrous 
stroma. In all, the tumor/stroma ratio was 60/40 with a standard de­
viation of 17.9. In the majority of tumors (59%) the amount of stroma 
varied considerably on different levels. In 66% of the tumors the 
stroma was mainly finely reticular, whereas In 49% also broad fibrous 
strands were found. Large areas of fibrosis or hyalinisation of 
fibrous tissue were rare. 
There was a considerable variation of arrangement of tumor cells 
between tumors and within the same tumor on different levels. Quite 
often, several different growth patterns were found within the same 
tumor. Solid or medullary arrangement of tumor cells was seen in 71% 
of the cases. 
An alveolar pattern was evident in 67%, whereas a trabecular growth 
was noted In 41%. Lobular growth was sporadically seen in 65% of the 
tumors and absent in 35%. 
As a rule, the tumor cells were relatively large. In most cases the 
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abundant cytoplasm was optically clear and vacuolated. In 24% of the 
cases the cytoplasm was in general basophilic. In most cases, the ma-
jority of the tumor cells was pleomorphic and only 20-35% of the cells 
were oval or round. The nuclei were relatively large with a nucleus/ 
cell ratio of 58% (standard deviation 10.4). In all tumors markedly 
atypical tumor cells were found. The nuclei showed a considerable va-
riation in size in 80% of the cases. Most often nuclei were round, but 
oval or irregularly shaped nuclei were also seen rather frequently. 
Usually nuclei had a central position, but, although in small num-
bers, excentrically located nuclei, were also seen in most tumors. 
Nuclear chromatin was most often coarsely granular and irregularly 
distributed, less frequently finely granular or evenly distributed. 
Variation in chromatin structure between nuclei was outspoken in 45% 
of the tumors. Nucleoli were found in all tumor nuclei, and prominent 
in 89% of the nuclei. 
Mitotic activity was seen in all tumors and in 57% of the tumors 
mitoses ware easily and frequently found. 
Lymphocytic infiltration of fibrous stroma was seen in over 90% of 
the tumors and was most often diffuse and prominent in 34% of the 
cases. In a larqe number of the tumors (64%) also scattered tumor 
areas with lymphocytic infiltration were seen. In 7% of the tumors 
lymphocytes had an outspoken follicular arrangement, whereas in 27% of 
the tumors a follicular arrangement was found in a minor degree. Focal 
granulomatous reaction was prominent in 21%, but less evident in 38% 
of the tumors. A diffuse granulomatous reaction could be observed in 
9% of the tumors. 
Solitary giant cells were found in 66% of the tumors. In 14% of 
the tumors these mononuclear giant cells were seen frequently, whereas 
in 52% sporadically. 
filant cells of Langhans type were frequently found in 14% and less 
often seen in 26% of the tumor sections. Giant cells of foreign body 
type were frequently seen in 22% of the tumors and present in lower 
numbers in 31%. 
Characteristic giant cells of syncytotrophoblastic type were not 
seen in any of the tumors in this study. 
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In almost all tumors small focal areas of necrosis were present. 
Extensive necrosis of tumor tissue, however, was often (385) multi-
focal and less frequent (2%) diffuse. In all, an average of 10% of tu-
morous tissue was necrotic. Hemorrhages were found in 495 of tumors, 
being extensive in 135 and multifocal in 75 of the cases. 
Eosinophilic granulocytes were found in 935 of tumors of which in 
295 in large numbers. Plasma cells were seen In 96S of tumors of which 
in 475 frequently. 
Invasion of tumor cells into the blood vessels was outspoken in 14% 
and less frequently seen in 28%. Invasion into the lymph vessels was 
seen in 275 and less frequently found in 55% of tumors. 
In 96% of tumors structures consistent with an ovarian capsule were 
found. Invasion of tumor cells into these capsules was extensive in 
88% and minimally to moderately in extent in 85 of the tumors. 
Invasion into lymphatic vessels of the capsules was extensive in 
25% and to a lesser degree present in another 245. Invasion of capsu-
lar blood vessels was extensive in 145 and present in 19%. 
Calcification was frequently found in 25 of tumors and was an inci-
dental finding in 13% of tumors. 
6.3.2. Quantitative analysis. 
6.3.2.A. Univariate analysis. 
For practical purposes only the significant results will be dis-
cussed. A full survey of the results of univariate analysis is given 
in Addendum 5. 
1. Stroma/volume ratio. 
The mean stroma/volume ratio did not appear to have much discrimi-
nating power for separation of the aforementioned clinical groups. 
However, there was one notable exception: the mean stroma/volune ratio 
of small tumors (< 15 cm.) was significantly higher compared to larger 
tumors ( > 15 cm) (p<0.05), indicating that small tumors have a higher 
amount of stroma compared to large tumors. Also the variability coef-
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ficient (VC) of the mean stroma/volume ratio was higher in small 
tumors compared to large tiinors (p<0.05). 
2. Nuclear measurements. 
The mean values oF the nuclear measurements and the respective varia­
bility coeFFicients (VC) oF tumor sections From patients who developed 
recurrent disease (RD) after unilateral surgery (n=9) compared to 
those from patients who did not have a recurrence (NRD) after the same 
kind of surgical treatment (n=28) are shown in Table 6.5. 
Tabi· β. S. Diffevenoea of morphcmetrio аіиев of timor aections from 
patiente oith recurrent disease (И.О.) and patiente ¡with-
out recurrent dieeaee both (N.R.D.) after unilateral sur-
gery (Student t-teet; eignifiaant). 
Morphometric parameters 
mean values of: 
AREA 
FERIM 
MD 
AXMOM 
AXRAT 
CIRC 
ASÏM 
VC of: 
AREA 
PERIH 
MD 
AXMOM 
AXRAT 
CIRC 
ASYM 
N.R.D. 
n=28 
5.33 
9.00 
3.00 
2.90 
0.72 
0.82 
0.25 
1.10 
1.0U 
0.62 
1.01 
0.3U 
0.23 
0.39 
R.D. 
n-9 
5.U2 
9.00 
3.05 
3.01 
0.72 
0.82 
0.26 
1.2U 
1.13 
0.67 
1.21 
0.1*3 
0.23 
o.Uo 
p-values 
ο.βο 
0.98 
0.63 
0.66 
0.55 
0.78 
0.11 
0.02° 
0.05® 
O.Ol»® 
0.00 Г 
0,01е 
0.97 
0.1.7 
VC - variability coefficient · square root of the standard deviation 
These findings suggest that in patients with recurrent disease the 
mean values of the nuclear morphometric parameters are similar to 
those in patients without recurrent disease. However, the variability 
coefficient (VC) of a number of nuclear features (mainly size depend­
ent) is significantly higher in patients with recurrent disease com­
pared to those in patients who did not have a recurrence after primary 
unilateral surgery (Table 6.5). 
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Analysis of the nuclear measurements of the timor sections correla­
ted with the clinical findings, demonstrated that the mean value of 
the nuclear feature ASYM from patients with stage lai (ns23) was sig­
nificantly higher than that from patients with another clinical stage 
(n=24) (p<0.04). Also the VC CIRC of the tumor sections from patients 
with stage lal w a 9 significantly higher than that from patients with 
another clinical stage (p<0,02). 
No other significant differences (p<0.05) could be demonstrated 
correlating nuclear measurements with the clinical findings (Addendum 
5). 
3. Numerical quantitation of eosinophilic granulocytes, plasma cells, 
mitotic activity and lymphocytic infiltration. 
The mean number of eosinophilic granulocytes and plasma cells in 
tumor sections in 22 patients with a longer duration of symptoms ( > 5 
weeks) was significantly higher than those from patients (n=20) with a 
short duration of symptoms ( < 5 weeks) (p < 0.03 and <0.04, respecti­
vely) as shown in Table 6.6. 
Tabi· β. β. Diffarenoee of oeil quantitation betaeen patiente uitìt a 
short duration of еущ>іств C< ί ывеке) and patiente with 
a long duration ( > S weeks) (student t-teet; β signifioant) 
Faranetere Duration 
short long р-твіиев 
n»20 n"22 
Mean values of: 
Eosinophilic granulocytes 
Plasma cells 
Mitoses 
LyŒphocytee 
Variability coefficient of: 
Eosinophilic granulocytes 
Flasoa cells 
Hitoses 
lynphocytes 
Furthermore, the VC of the mean number of plasma cells in tumor 
sections from patients with a longer duration of symptoms was higher 
0.1T 
O.lU 
0.33 
13.79 
0.52 
0.53 
0.76 
2.9T 
o.Uo 
0.56 
0.2U 
18.56 
0.73 
0.68 
з.эи 
0.03 
o.oV9 
0. й 
0.13 
0.07 е 
0.02 е 
0.15 
0.25 
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than that from patients with a shorter duration of symptoms (p<0.02) 
(Table 6.6). 
The mean number of mitotic figures and mean amount of lymphocytes 
and their respective VC's did not appear to be different for these 2 
groups of patients (Table 6.6). 
The mean nunber of eosinophilic granulocytes, plasma cells, mitotic 
figures and lymphocytes and their respective VC did not appear to be 
significantly different when correlated with clinical findings such as 
tumor size and stage (stage lai versus all other stages), nor was 
there a difference between patients treated by USO and patients trea­
ted by USO followed by postoperative therapy, nor was there a signifi­
cant difference in this respect between patients with a different out­
come (recurrent disease versus non-recurrent disease and non-survival 
versus survival). 
6.3.2.Θ. Multivariate analysis. 
Multivariate analysis of the morphometric data was limited to in­
vestigate the differences between patients with stage lai e nd patients 
with other stages and between patients who, after unilateral surgery, 
developed recurrent disease and patients who, after the same kind of 
surgical treatment, did not develop recurrent disease. 
A multivariate analysis of the morphometric data from survivors 
versus non-survivors did not seem feasible since the number of non-
survivors in homogeneous groups with respect to treatment was too 
small. 
Multivariate analysis of the morphometric data to detect differen­
ces concerning duration of symptoms and tumor size was not done since 
such an analysis would not contribute to a better understanding of 
histological risk factors in relation to prognosis. 
Comparing the morphometric data from patients with stage lai (n=23) 
with those from patients with other stages (n=24), it appeared that 
the mean value and the VC of the ASYM of the tumor sections from pa­
tients with stage lai w a s significantly higher (p <0.04). The VC of 
the CIRC also appeared to be significantly higher in patients with 
stage lai (Ρ <0.02). Stepwise regression analysis did not add any 
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other parameter to these 2 parameters and subsequently did not improve 
the results of the univariate analysis. This finding might be ex-
plained by the fact, that all parameters but VC ASYM and VC CIRC 
showed high mutual correlation coefficients ( |r| =0.5 to 0.8, Pearson 
correlation coefficient). 
In conclusion it does not appear to be possible using multivariate 
analysis of these quantitative morphometrlc parameters to discriminate 
sufficiently between patients with stage lai an^ a^ other stages. 
Multivariate analysis was also carried out to differentiate between 
patients who develop recurrent disease and those who did not after 
primary treatment. 
It appeared from the literature (Chapter 4) and from the present 
series (chapter 5) that patients who underwent non-conservative treat-
ment i.e. total abdominal hysterectomy and bilateral salpingo-oopho-
rectomy were less prone to the development of recurrent disease com-
pared to patients who were treated by unilateral salpingo-oophorectomy 
(USO) only. Therefore, to avoid a bias of the surgical therapy used, 
only the morphometrlc data from patients in which only the affected 
ovary was removed were entered for analysis. To investigate the effect 
of postoperative therapy after USO on the possible development of re-
current disease the morphometrlc parameters from the following sub-
groups of patients were analyzed: 
1. No recurrent disease, no postoperative therapy (n-lS). 
2. Recurrent disease, no postoperative therapy (n-S). 
3. ito recurrent disease, postoperative therapy (n=13). 
Only one patient developed recurrent disease after USO and chemo-
therapy and was not considered for analysis being a single case. 
The 24 aforementioned morphometrlc parameters were used for multi-
variate analysis. 
Using the Student t-test, the morphometrlc data of the primary tu-
mors from the first and third subgroup did not show any significant 
difference (Addendum 6). This finding indicates, that postoperative 
Ill 
1.11 
1.0k 
0.62 
1.03 
0.32 
I.26 
1.13 
0.68 
1.21» 
0.1»3 
0.12 
0.22 
0.15 
0.01° 
0.07 
therapy did not make any difference in these 2 groups since patients 
from both groups underwent unilateral removal of the affected ovary 
and moreover these patients did not develop recurrent disease after 
primary treatment. 
However, between the first and second group of patients there were 
differences, although none but one (VC AXM0M) proved to be significant 
(p<0.01) (Table 6.7). 
Table β.7. Comparison of morphometrie parameters from patients with 
(R.D.) or without recurrent disease (N.R.D.) using Stu­
dent t-test ( ^significant) 
N.R.D. R.D. 
morphometrie parameter n=15 n=9 ρ 
Variability coefficient mean mean 
AREA 
PERIM 
MD 
ΑΧΜ0Μ 
AXRAT 
Although the VC ASYM in tumor sections of patients in group 1 and 2 
showed a significant difference (p<0.02), this parameter was not used 
for multivariate analysis as there was no significant difference at 
all in the value of this feature between subgroups 2 and 3 (p<0.80). 
With stepwise regression analysis using the aforementioned 5 selec­
ted parameters (Table 6.7) the mean values of the VC ΑΧΜ0Μ and VC 
AXRAT appeared to be most discriminative between patients who deve­
loped recurrent disease and those who did not. Moreover, adding the 
remaining 3 parameters (VC AREA, VC PERIM and VC MD) only caused a 
slight increase of the multiple correlation squared correlation coef­
ficient (RSQ) (0.30 and 0.34, respectively), which is a measure of de-
pedence between the parameters used for multivariate analysis. Also 
the use of age and pregnancy at the time of diagnosis together with VC 
ΑΧΜ0Μ and VC AXRAT did not appear to increase the RSQ significantly 
(RSQ: 0.31). When using age and pregnancy at the time of diagnosis 
alone, the RSQ amounted only to 0.02. 
Using VC ΑΧΜ0Μ and VC AXRAT in the present series most patients who 
developed recurrent disease could be distinguished from patients who 
did not develop recurrent disease (Fig. 6.2). 
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Figure 6.2. Scattergran of patients with recurrent disease and without 
recurrent disease with VC AXMON and VC AXRAT. (v= non-re­
current disease; Δ = recurrent disease, survivor; • г re­
current disease, non-survivor; · = lost to follow up). 
The specificity and the sensitivity (Addendum 1) of this statistical 
procedure, using the VC AXRAT and VC AXMOM to predict recurrent di­
sease, was 96% and 56%, respectively (Table 6.Θ). 
Table β.β. Specificity0 and sensitivity of VC AIRAT and VC AXMOM iml-
tivai-wte analysis in ssparating patients vithout recurrent 
disease (SRD) and those with recurrent disease (BD). 
Clinical 
analysis 
^HRD 
V (І) 
0(*) 
Total 
it) 
Classification Ъу 
V 
NED 
9б.1.3 
Ц 
liU.UI» 
31 
81». 21 
mult ivar iate 
V 
RD 
1 
3.57 
5І56-
6 
15.79 
an« Oy eis 
Total 
2β 
100,00 
9 
100.00 
37 
100.00 
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6.3.3.A. Alternative statistics: Univariate analysis. 
Testing the significance between differences of patients who de­
veloped recurrent disease after primary treatment and patients who did 
not, only those patients were considered, who underwent unilateral 
ealpingo-oophorectomy. This limitation was introduced to avoid a bias 
of therapy (see also page 103). 
Considering the 90th percentile of morphometric values only the nu­
clear feature ASYM showed a significant difference with a ρ value of 
0.05 (Table 6.9). 
Analysis of the aguare root of the "interquartile range" between 
the two groups under study the nuclear features AREA and AXMOM ap­
peared to be to significantly different (p < 0.04 and 0.05, respecti­
vely) (Table 6.9). 
Table 6.9. P-values comparing morphometrïa data from patients with 
and without recurrent disease (VC=variability aoeffi-
aient=square root of standard deviation of the mean; p90= 
90th percentile; SQRT.intqr^square root of the interquar-
tile range). 
Parameters 
eosinophilic granulocytes 
plasma cells 
mitoses 
lymphocytes 
ABEA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
S-V ratio 
mean 
0.67 
о.зі* 
0.87 
0.18 
0.80 
O.98 
0.78 
О.63 
0.66 
0.11 
0.55 
O.9I 
VC 
O.ltU 
0.70 
0.59 
0.60 
0.02 
0.05 
0.97 
O.Olt 
0.00 
0.1*7 
0.01 
0.53 
p90 
0.50 
0.30 
0.79 
0.27 
0.18 
0.23 
0.1*1» 
0.18 
0.23 
0.05 
0.27 
0.99 
SQRT.intqr. 
0.83 
0.91» 
O.85 
O.58 
0.0Ц 
0.09 
0.78 
O.O6 
0.05 
0.17 
0.70 
0.73 
6.3.3.В. Alternative statistics: Multivariate analysis. 
Multivariate analysis of the values of the 90th percentile of the 
nuclear measurements did not contribute information to the results of 
the univariate analysis as shown in Table 6.9. 
Multivariate analysis of the square root of the interquartil range 
also did not render extra information compared to the univariate ana­
lysis of the 90th percentile values. 
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6.4. Discussion. 
The liability of all studies on pure dysgerminoma of the ovary in-
cluding the present one is in the relatively small number of patients 
reported on. Furthermore, the relatively at random selection of tumor 
blocks from the patients' tumors in the present series by the coopera-
ting pathologists is an uncertain factor in the assessement of the re-
liability of the resulta of the quantitative morphometric study. But 
then, due to the low incidence it appears to be hardly possible to as-
semble a large number of standardized specimen. 
The sampling problem (non-standardized tumor blocks) was again il-
lustrated by the fact that a number of the respective tumor sections 
were unsuitable for quantitative morphometry, which decreased the num-
ber of patients available for comparative studies. 
Semi-quantitative study of pure dysgerminoma of the ovary showed 
that the tumor generally contained varying amounts of fibrous stroma, 
which was mainly finely reticular, but broad fbrous strands were not 
uncommon. Hyalinisation of fibrous tissue was seen only rarely. 
The arrangement of tumor cells varied considerably between tumors 
and within the same tumor on different levels. The tumor cells were 
arranged in medullary, alveolar or trabecular growth patterns. 
Tumor cells contained abundant cytoplasm, which was usually vacuo-
lated or optically clear. Basophilia of the cytoplasm was observed in 
about 25Ä of the cells. 
Most tumors cells were irregular in shape, with only a minority 
round or oval. 
The nuclei were relatively large and showed a considerable varia-
tion in size. Most often nuclei were round, but oval and irregularly 
shaped nuclei were also seen rather frequently. 
The amount of nuclear chromatin varied largely and was most often 
coarsly granular and irregularly distributed. In almost all nuclei 
prominent nucleoli were evident. In the majority of tumor cells mito-
ses were easily and frequently found. 
Diffuse lymphocytic infiltration of fibrous stroma was seen in al-
most all cases. Lymphocytic infiltration of tumorous tissue however, 
was either diffuse or scattered. 
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In about one third of the cases focal or granulomatous reaction of 
tumorous tissue was prominent. Varying amounts of eosinophilic 
granulocytes and plasma cells were seen in most tumors. Multinucleated 
giant cells of the langhans type or foreign body type were found in 
two thirds of tumors. Syncytiothrophoblast giant cells were not found. 
In almost all tumors mostly focal areas of necrosis of tumor areas 
were seen. In all, about 10% of tumorous tissue was necrotic. 
Hemorrhages were found in half of the tumors. 
Blood vessel and lymph vessels invasion were seen in one third and 
in about half ι respectively of the tumors. 
Capsular invasion was seen in the majority of the cases, where cap­
sular tissue was present in the available slides. In about one third 
of the cases the capsular invasion included lymphatic and blood ves­
sels as well. 
Calcifications in varying amounts were found in almost one third of 
the cases. 
A most remarkable finding in the present series was that the mean 
number of lymphocytic infiltration in no way differed significantly 
between the various groups of patients. Even more, the mean amount of 
lymphocytic infiltration in the primary timor from patients who deve­
loped recurrent disease or who died of disease was higher than those 
from patients without recurrent disease or who survived. Although 
these findings were not statistically significant, it suggests that 
the infiltration of lymphocytes can not be considered to be Indicative 
for the prognosis of patients with pure dysgerminoma of the ovary. 
This finding is in contrast to both non-guantitative and quantitative 
data from literature (Asadourian and Taylor, 1969; Talermen et al., 
1973; Steffen and Genton, 1980). 
In patients with a longer duration of symptoms ( >5 weeks) the mean 
number of eosinophilic granulocytes and plasma cells, was significant­
ly higher than that in patients with a shorter duration ( < 5 weeks). 
This might indicate that in patients with dysgerminoma of the ovary 
there is some delayed immune reaction to tumor growth. However, if 
there is an immune reaction it still leaves unexplained the fact that 
in the present series there was no difference concerning the amount of 
lymphocytic infiltration in both groups of patients. 
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Another remarkable finding was that there was not even a remote 
difference of mitotic rate between the primary tumors from patients 
who developed recurrent disease after primary treatment and those from 
the patients without recurrent disease. The same applies for the pri­
mary tumors of survivors and non-survivors. Also the mean mitotic rate 
of small tumrs and large tumors did not differ. From the literature 
it however, appeared that In patients with more than θ mitotic figures 
in 5 high-power fields the mortality rate was high (235) compared to a 
IOS mortality rate in patients of which the tumor showed a lower num­
ber of mitotic figures (Asadourian and Taylor, 1969). 
An interesting finding rendered the analysis of quantitative data 
of tumor sections from patients with stage lai compared to those with 
other (=higher) stages. It appeared that the timor sections from pa­
tients with stage lai contained significantly more asymmetrical nuclei 
than those from the patients with other stages, furthermore, there was 
more variation of circularity (^roundness) of the nuclei in the tumor 
sections from patients with stage Ιβχ disease. Also the mitotic rate 
in tumors from patients with stage laj tended to be higher than that 
in patients with other stages. If one considers the duration of symp­
toms in both groups of patients, it appears that, again not signifi­
cantly, the duration of symptoms is shorter in the group of patients 
with stage lai disease than in patients with other stages. 
In view of the high recurrence rate in patients with stage lei af­
ter unilateral surgery, and the findings of quantitative morphometric 
analysis one may wonder whether in the present series tumors from pa­
tients with stage la^ disease represented a more aggressive kind of 
pure dysgerminoma of the ovary. It has already been stressed that ade­
quate staging is of the utmost importance notably In stage lai P a" 
tients, if one is contemplating conservative therapy (sunilateral sal-
pingo-oophorectomy). These findings seem to lend support to this 
recommendation. 
Univariate analysis of the nuclear measurements in tumor sections 
from patients who developed recurrent disease and those from patients 
who did not develop recurrent disease demonstrated that only the 
variability coefficients (square root of the standard deviation) of 
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the mean values of the nuclear parameters had a discriminating power 
to distinguish between these clinical sub-groups. It appeared that all 
but two of these parameters were significantly higher in the recurrent 
disease group compared to the non-recurrent disease group (p 0.001 to 
0.05). This means that nuclear pleomorphism in patients with recurrent 
disease was significantly more pronounced. It might also be concluded, 
since no differences were found with respect to the mean values of the 
nuclear parameters, that it does not seem correct to relate a phenome-
non like mere atypia with an unfavourable outcome i.e. the development 
of recurrent disease, as to a larger extent the variation of the de-
gree of cellular atypia within one tumor, as expressed by the variabi-
lity coefficient, made it possible to identify the tumors which even-
tually recurred. 
These findings seems to be partly In agreement with those of other 
authors, who reported after semi-quantitative investigations a higher 
mortality rate in patients with a severe cellular atypia compared to 
patients with less cellular atypia (Asadourian and Taylor, 1969; 
Morimoto, 1979). 
The use of multivariate analysis of the morphometric parameters to 
identify parameters which could differentiate between tumor sections 
from patients who developed recurrent disease and those from patients 
who did not, showed the VC AXRAT and VC AXMOM to be the two most 
powerfull discriminators, indicating, that in the present series, the 
variability of shape was higher in patients with recurrent disease. 
However, it should be noted that these discriminators are only ap-
plicable in the present series. The small number of patients did not 
allow for a comparison between a learning set versus a test set to 
check the reliability of the discriminators in the multivariate analy-
sis. It might be concluded that, again only for the present series, 
the specificity and sensitivity of this statistical procedure were 96% 
and 56?, respectively. 
It appears, when comparing the results of alternative statistics 
(90th percentile; sguare root of the interguartile range) with the 
ones in Chapter 6.3.2.B, that the choice of values (=range of values) 
considerably influences the outcome of correlation studies between the 
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guantitative morphometrlc data and clinical data such as the develop-
ment of recurrent disease after unilateral surgery. 
Depending on the choice of values, different quantitative para-
meters emerge as discriminators. This dependency of the level of 
values should be taken Into consederation when selecting values for 
quantitative studies. 
lects for quantitative studies the most outspoken or characteristic 
microscopic fields is likely to start his measurements with a prese-
lection towards maximum values. 
Quantitative methods applied in histologic examination in order to 
assess the outcome (i.e. recurrent disease and survival) of patiente 
with malignant disease have several attractive advantages. Quantita-
tion of histologic features allows for comparison and correlation with 
clinical data (Baak et al., 1977). Moreover, these methods make it 
possible to compare in an objective way the results with those of 
other studies. The present series being the first of Its kind on pure 
dysgermlnoma of the ovary might be considered as a starting point of a 
discussion on this subject and the findings warrant further study. 
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SUMMARY 
The aim of the present study was to draw an inventory of clinical 
and pathological aspects of patients with pure dysgerminoma of the 
ovary in order to identify prognostic risk factors in these patients. 
Part I (Chapters 1 to 5) concerns a survey on the literature, while 
part II (Chapters 5 and 6) represents the results of the investiga-
tion of clinical data and semi-quantitative and quantitative morpho-
logic aspects of pure dysgerminoma in 54 patients. 
In Chapter 1, a short review is given of the embryonic development 
of germ cells and the ovaries. It has been generally accepted, that 
pure dysgerminoma of the ovary arises from germ cells, which are pre-
sent in the female gonad at the time of birth. 
The embryonic factors, which might cause a malignant dedifferentia-
tion of these germ cells remain unclear. There might be a correlation 
between the absence of the pre-granulosa layer and the development of 
extra gonadal germ cell tumors. In this respect a congenital defective 
or absent pre-granulosa layer might be causative to the malignant de-
differentiation of germ cells in the ovary. 
In Chapter 2 a short review is given of the histopathological clas-
sification of tumors of the ovary and in particular of tumors, arising 
germ cells. 
The morphology of germ cell tumors is described. The totipotency of 
germ cells is illustrated by the wide variety in morphology of its 
derivative tumors. 
The term "dysgerminoma" should be solely reserved for pure dysger-
minoma of the ovary. The term "mixed dysgerminoma" does not do justice 
to the presence of other germ cell elements. 
In Chapter 3, by means of review of the literature, the morphology 
of dysgerminoma and possible prognostic factors, based on histologic 
features, are discussed. 
Dysgerminoma of the ovary, most commonly is a solid, tumor which is 
often lobulated. The tumor is surrounded by a smooth tough capsule 
capsule having a white, yellow or pink colour. 
On cut surface old and more recent hemorrhages of various sizes are 
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commonly found. Areas of necrosis may also be present. Hemorrhages 
could be responsible for the presence of small cavities. 
Microscopically, dysgerminoma of the ovary reveals distinctive and 
easy recognisable features: tumor cell nests of varying shapes sur-
rounded by a varying amount of stroma. The tumor cells are round, oval 
or polygonal containing a nucleus of similar shape. The nuclei are 
surrounded by a delicate pale granular eosinophilic cytoplasm and 
usually contain an evenly dispersed granular chromatin and one or two 
nucleoli. 
Mitotic activity may vary from slight to considerable. 
In exceptional cases multinucleated syncytiotrophoblast giant-cells 
are found. These cells may also be demonstrated using anti-human cho-
riogonadotropin (hCG) immunoperoxldase. 
The surroundig stroma may be hyallnlsed and is almost always Infil-
trated by a varying amount of lymphocytes. Eosinophilic granulocytes 
and plasma cells ere commonly found within the stroma. Granulomas are 
sometimes present end are composed of histiocytes surrounded by lym-
phocytes, plasma cells and multinucleated giant cells, both of the 
Langhans and foreign body type. 
The differences in the morphology of dysgerminoma of the ovary are 
mainly qualitative and less quantitave in nature. 
The prognostic significance of various histological features such 
as architecture, stroma/tumor ratio, cellular atypia and mitotic acti-
vity is a matter of disagreement. There is general agreement on the 
fact that a large lymphocytic infiltration of the stroma, as a reflec-
tion of immunological resistance, is correlated with a favourable out-
come. However, others consider, that prognosis can not be assessed 
from the histological appearance of the tumor due to the histologic 
variation within the same tumor. 
In Chapter 4 the literature on clinical and epidemiological aspects 
of patients with dysgerminoma of the ovary is reviewed. 
The frequency of dysgerminoma of the ovary compared to other tunors 
of the ovary (1 to 2%) and also compared to other malignant tumors of 
the ovary (3 to 58) have been reported. Due to the low frequency, the 
clinical data from literature all have a retrospective nature. 
Dysgerminoma of the ovary is most commonly found in patients youn-
ger than 40 years of age. Particularly in older studies a number of 
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post menopausal patients has been reported on, but with an increasing 
knowledge of the characteristic histologic features it has become evi-
dent that this tumor is only most rarely found in older patients. 
The high freguency of the tumor in pregnant patients (* 14S>) has 
been explained by some authors by the age distribution of the pa-
tients. However, patients with other malignant germ cell tumors have a 
similar age distribution and in these patients pregnancy is less com-
mon. A reasonable explanation for this phenomenon is not easily found. 
It has been generally agreed upon that dysgerminoma is a relatively 
rapid growing tumor in view of the usually short duration of symptoms 
and the large sized tumors found. However, a slow growth of the tumor 
might lead to a certain habitution of abdominal discomfort. Also, in 
view of the anatomical relationship of the ovary to the surrounding 
organs, tumor growth would not easily cause symptoms in small tumors. 
The symptoms of patients with dysgerminoma of the ovary are rather 
insidious. The most common symptoms are an increase of abdominal girth 
and a palpable abdominal tumor, which might be accompanied by abdomi-
nal pain. 
Both endocrinologie and genetic manifestations are, according to 
literature, uncommonly associated with dysgerminoma of the ovary. 
In view of the age of the majority of patients and certainly in 
case of pregnant patients not all pre-operative diagnostic possibili-
ties will be used. Quite often the diagnosis is made during laparotomy 
or post-operatively. 
In contrast to most other germ cell tumors the role of tumor mar-
kers in pure dysgerminoma of the ovary is not an important one. How-
ever, lactate dehydroqeneae (LDH) and its iso-enzymes have been found 
to be pre-operatively increased in a rather large proportion of 
patients with dysgerminoma. 
Clinically, dysgerminoma of the ovary is most commonly found (70S) 
in FIGO stage I. Of these, in almost 90%, disease ia limited to one 
ovary (la). 
The most common route of spread is along the retroperitoneal lymph 
vessels. It has been reported that in 30% of patients with stage I 
disease metastatic spread to retroperitoneal lymph nodes was found, 
which in fact means that these patients had stage III disease. 
In view of its propensity for lymphogenic spread, lymphangiography, 
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is by large the most important type of radiological examination in 
patients with dysgerminoma of the ovary. A chest X-ray might be impor­
tant for the detection of metastases to the mediastinal lymph nodes. 
CT-scanning also might be useful1 pre-operatively. Both lymphangio­
graphy and CT-scanning however, have an infiltrative nature or a high 
radiation exposure to the patient and may not be commonly used pre-
operatively for these very reasons. 
Surgical therapy is considered to be the first choice of treatment 
in patients with dysgerminoma of the ovary. The mode of surgical 
treatment however, in stage la\ Is a matter of discussion. Especially 
in publications of older date often a radical approach, meaning abdo­
minal hysterectomy with bilateral salpingo-oophorectomy, had been ad­
vocated. Recently it has been suggested that those recommendations are 
based on series including patients with mixed germ cell tumors adver­
sely affecting prognosis. 
In recent publications it is generally agreed, that, in patients 
with stage Іа^ disease unilateral salpingo-oophorectomy (USO) combined 
with a biopsy of the contralateral ovary, because of an approximatly 
10% bilateral involvement, should be sufficient. However, especially 
in these cases adequate staging procedures are mandatory. 
There is more agreement upon the treatment of patients with any 
other stage than stage lai· These patients should be treated by β to­
tal abdominal hysterectomy with bilateral salpingo-oophorectomy. Sur­
gical treatment is then followed by post-operative therapy meaning in 
most cases radiotherapy. 
In view of the remarkable radiosensitivity of this tunor, radiothe­
rapy plays a special role in the treatment of patients with dysgermi­
noma of the ovary. Doses and field sizes are mainly dependent on 
spread of the tumor. 
In view of the tumors' propensity for lymphogenic spread special 
attention should be given to the para-aortic, mediastinal and supra­
clavicular lymph nodes. Some authors recommend in case of radiothe­
rapy, to irradiate these lymph node chains to sterilize occult meta­
stases to these locations. In view of the favourable results of radio­
therapy used as adjuvant therapy in patients with dysgerminoma of the 
ovary not much attention has been given in literature to the use of 
chemotherapy in these patients. 
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From the literature it appears that the recurrence rate in patients 
with early stage disease (Stage la) varies between 15 and 52%. Appro­
ximately 75% of the recurrences are found within 2 years after primary 
treatment. Recurrences are often located both Intraperitoneally and 
retroperitoneally. 
As in primary treatment surgical therapy is also very important in 
the treatment of recurrent disease. Radiotherapy and chemotherapy are 
also commonly used in this respect. 
The overall 5 year survival rate of patients with pure dysgerminoma 
of the ovary according to literature varies between 75 and 91%. 
From the literature it appears, that there is no agreement as to 
the clinical factures affecting prognosis. It has become clear how­
ever, that recurrent disease has an adverse effect on prognosis. The 
survival rate after recurrence varies between 50 and 70S. 
In Chapter 5 clinical aspects of 54 patients diagnosed in the 
Netherlands between 1970 and 1981 are discussed. 
The incidence of dysgerminoma of the ovary in the Netherlands du­
ring the above mentioned period was 0.72 per 1.000.000 women. 
The youngest patient in the present series was 5 years of age at 
the time of diagnoses, whereas the oldest patient was 40 years of age. 
The median age was 20.5 years of age. In 902 of the patients the age 
was less than 30 years at the time of diagnosis. 
Abdominal pain (58.58) and a palpable abdominal massr (7030 were 
most commonly found. 
The short duration of symptoms has been illustrated by a median du­
ration of only 5 weeks. 
Only in 6 patients the human choriogonadotropin (hCG) serum levels 
were determined. Two patients had increased levels. Immunohistological 
examination however, did not render any clues to the source of hCG 
production. 
In 24 patients pre- and post operatively serum levels of lactate 
dehydrogenese (LDH) were determined. In θ (3380 of these patients, LDH 
serum levels were normal both before and after operation. In 16 pa­
tients (67%) increased serum levels of LDH were found pre-operatively 
and in 14 of these, normal serum levels were found post-operatively. 
In the remaining 2 patients serum levels of LDH were still increased 
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post-operatively. It should be noted that both patients had widespread 
disease (stage IV) and post-operatively residual timor. 
In 41 patients a chest X-ray was taken. In 2 of these, signs were 
found of disease spread to the mediastinal lymph nodes. In 28 patients 
lymphangiography was done. There was only one pre-operative study. In 
37% of patients who underwent lymphangiography no abnormal findings 
were present, whereas in 23% suspicious retroperitoneal lymph nodes 
were seen. 
Ultrasound examination was done in 11 patients. Only in 2 patients 
the echoscopist suggested the presence of a malignancy. 
Other radiological studies (intravenous urography, plain film of 
the abdomen, large bowel contrast study, liver scan, CT-scan and bone 
scan) did not reveal abnormal findings. 
The distribution of clinical stages showed that in 63й of patients 
stage I was found of which in 85% of the cases the tumor was limited 
to one ovary (stage la). Of these, 86% had tinoг limited to one ovary 
without overt penetration of the capsule (atage la}). 
All patients were primarily treated by surgery. The majority of pa­
tients underwent a unilateral salpingo-oophorectomy (USD). Thirty two 
patients in stage I underwent USO, while 5 and 4 patients with stage 
II and III disease, respectively, underwent USO. 
It can be concluded from the analysis of clinical data that in 
general in the present series adequate staging procedures, according 
to current standards, had not been performed. It should be noted how­
ever, that the majority (57%) of the patients was diagnosed prior to 
1976, which year marked the introduction of the revised version of the 
FIGO staging classification. 
Only in 7 patients with stage I disease, who underwent USO, biop­
sies were taken from the contralateral ovary. Only in 4 patients with 
unilateral disease biopsies were taken of retroperitoneal lymph nodes. 
In 3 of these, histological examination showed tumor deposits. 
In all, 26 patients (48%) were treated post-operatively. Of these 
20 patients received radiotherapy, and in 3 patients post-operative 
chemotherapy was started. In the remaining 3 cases combined radio­
therapy and chemotherapy was given. 
Eighteen patients, who underwent unilateral salpingo-oophorectomy 
all had a normal menstrual cycle after therapy. However, 82% of the 
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patients who received radiotherapy became amenorrhoeic after 
treatment. This finding indicates that in patients who will receive 
radiotherapy in the course of postoperative treatment oophoropexy 
should be considered. According to literature the damaging effects of 
radiotherapy are minimal in patients who underwent oophoropexy. In 67Й 
of the patients who received chemotherapy a normal menstrual cycle 
remained after treatment. 
The overall survival in the present series of 54 patients after 5 
and 10 years was 90?·. In stage I the survival after 5 and 10 years was 
94Й and in stage lai ^Ье 5 and 10 years survival was 96%. 
In the present series 11 patients (203!) developed a recurrence. In 
10 of these, the recurrence free survival time varied between 2 and 44 
months. In 1 patient a recurrence was found in the remaining ovary 77 
months after completion of treatment, stressing the need for a long 
term follow-up. 
In 4 patients (643!) recurrent disease was found without any symptom 
present. 
Most commonly (9 patients) recurrent disease was located in retro­
peritoneal or supraclavicular lymph nodes. 
An analysis of clinical data, which might affect prognosis showed 
that age did not affect stage and development of recurrent disease. 
However, only 1 patient (3,73!) younger than the median age of 20.5 
years died, whereas 273! of the patients older than this age died. 
The duration of symptoms did not appear to have any effect on prog-
nois. 
In 30S of patients, who were pregnant at the time of diagnosis, re­
current disease was found. Conversely, in the remaining group of 
non-pregnant patients 19S developed recurrent disease. None of the 
pregnant patients died of disease. 
The stage of disease did not appear to have a distinct effect on 
prognosis, which might be related with the small number of patients 
studied. It should be noted however, that both patients in the present 
series with stage IV died of disease. It is of interest that in 2S% 
(7/25) of patients with stage lai disease, a recurrence developed. 
This may be due to the mode of surgical treatment (unilateral sal-
pingo-oophorectomy), but is certainly also associated with the staging 
procedures. 
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An analysis of the effect of treatment on prognosis showed that a 
large proportion (368) of patients, who underwent a unilateral sal-
pingo-oophorectomy (USO) only, developed recurrent disease, whereas 
only β small proportion (6%) of patients with USO followed by either 
radiotherapy of chemotherapy developed recurrent disease. This diffe­
rence could be caused by the presence of metastases, which will be 
eradicated by postoperative therapy. 
Tumor size did not appear to have any effect on prognosis. 
The survival rate of patients with recurrent disease was 73S and 
was worse than that of the remaining patients (95S>). It might be con­
cluded that adequate staging procedures are correlated with the prog­
nosis. 
In Chapter 6 histopathologlcal aspects of pure dysgerminoma of the 
ovary are discussed. After a semi-quantitative description of this tu­
mor in 51 patients the correlations between quantitative morphometrlc 
and clinical data are described. Notably the relationship between his­
tology and prognosis has been investigated. 
In all 54 patients tunor sections were present, however of 51 pa­
tients these were suitable for morphometrlc examination. In 47 pa­
tients also parrafin blocks were available from which standardized 5 
micron tumor sections (Haematoxylin-Eosin stained) were prepared. 
All tumor slides had been reviewed in order to exclude other tumor 
types and notably the admixture of dysgerminoma with other germ cell 
elements. 
Semi-quantitative evaluation was done according to a number of his­
tological parameters, which, according to literature, could be 
considered as characteristic for dysgerminoma of the ovary. This list 
of items will be used in a future study to assess interobserver varia­
bility. 
Three types of quantitative morphometrlc techniques were performed: 
1. Measurement of stroma/volume ratio. 
By projecting the microscopic picture of a tumor section on a so 
called "graphic tablet", using a 450 point test grid the number of 
pointa covering stromal parts could be counted and the ratio of 
these to the total number of points covering the tissue section 
could be calculated. 
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2. Nuclear measurements. 
For this type of measurement tumor sections were projected on a 
graphic tablet, which rendered nuclear cross sections. The outlines 
of these were traced and measures of shape and size were calculated 
with the aid of a computer. 
J. Numerical quantitation of eosinophilic granulocytes, plasma cells, 
mitotic activity and lymphocytes in the tumor sections. 
For statistical analysis the mean values of 12 quantitative morpho-
metric parameters were calculated and correlated with the clinical 
data from the respective patients. Furthermore, the standard deviation 
of these mean values were calculated. Because of the wide range of 
standard deviations the square root of these were calculated, rende-
ring the so called variability coefficients (VC). The mean values of 
these variability coefficients were also correlated with the clinical 
data. So in all, 24 quantitative morphometric parameters were used. 
Correlation with clinical data was performed using univariate and mul-
tivariate analysis. 
The 51 patients selected for this investigation were classified ac-
cording to a number of clinical subgroups. The morphometric data from 
patients with a short duration of symptoms (< 5 weeks) and a long du-
ration of symptoms ( > 5 weeks) were compared. Also a comparison was 
made between the morphometric data from pregnant patients and those 
from non-pregnant patients and between the morphometric data from pa-
tients with a small primary tumor (<15 cm) versus those from patients 
with a large primary tumor (> 15 cm). Another comparison was made be-
tween morphometric data from patients with clinical stage lai anc' 
those from patients with all other stages. To investigate whether a 
selection had taken place concerning therapy, morphometric data from 
patients who underwent a unilateral salpingo-oophorectomy (USO) were 
compared with those from patients who underwent USO followed by post 
operative therapy. Next, morphometric data from patients, who deve-
loped recurrent disease were compared with those from patients who did 
not develop recurrent disease. Finally, morphometric data from pa-
tients who died of disease were compared with those from patients who 
survived. 
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Semi-quantitative examination confirmed the data from literature. 
Microscopically dysqerminoma of the ovary showed characteristic tunor 
cellnests surrounded by varying amount s of stroma, infiltrated by 
lymphocytes. Tumor cells contained varying amounts of clear cytplasm. 
The nuclei often contained granular chromatin and also prominant 
nucleoli. Inflammatory reactions i.e. granulomas (epitheloid histiocy­
tes surrounded by lymphocytes, eosinophilic granulocytes, plasma 
cells, multinucleated giant cells, both of the Langhans- and foreign 
body type) were often present. Necrosis and hemorrhages were most com­
monly present. 
Invasion by tumor cells into the capsule and into capsular blood-
and lymph vessels was often seen. 
All features appeared to be present within the same tumor in 
varying degrees. 
With univariate analysis the amount of stroma in dysqerminoma of 
the ovary appeared not to have any predictive value concerning progno­
sis. As the amount of stroma is also related with the architecture of 
the tumor, the latter did not have any effect, contrary to data from 
the literature, on prognosis. 
The number of lymphocytes was in no case indicative of prognosis. 
These findings are in disagreement with those from the literature in 
which frequently a large amount of lymphocytes had been correlated 
with β favourable prognosis, while, on the contrary in the present 
series, although not significantly, the number of lymphocytes in tunor 
from patients with recurrent disease and those who died of disease was 
higher than that from patients who did not develop recurrent disease 
or who survived. 
Also the number of mitoses did not appear to have a predictive va­
lue concerninq the proqnosis. 
An indication for an immunological reaction on tumor qrowth, which, 
according to literature, has been reserved for lymphocytes, had been 
found in the quantitation of eosinophilic granulocytps and plasma 
cells in tumor sections. The number of eosinophilic granulocytes and 
plasmacel1з was significantly higher in patients with a longer dura­
tion of symptoms ( > 5 weeks) compared with that from patients with a 
short duration of symptoms (<5 weeks). 
It appeared that cell quantitation could not discriminate between 
any of the other clinical subgroups. 
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Using univariate analysis a comparison of the nuclear parameters 
from patients with stage lal a n^ those with higher stages did show 
some significant differences. The nuclei from patients with stage la^ 
appeared to be more asymmetrical and also showed a higher variability 
in circularity, meaning roundness of the nuclei. The variability of 
other shape factors of nuclei in patients with stage lai, although not 
significant, appeared also to be higher. The duration of symptoms, ac-
cording to the clinical data, of patients with stage lai tended to be 
shorter than those from other patients and furthermore, the number of 
mitosis tended also to be higher In stage lai- In view of these fin-
dings, it seems that tumor growth in stage lai represents a more 
aggressive kind of dysgerminoma. These findings also support recomen-
dations on an adeguate staging procedure, which becomes even more im-
portant if one is contemplating unilateral removal of the affected 
ovary in stage lai. 
Univariate analysis of nuclear parameters from patients with recur-
rent disease compared to that from patients without recurrent disease 
demonstrated that the variability of shape is significantly higher in 
patients with recurrent disease. It may be concluded that in general 
spoken nuclear pleomorphism in patients with recurrent disease was 
significantly more pronounced. 
With respect to the finding that the mean values of nuclear parame-
ters did not have any discriminative power it may be concluded that 
definitions on cellular and nuclear atypia in pure dysgerminoma of the 
ovary are hardly available. 
Using multivariate analysis of the morphometric parameters the va-
riability of both the AXIS ratio and AXMOM were simultaneously higher 
in patients who developed recurrent disease, compared to those from 
patients who did not develop recurrent disease. These findings indi-
cate that variability in shape is higher in patients with recurrent 
disease. It should be noted however that, as yet this discrimination 
is only applicable for the present series. Further study is necessary 
to find out whether the discrimination is as powerfull as found in the 
present series. 
The use of the 90th percentile and the sguare root of the inter-
guartile range for statistical analysis demonstrated that the choice 
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of values could render quite a change of results comparing morphone-
tric and clinical data. This finding indicates, that the choice of va-
lues should be taken into consideration when performing such a study. 
The findings in this thesis indicate that prognosis is ultimately 
dependent on surgical staging. An adequate staging procedure will give 
clues to the proper treatment in patients with pure dysgerminoma of 
the ovary. 
Furthermore, it appeared that histological parameters which up to 
now according to literature had a predictive value for the prognosis 
do not have that very value but the degree of nuclear pleomophism had 
a significant correlation with prognosis. The results of this study 
therefore, indicate that quantitative morphometry should play a rôle 
in the diagnosis and the choice of therapy in patients with pure 
dysgerminoma of the ovary. 
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SUCNVATTING 
Deze studie werd verricht om bij patiënten met een zuiver dysgermi-
noma ovarii klinische en pathologische aspecten te onderzoeken die 
mogelijke risico factoren met betrekking tot de prognose zouden kunnen 
zijn. 
Het eerste deel (hoofdstuk 1 tot en met 4) bevat een overzicht van 
de literatuur gegevens, terwijl in deel 2 (hoofdstuk 5 en 6) van dit 
proefschrift het eigen onderzoek naar de klinische bevindingen en 
semi-quantitatieve en quantitatieve aspecten van pure dysgerminomen 
bij 54 patiënten wordt beschreven. 
In hoofdstuk 1 wordt ingegaan op de embryologische ontwikkeling van 
kiemcel en ovarium. Algemeen wordt aangenomen, dat het zuivere dysger-
minoma ovarii haar oorsprong heeft in de kiemcellen welke bij de ge-
boorte aanwezig zijn in de vrouwelijke gonade. Een embryologische oor-
zaak van een maligne dedifferentiatie van deze kiemcellen is niet 
gevonden. 
Wellicht is er een verband tussen het ontbreken van een pre-granu-
losa laag en het ontstaan van extragonadaal gelegen kiemcel tumoren. 
In dat licht zou een aanlegstoornis van de pre-granulosa laag rond de 
kiemcellen mede een oorzaak kunnen zijn van een maligne dedifferen-
tiatie van de kiemcellen in het ovarium. 
In hoofdstuk 2 wordt een kort overzicht gegeven van de verdeling 
van ovarium tumoren en die van de kiemceltumoren in het bijzonder. 
Er wordt ingegaan op de morfologie van de verschillende kiemceltu-
moren. De diversiteit van de morfologische beelden van de kiemcel 
tumoren illustreert het multipotente karakter van de kiemcellen. 
Strikt gesproken zou de benaming dysgerminoom gereserveerd moeten 
worden voor het zuivere dysgerminoom. De benaming "gemengd dysgermi-
noom" geeft niet de aard van gelijktijdig aanwezige anderekiemcel-
tumoren aan. 
In hoofdstuk 3 worden middels literatuuronderzoek de morfologie van 
het dysgerminoom en eventuele op de histologie gebaseerde prognos-
tische factoren beschreven. 
Het dysgerminoma ovarii vormt merendeels een sollede tumor met een 
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lobulalr aspect. De tumor wordt omgeven door een glad kapsel, welke 
wit, geel, roze of daar tussen liggende tinten kan vertonen-
Op doorsnede worden vaak oude en verse bloedingen van wisselende 
omvang waargenomen. Ook gebieden van necrose kunnen worden aangetrof-
fen. De bloedingen kunnen verantwoordelijk zijn voor de aanwezigheid 
van kleine holtes. 
Bij microscopische onderzoek blijkt, dat het dysgerminoom een ken-
merkend beeld vormt en als zodanig makkelijk te herkennen ia: timor 
celnesten van verschillende vorm worden omgeven door een wisselende 
hoeveelheid bindweefael. De tumorcellen hebben een ronde, ovale of 
polygonale vorm en bevatten een kern die dezelfde vorm kan aannemen. 
De kernen zijn omringd door een delicaat, eoslnofiel cytoplasme en be-
vatten een licht granulair chromâtine en een of twee nucleoli. 
In de tumor kunnen per niveau wisselende aantallen mitosen worden 
aangetroffen. 
In enkele uitzonderlijke gevallen worden meerkernige syncytiotrofo-
blast reuscellen aangetroffen. Deze cellen kunnen ook met behulp van 
anti-humaan choriogonadotrofine (hCG) in de immunoperoxldaae reactie 
worden aangetoond. 
Het omringende stroma vertoont some hyalinisatle en is bijna altijd 
geïnfiltreerd door een wisselende hoeveelheid lymfocyten. Daarnaast 
worden vaak eosinoflele granulocyten en plasmacellen waargenomen. Gra-
nulomen kunnen soms aangetroffen worden. Deze worden gevormd door 
histiocytaire cellen omringd door lymfocyten, plasmacellen en 
meerkernige reuscellen van het Langhanse of vreemdlichaam type. 
Verschillen tussen dysgerminomen hebben gezien het voorgaande eer-
der een kwantitatief dan een kwalitatief karakter. 
Over de prognostische betekenis van de verschillende histologische 
kenmerken zoals architectuur, stroma-tumor ratio, celatyple en mitose 
activiteit bestaat over het algemeen geen overeenstemming. Vaak wordt 
aangenomen, dat een sterke lymfocytaire infiltratie van het stroma, 
als uiting van een goede immunologische afweer van de patient, 
gecorreleerd is met een goede prognose. 
Anderen menen echter, dat gezien de histologische variatie binnen 
een en dezelfde tumor weinig prognostisch belang gehecht moet worden 
aan het histologie beeld van de tunor. 
In hoofdstuk 4 wordt ingegaan op literatuur gegevens aangaande de 
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klinische en epidemiologische aspecten van patiënten met een dysger-
minoma ovarii. 
Het voorkomen van het dysgerminoma ovarii is vergeleken met dat van 
andere ovarium tumoren (1 tot 2%) en in het bijzonder met dat van ma-
ligne ovariumtumoren (3 tot 5%). Aangezien het dysgerminoma ovarii 
weinig voorkomt, heeft dit weer tot gevolg dat de beschikbare kli-
nische gegevens alle retrospectief zijn verkregen. 
Het dysgerminoma ovarii blijkt voornamelijk voor te komen bij pa-
tienten welke jonger zijn dan 40 jaar. Met name in oudere publicaties 
wordt melding gemaakt van een aantal post menopauzele patiënten, maar 
met een toeneming van de kennis van het histologische beeld, wordt 
duidelijk, dat deze tumor uiterst zelden voorkomt bij oudere patiën-
ten. 
De relatief hoge incidentie van deze tumor bij zwangeren (* 14Й) 
wordt door sommige auteurs in verband gebracht met de leeftijdsver­
deling van de patiënten.De andere kiemceltumoren, die frequent bij 
jonge patiënten voorkomen, worden echter minder vaak bij zwangere 
patiënten waargenomen. Een duideljke verklaring voor dit fenomeen is 
dan ook niet te geven. 
Algemeen wordt aangenomen dat dysgerminomen een hoge groeisnelheid 
hebben, aangezien er bij het waarnemen van de eerste symptomen veelal 
grote tumoren worden gevonden. Het is echter ook mogelijk dat bij een 
langzame groei van de tumor er een zekere gewenning bij de patiente 
optreedt. Tevens zullen gezien de anatomische verhoudingen van het 
ovarium tot de omringende organen er niet snel symptomen optreden. 
De Symptomatologie bij patiënten met een zuiver dysgerminoma ovarii 
is weinig kenmerkend. De meest voorkomende symptomen zijn een toene-
ming van de buikomvang, een palpabele abdominale tumor, al dan niet 
gepaard gaande met buikpijn klachten. 
Zowel endocrinologische als genetische afwijkingen worden blijkens 
literatuuropgaven in verband met een puur dysgerminoom weinig gezien. 
Gezien de leeftijd van het merendeel van de patiënten met een dys-
germinoma ovarii en zeker bij zwangere patiënten zullen vaak niet alle 
pré-operatieve diagnostische mogelijkheden benut worden. Het blijkt 
veelal, dat pas tijdens of na de operatie de diagnose gesteld wordt. 
In tegenstelling tot vele andere kiemcel tumoren spelen de tot nu 
toe onderzochte tumormarkers bij het zuiver dysgerminoma ovarii een 
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geringe rol. Wel zijn lactaat dehydrogenase (LDH) en de iso-enzymen 
hiervan bij een aanzienlijk deel van patiënten met een dyagerminoom 
pré-operatief verhoogd. 
Het dysgermlnoma ovarii blijkt voornamelijk (708) in het FIGO-sta-
dium I voor te komen. In bijna 90% van de gevallen met stadium I is 
het dyagerminoom beperkt tot 1 ovarium. 
De meest voorkomende vorm van verspreiding is via de lymfewegen. 
Zo werd in 30% van patiënten met het vermoeden van stadium I door 
sommige auteurs metastases in retroperitoneale lymfeklieren gevonden 
hetgeen impliceert, dat deze patiënten stadium III haddenl 
Veruit het belangrijkste radiologisch onderzoek bij patiënten met 
een dysqerminoom van het ovarium is, gezien het veelvuldig voorkomen 
van lymfogene metastasen, het lymfoqrafisch onderzoek. Een röntgen op-
name van de thorax kan van belang zijn om metastasen met name in de 
mediastinale lymfeklieren te ontdekken. Ook de CT-scan zou pre-opera-
tief van nut kunnen zijn. Echter zowel de lymfografie als de CT-scan 
zijn infiltratief van aard of hebben een grote stralen belasting. 
Derhalve wordt pré-operatief onderzoek met deze methodieken bij jonge 
patiënten veelal nagelaten. 
Chirurgisch behandeling geldt als eerste keus voor de genezing van 
patiënten met een zuiver dysgerminoma ovarii. Over de wijze van deze 
chirurgische behandeling bij patiënten in stadium lai bestaat geen 
overeenstemming. Vooral in vroegere publicaties wordt veelal gepleit 
voor een radicale behandeling, hetgeen inhoudt een abdominale uterus-
extirpatie met medenemen van beide adnexen. De toenmalige adviezen 
waren gebaseerd op series patiënten, waarbij in een aantal gevallen 
sprake was van gemengde kiemcel tumoren, welke de prognose in nega-
tieve zin beïnvloedden. 
Uit de recente publicaties blijkt, dat bij patiënten met een 
stadium la^ een éénzijde adnexextirpatie, in combinatie met een diag-
nostische wigexcisie van het contralaterale ovarium voldoende is. In 
ongeveer IOS van de gevallen komt het dyagerminoom dubbelzijdig voor. 
Indien men volstaat met het verrichten van een eenzijdige adnexextir-
patie is een adequate stagering van groot belang. 
Meer overeenstemming bestaat er over de behandeling van patiënten 
die hoger gestageerd worden dan stadium lai· De therapie bij deze pa-
tienten bestaat uit een abdominale uterusextirpatie met medenemen van 
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beide adnexen. De operatieve behandeling wordt gevolgd door 
postoperatieve therapie, welke meestal bestaat uit radiotherapie. 
Vanwege de opvallende stralengevoeligheid van de tumor neemt radio-
therapie een belangrijke plaats in bij de behandeling van patiënten 
met een dysgerminoma ovarii. Doseringen en veldgrootte zijn 
voornamelijk afhankelijk van de uitbreiding van de tumor. Gezien de 
voorkeur voor lymfogene uitzaaiingen zal aandacht moeten worden 
geschonken aan de para-aortale, mediastinale en supraclaviculalre 
lymfeklieren. Door sommige auteurs wordt dan ook geadviseerd om in 
geval van radiotherapie altijd de genoemde lymfeklieren mee te 
bestralen om reeds plaatsgevonden, niet ontdekte, uitzaaiingen te 
steriliseren. 
Gezien de succesvolle resultaten van radiotherapie als nabehande-
ling bij patiënten met een dysgerminoma ovarii word in de literatuur 
weinig aandacht geschonken aan de toepassing van chemotherapie als 
nabehandeling. 
Het percentage recidieven bij patiënten met een dysgerminoom vari-
eerde in de literatuur tussen de 15 en 52Й. Ongeveer 75S van de reci­
dieven worden binnen 2 jaar na de eerste behandeling ontdekt en worden 
vaak zowel intreperìtoneaal als retroperitoneaal gevonden. 
Evenals bij de eerste behandeling is chirurgische therapie van 
groot belang bij de behandeling van een recidief. Verder komen In aan-
merking radiotherapie en chemotherapie. 
De overleving voor patiënten met een zuiver dysgerminoom van het 
ovarium varieert tussen de 75 en 91%. 
Uit literatuur gegevens blijkt dat er geen overeenstemming bestaat 
ten aanzien van klinische factoren, welke de prognose zouden kunnen 
beïnvloeden. Wel is het duidelijk dat het ontstaan van een recidief de 
prognose in negatieve zin aanzienlijk beïnvloedt. De overlevingskans 
na een recidief varieert tussen de 50 en 70*. 
In hoofdstuk 5 worden de klinische aspecten beschreven van 54 pa-
tienten, bij wie in de periode 1970 tot 1981 in Nederland een zuiver 
dysgerminoom van het ovarium werd gediagnostiseerd. 
De incidentie van het dysgerminoma ovarii in Nederland bedroeg over 
het genoemde tijdvak 0.72 per 1.000.000 vrouwen. 
138 
De jongste patiente in het onderzoek was 5 jaar ten tijde van de diag-
nose, terwijl de oudste patiente 40 jaar was. De mediane leeftijd 
bedroeg 20,5 jaar. Negentig procent van de patiënten was jonger dan 30 
jaar ten tijde van de diagnose. 
Buikpijn (58,58) en een palpabele abdominale tumor(70ï) waren de 
meest voorkomende symptomen. 
De mediane duur van symptomen bedroeg, voordat behandeling plaats-
vond, slechts 5 weken. 
Er werd bij 6 patiënten het hCG gehalte in het bloed bepaald. Twee 
patiënten hadden verhoogde spiegels. Bij histologisch onderzoek konden 
geen aanwijzingen gevonden worden voor de bron van deze hCG produktie. 
Bij 24 patiënten werd het serum lactaat dehydrogenase pré- en post-
operatief bepaald. Bij 8 patiënten (33%) bleken de LDH spiegels voor 
en na normaal de operatie te zijn. Bij 16 patiënten (67%) werden ver-
hoogde spiegels van de LDH gevonden voor de operatie. Bij 14 van hen 
waren de spiegels post-operatlef normaal, terwijl bij 2 patiënten de 
LDH spiegels post-operatief verhoogd bleven. Opgemerkt moet worden dat 
beide patiënten uitgebreide metastasen (stadium IV) hadden en er ook 
post-operatief tumor aanwezig was. 
Bij 41 patiënten werd een röntgenfoto van de thorax gemaakt. Bij 2 
patiënten werden aanwijzingen gevonden voor het bestaan van metastasen 
in medlastinale lymfeklieren. Bij 28 patiënten werd lymfografie ver-
richt, waarvan slechts in 1 geval pré-operatief. Bij 75% van de pa-
tienten die een lymfografie ondergingen werden geen afwijkingen vast-
gesteld. Bij 25% van deze patiënten werden verdachte retroperitoneale 
lymfeklieren gevonden. 
Echografie werd verricht bij 11 patiënten. Slechts bij 2 patiënten 
veronderstelde de echoscopist dat er sprake was van een maligne 
proces. 
Overige radiologische onderzoeken (intraveneuze pyelografie, buik-
overzicht, X-colon, leverscan, CT-scan en botseen) leverde geen bij-
drage tot de diagnostiek. 
De stadiumverdeling liet zien dat er in 63% van de gevallen sprake 
was van een stadiun I. In dit stadium was in 85% van de gevallen de 
tumor beperkt tot 1 ovarium (stadium Ia). Van deze laatste groep was 
in 86% de kapsel niet doorbroken (stadium laj). 
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Alle patiënten werden in eerste instantie chirurgisch behandeld. 
Het merendeel van deze patiënten onderging een éénzijdige adnexextir-
patie. Deze operatie werd bij 32 patiënten in stadium I uitgevoerd, 
terwijl in respektievelijk 4 en 5 gevallen deze behandeling werd uit-
gevoerd in stadium II en III. 
Gesteld mag worden dat over het algemeen een adequate stagering 
naar huidige maatstaven In deze groep van patiënten niet werd doorge-
voerd. Darbij dient te worden aangetekend, dat de meerderheid van de 
patiënten (575!) behandeld werd voor 1976, In welk jaar de huidige 
FIGO stagering werd gepubliceerd. 
Bij slechts 7 patiënten met stadium I, die een éénzijde adnexextir-
patie ondergingen, werden biopten genomen van het contralaterale ova-
rium. Slechts bij 4 patiënten met stadium I werden biopten genomen van 
retroperitoneale lymfeklieren. Bij 3 van deze patiënten werden bij 
histologisch onderzoek van de biopten metastasen gevonden. 
Aan 26 patiënten (48%) werd post-operatieve therapie gegeven. In 20 
gevallen betrof het radiotherapie en 3 patiënten kregen chemotherapie. 
In de drie overgebleven gevallen betrof het een combinatie ven radio-
therapie en chemotherapie. 
Achttien patiënten, die een eenzijdige adnexextirpatie ondergingen, 
hadden allen een normale menstruele cyclus na de ingreep. 
Tweeëntachtig procent van de patiënten die radiotherapie ondergingen, 
had na de behandeling geen menstruatie meer. Bij deze patiënten zou 
verplaatsing van het ovarium te overwegen zijn. Volgens 
literatuuropgaven zijn de schadelijke neven effecten van radiotherapy 
minimaal bij patiënten die radiotherapie ondergaan. In 67S van de 
patiënten die chemotherapie kregen bleef een normale menstruele cyclus 
na de behandeling staan. 
De actuarische overleving van de totale groep van 54 patiënten 
bedroeg na 5 en 10 jaar 90S. Voor patiënten met stadiun I bedroeg de 
overleving na 5 en 10 jaar 94й. Voor patiënten met stadium la^ bedroeg 
de overleving na 5 en 10 jaar 96%. 
Van de totale groep van patiënten werd bij 11 patiënten (208) een 
recidief gevonden. In 10 gevallen trad het recidief op 2 tot 44 maan-
den na de eerste behandeling. Bij 1 patiente werd zelfs 77 maanden na 
beëindiging van de therapie een recidief gevonden in het achter ge-
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bleven ovarium, hetgeen de noodzaak van een langdurige follow-up 
benadrukt. 
Bij 4 patiënten werd een recldlef gevonden zonder dat er symptomen 
waren. 
De lokalisatie van het recidief was in het merendeel van de geval-
len (9 patiënten) in de retroperitoneale en supraclaviculalre lymfe-
klieren aanwezig. 
Bij de beoordeling van de klinische factoren, welke de prognose 
zouden kunnen beïnvloeden bleek, dat de leeftijd geen invloed had op 
het stadium of op het optreden van een recidief. Er overleed slechts 1 
patiente (3,7й), jonger dan de mediane leeftijd van 20,5 jaar over­
leed, terwijl er 4 patiënten (27%) overleden die ouder waren dan 20,5 
jaar. 
De duur van de symptomen bleek geen invloed te hebben op de prog-
nose. 
Bij 30% van de patiënten, die zwanger waren ten tijde van diagnose, 
werd een recidief gevonden. Daarentegen werd in de groep niet-zwangere 
patiënten, slechts bij 19% een recidief werd gevonden. Geen van de 
zwangere patiënten overleed ten gevolge van de ziekte. 
De stagering had in de onderzochte groep geen duidelijk effect op 
de prognose, hetgeen wellicht verband houdt met het relatief kleine 
aantal onderzochte patiënten. Opgemerkt dient te worden dat beide pa-
tienten met stadium IV overleden. Het is van belang om vast te stel-
len, dat er in 28% (7/25) van de patiënten met stadium Ιβχ een reci­
dief werd gevonden. Dit kan het gevolg zijn van de aard van de chirur­
gische therapie (eenzijdige ednexextirpatle), maar het kan evenzeer 
verband houden met de stagering. 
Bij de analyse van de invloed, welke de behandeling heeft op de 
prognose bleek, dat patiënten die slechts een eenzijdige adnexextir-
patie ondergingen vaker een recidief ontwikkelden (36%) dan degenen, 
die een éénzijdige ednexextirpatle ondergingen gevolgd door radio-
therapie of chemotherapie. Bij deze laatstgenoemden werd slechts in 6% 
een recidief gevonden. Deze verschillen zouden verband kunnen houden 
met de aanwezigheid van niet opgemerkte metastasen, die met een nabe-
handeling worden gesteriliseerd. 
De grootte van de tumor bleek niet van invloed te zijn op de 
prognose. 
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De overleving van patiënten met een recldief bedroeg 73S en was 
beduidend lager dan het overlevingspercentage van de overige patiënten 
(95S). 
In hoofdstuk 6 worden de hlstopathologische aspecten van het zui-
vere dysgerminoma ovarii besproken. Er wordt na een semi-guantitatieve 
beschrijving van de tumor bij 47 patiënten, ingegaan op een mogelijke 
samenhang tussen quantitatief morfometrische gegevens en de klinische 
aspecten. Met name werd onderzocht of er een relatie is tussen de 
histologie en de prognose. 
Van alle 54 patiënten waren coupes van de tumor aanwezig. Van 51 
patiënten waren de coupes geschikt voor het morfometrisch onderzoek. 
Tevens konden van hettumor weefsel van 47 patiënten gestandariseerde 5 
micron coupes (Haematoxyline-Eosine gekleurd) worden gesneden. 
Alle coupes werden gereviseerd om andere tumor types, maar vooral 
ook om de aanwezigheid van andere kiemcel tunoren uit te sluiten. 
Een semi-quantltatieve evaluatie van de coupes werd verricht op het 
voorkomen van een aantal histologische kenmerken, welke volgens lite-
ratuur opgaven karakteristiek zijn voor het dysgerminoom van het 
ovarium. 
Drie types van quantitatief morfometrisch onderzoek werden uit-
gevoerd: 
1. Meting van stroma/volume ratio. 
In een geprojecteerd beeld van coupes op een zogenaamd "graphic 
tablet" werden in een raster met 450 punten de met rasterpunten 
samenvallende stroma delen geteld en berekend ten op ziehte van het 
totale door het raster bedekte oppervlak van de tumor. 
2. Kerngegevens. 
Ook hierbij werd gebruik gemaakt van geprojecteerde coupes op het 
graphic tablet. Aldus geprojecteerde doorsneden van kernen werden 
overgetrokken waarna met behulp van een computer een aantal vorm-
en grootte parameters van de kernen konden worden berekend. 
3. Tellingen van het aantal eosinofiele granulocyten, plasma cellen, 
mitose figuren en lymfocyten. 
Voor de statistische analyse werden de gemiddelde waarden van in 
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totaal 12 quantitatieve morfometrische parameters berekend en gecorre-
leerd met de klinische gegevens van de betreffende patiënten. Tevens 
werd de standaard deviatie berekend van deze gemiddelde waarden. Aan-
gezien de standaard deviaties een grote spreiding vertoonden, werd de 
wortel berekend van de standaard deviaties. De gemiddelde waardes van 
deze zogenaamde variability coëfficiënten (VC) werden ook gecorreleerd 
met de klinische parameters. In totaal werden dus 24 quantitatieve 
morfometrische parameters gebruikt. De correlatie met de klinische 
gegevens werd getoetst middels univariate en multivariate analyse. 
De 51 patiënten geschikt voor dit onderzoek werden ingedeeld in 
verschillende klinische subgroepen. Zo werden vergelijkingen gemaakt 
tussen patiënten met een korte duur (< 5 weken) en een lange duur van 
klachten ( > 5 weken). Tevens werden de morfometrische gegevens verge-
leken van zwangere en niet zwangere patiënten. Ook werden morfome-
trische gegevens van patiënten met een kleine primaire tumor (< 15 cm) 
vergeleken met die met een grote primaire timor ( > 15 cm). Er werd 
eveneens een vergelijking gemaakt tussen patiënten met stadium laj en 
die met de andere stadia. Om na te gaan of er een aelectie had plaats-
gevonden ten aanzien van de therapie werden de patiënten bij wie 
uitsluitend een eenzijdige ednexextirpatie werd uitgevoerd vergeleken 
met diegenen, die een eenzijdige adnexextirpatie ondergingen gevolgd 
door postoperatieve therapie. Vervolgens werd gekeken naar de morfo-
metrische gegevens van patiënten met en zonder recidief. Als laatste 
werden de morfometrische gegevens van de patiënten, die overleden 
waren tan gevolge van het dysgerminoma ovarii vergeleken met diegenen 
die van de ziekte genazen. 
Semi-quantitatief onderzoek bevestigde de gegevens uit de litera-
tuur. Het dysgerminoma ovarii vertoonde microscopisch een kenmerkend 
beeld van tumor cel nesten omgeven door een wisselende hoeveelheid 
bindweefsel, welke door lymfocyten waren geïnfiltreerd. De tumor 
cellen bevatten veel helder cytoplasme. De celkernen bevatten vaak een 
wisselende hoeveelheid granulair chromatlne en tevens duidelijke 
nucleoli. Ontstekinga reacties in de vorm van granulomen (epitheloïd-
cellige histiocyten, omgeven door lymfocyten, eosinofiele granulo-
cyten, plasma cellen, meerkernige reuscellen van het Langhans- en 
vreemdlichaam type) werden bijna altijd waargenomen, evenals gebieden 
met necrose en bloedingen. 
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Invasie van tumor cellen in het kapsel en in aldaar aanwezige 
bloed- en lymfevaten werd vaak waargenomen. 
In een en dezelfde tumor werden de meeste kenmerken in wisselende 
frequentie aangetroffen. 
Bij univariate analyse bleek, dat de hoeveelheid stroma qeen voor-
spellende waarde had voor de prognose. Aangezien de stroma hoeveelheid 
ook gerelateerd is met de bouw van de tumor, lijkt derhalve de bouw 
van de tumor in tegenstelling tot de literatuur gegevens geen invloed 
te hebben op de prognose. 
Met aantal lymfocyten was in geen geval indicatief voor de prog-
nose. Dit is in tegenspraak met de gegevens uit de literatuur, waar 
vaak melding wordt gemaakt van een correlatie tussen een groot aantal 
lymfocyten en een goede prognose. In dit onderzoek bleek zelfs, dat, 
alhoewel niet significant, het aantal lymfocyten in tumoren van pa-
tienten, die een recidief kregen of stierven, hoger was dan dat van 
patiënten die geen recidief kregen of de ziekte overleefden. 
Ook het aantal mitosen bleek in geen geval een voorspellende waarde 
te hebben voor de prognose. 
Een aanduiding voor een immunologische reactie op tumorgroei, welke 
in de literatuur meer wordt toegeschreven aan de lymfocyten, wordt wel 
gevonden bij telling van eosinofiele granulocyten en plasmacellen. Het 
aantal eosinofiele granulocyten en plasma cellen was significant hoger 
bij patiënten met een lange duur van symptomen (> 5 weken) vergeleken 
met patiënten met een korte duur van symptomen (<5 weken). 
Verder bleek dat bij deze manier van celtellingen qeen onderscheid 
gemaakt kon worden tussen de diverse klinische subgroepen. 
Met behulp van univariate analyse leverden vergelijkingen tussen de 
kern parameters van patiënten met stadium laj en die van patiënten met 
een ander (= hoger) stadium enkele significante verschillen op. De 
tumor kernen van patiënten met een stadium lei bleken significant meer 
asymmetrisch te zijn dan die van patiënten met andere stadia. Tevens 
waa er in de kernen van patiënten met stadium lai e e n grotere sprei-
ding in de circulariteit, hetgeen neerkomt op rondheid van de kernen. 
De spreiding van de andere vorm parameters van de kernen waren bij 
patiënten met stadium lai, alhoewel niet significant, groter dan bij 
patiënten met andere stadia. De duur van klachten bij patiënten met 
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Stadium lay leek korter te zijn vergeleken met de andere patiënten. 
Dit zou kunnen wijzen op een snelle groei van de tumoren bij patiënten 
met stadium lai. 0 o k het aantel mitoses leek in stadium lai groter te 
zijn dan in de andere stadia. Gezien deze bevindingen zouden de 
tumoren bij patiënten met stadium lai een meer aggressieve vorm van 
het dysgerminoom kunnen vertegenwoordigen. Deze bevindingen lijken ook 
de noodzaak van een optimale stagerings procedure te ondersteunen. 
Indien men besluit tot het verwijderen van één adnex in stadium lal, 
is derhalve grote zorgvuldigheid geboden. 
Bij univariate analyse van de kern parameters van patiënten met een 
recidlef vergeleken met die van patiënten zonder recidief bleek dat de 
spreiding in de waarden van de vorm parameters significant groter was. 
Hieruit kan afgeleid worden, dat over het algemeen de kern polymorfle 
in patiënten met een recidief significant meer uitgesproken was. 
Met behulp van de multivariate analyse konden de morfometrische pa-
rameters wel verschil maken tussen patiënten met een recidief en die 
zonder recidief. Met name de spreiding van de axis ratio en de sprei-
ding van het axis moment waren de meest "krachtige" parameters. Deze 
bevindingen lijken nogmaals een aanwijzing te zijn voor het feit dat 
de spreiding in de kern vorm groter is bij patiënten met een recidief. 
Er dient echter opgemerkt te worden dat dit onderscheid alleen geldt 
voor deze patiëntengroep. Verder onderzoek bij andere patiënten zal 
moeten uitwijzen of het bij dit onderzoek gevonden onderscheid kan 
worden bevestigd. 
Het gebruik van de van de 90ste percentiel waarden en de wortel van 
de interquartlel range voor een statistische analyse liet zien dat de 
verschillen in de keuze van waarde grote verschillen in resultaat tot 
gevolg had bij een vergelijking van morphometrische en klinische data. 
Hieruit kan afgeleid worden, dat in een studie als deze rekening 
gehouden zal moeten worden met een keuze van de waarde en dat in dit 
verband met de mate waarin een keuze van de te meten fenomenen leidt 
tot een preselectie van de meetwaarden. 
De bevindingen in dit proefschrift duiden erop dat de prognose 
sterk afhangt van een goede stagering. Immers een juiste atagering zal 
voor patiënten met een puur dysgerminoom van het ovarium lelden tot de 
optimale therapie. 
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Tevens bleek dat histologische parameters, die volgens literatuur 
opgaven prognostische waarde zouden hebben, bij dit onderzoek niet als 
zodanig naar voren kwamen, maar dat de mate van polymorfie van de kern 
een significante correlatie heeft met de prognose. Derhalve dient 
quantitatief morfologisch onderzoek een rol te spelen bij de diagnos-
tiek en de keuze van de behandeling bij patiënten met een zuiver 
dysgerminoma ovarii. 
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Addendua 1. 
Formulation of efficiency of a parameter. 
TN = true negatives. 
TP = true positives. 
FN г false negatives. 
FP = false positives. 
These are often used to describe the value of a certain parameter. The 
ratios of these 
Accuracy = percentage correctly classified cases = 
TN + TP loo 
TN + TP + FN + FP 
Sensitivity = positive in disease = TP хЮО 
TP + FN 
Specificity = negative in health = TN χίΟΟ 
TN + FP 
14Θ 
Adetendm 2 
Questionaire on clinical data. 
1. Number. Based on pathology laboratory nunber. 
2. Date of birth. 
3. Date of diagnosis. 
4. Age in years. 
5. Menstrual history. 
6. Contraceptive use. 
7. Number of pregnancies/infants. 
β. Dysqerminoma associated with pregancy or post-partum period. 
9. Signs and symptoms. 
10. Duration of symptoms. 
11. Clinical stage (FIGO). 
12. Retrospectively staged. 
13. Mode of surgical treatment. 
14. Peritoneal washings. 
15. Lymph node sampling. 
16. Lymphadenectomy. 
17. Residual disease after surgery. 
18. Affected ovary (LT/RT). 
19. Adjuvant therapy. 
20. Mode of radiotherapy, dosage, duration, side-effects. 
21. Alternation of XRT dosage because of side-effects. 
22. Change of adjuvant therapy because of XRT side-effecta. 
23. Mode of chemotherapy, nunber of courses, duration of chemotherapy. 
24. Side-effects of chemotherapy. 
25. Change of chemotherapy dosage because of side-effects. 
26. Change of adjuvant therapy due to chemotherapy side-effects. 
27. Recurrent disease. 
2Θ. Recurrent disease discovered after patients complaints. 
29. Location of recurrent disease. 
30. Recurrence free interval. 
31. Age at time of diagnosis. 
32. Second look operation. 
149 
J3. Indication for second look operation. 
34. Tumor deposits found during second-look operation. 
35. Location of tumor deposits at second-look operation. 
36. Mode of surgical treatment at second-look operation. 
37. Peritoneal washings at second-look operation. 
38. Lymph node sampling at second-look operation. 
39. Lymphadenectomy at second-look operation. 
40. Residual disease after second-look operation. 
41. Adjuvant therapy. 
42. Mode or radiotherapy, dosage, duration, side-effects. 
43. Alternation of XRT dosage because of side-effects. 
44. Change of adjuvant therapy because of XRT side-effects. 
45. Mode of chemotherapy, number of courses, duration of chemotherapy. 
46. Side-effects of chemotherapy. 
47. Change of chemotherapy dosage because of side-effects. 
48. Change of adjuvant therapy due to chemotherapy side-effects. 
49. Subseguent surgery after second-look operation. 
50. Indication to subsequent surgery. 
51. Adjuvant therapy after subsequent surgery. 
52. Menstrual cycle after primary therapy. 
53. Menstrual cycle after secondary therapy. 
54. Contraceptives after therapy. 
55. Pregnancies after therapy. 
56. At term deliveries after therapy. 
57. Congenital deformities in offspring. 
58. Miscarriage/immature/premature delivery. 
59. Legal abortion. 
60. Date of last follow-up. 
61. Condition at last follow-up. 
63. Date of death. 
64. Age at time of death. 
65. Autopsy. 
66. Cause of death. 
67. Routine laboratory tests. 
68. Abnormal routine laboratory tests. 
69. Chest X-ray at the time of diagnosis and during follow-up. 
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70. Lymphangiogram at time of diagnosis and during follow-up. 
71. Other radiological examinations at time of diagnosis. 
72. Tumormarkers (B-hCG/AFP) at time of diagnosis. 
73. LDH or iso-enzyms at time of diagnosis. 
74. Tumormarkers (B-hCG/AFP) at time of recurrent disease. 
75. LDH or iso-enzyms at time of recurrent disease. 
76. Size and weight of the primary tumor. 
Addendin 3 
Check list for aemi-quantitative histological examination. 
1. Number of histology sections examined. 
2. Architecture of tumor nests: - medullary solid. 
- alveolar. 
- lobular. 
- strands/trabecular. 
3. Features of connective tissue: - delicate network. 
- large fibrous strands. 
- loose. 
- dense· 
4. Tumor/stroma ratlo(ÍS): Tumorous tissue - % of the total 
area in which the tumor is located. 
5. Degree of hyalinisation of the surrounding stroma. 
6. Degree of variation of the surrounding stroma as found 
on different levels. 
7. Nuclear features: - amount of cytoplasm. 
- vacuolization of cytoplasm. 
- degree of clarity of cytoplasm. 
- degree of basophilia of cytoplasm. 
- cellular shape: - round. 
- oval. 
- polygonal. 
All question should be answered with 0-1-2-3-4 
unless stated other wise. 
Explanation of numerical answers: 
0 
no 
not-ap-
plicable 
none 
— 
mean 
« 
29 
0 
35 
4 
0 
9 
7 
56 
71 
2 
0 
9 
4 
24 
0 
0 
0 
1 
sporadic 
slight 
dubious 
-/+ 
2 
small 
little 
scanty 
+ 
3 
average 
moderate 
temperate 
++ 
4 
yes/large 
much 
strong 
numerous 
• m -
4.5; range 1 - 1 9 tumor sections 
% 
18 
7 
45 
22 
9 
24 
36 
40 
mean 55. 
22 
0 
2 
0 
7 
27 
33 
11 
17 
% 
22 
27 
20 
31 
24 
22 
40 
0 
% 
22 
47 
0 
33 
42 
45 
18 
4 
.91% ) std: 17.88 
7 
39 
20 
29 
33 
24 
31 
69 
16 
0 
35 
47 
42 
33 
22 
33 
20 
53 
% 
9 
20 
0 
9 
24 
4 
4 
0 
0 
24 
29 
20 
22 
2 
2 
0 
24 
- nucleus/cytoplasm ratio (%): nucleus = 
% of the total cell area. 
- atypla of tumor cells. 
8. Nuclear features: - estimation of size of the nucleus. 
- variation of nuclear sizes. 
- Nuclear shape: - round. 
- oval. 
- polygonal. 
- Location of nucleus within the cell: - centrally. 
- excentrally 
- nuclear chromatine: - coarsely granular. 
- finely granular. 
- chromatin distribution: - evenly. 
- unevenly. 
- variation of chromatin structures. 
- nucleoli. 
9. Mitotic activity. (HPF: 40/10): estimation in 10 HPF. 
10. Lymphocytic infiltration into: - stroma: - diffuse. 
- multifocal. 
- tumor tissue: - diffuse. 
- multifocal. 
11. Presence of follicular architecture of lymphocytes. 
12. Granulomatous reation: - diffuse. 
- focal. 
13. Presence of giant cells: - mononuclear. 
- Langhans type. 
- foreign body type. 
- syncytiotroblsst type. 
14. Necrosis: - diffuse. 
- focal. 
- multifocal. 
15. Necrosis/tumor ratio (S): necrosis = % of tumor tissue. 
16. Hemorrhages: - diffuse. 
- focal. 
- multifocal. 
0 1 2 3 4 
0 
0 
0 
0 
0 
11 
0 
16 
0 
25 
18 
0 
2 
0 
0 
4 
24 
9 
31 
67 
76 
40 
34 
6 
47 
100 
89 
4 
43 
96 
51 
91 
Mean 
0 
0 
0 
4 
4 
47 
0 
80 
2 
56 
67 
7 
13 
0 
9 
18 
38 
33 
51 
18 
9 
16 
34 
13 
18 
0 
9 
29 
7 
Mean 
4 
24 
0 
58%; std: 
0 
4 
20 
9 
53 
18 
0 
4 
16 
17 
9 
11 
56 
11 
33 
22 
22 
24 
13 
9 
7 
22 
18 
13 
13 
0 
0 
20 
13 
9.56%; std: 
0 
18 
2 
10.40 
2 
29 
47 
65 
38 
20 
24 
0 
53 
2 
4 
47 
29 
20 
33 
31 
16 
18 
4 
0 
2 
13 
0 
7 
11 
0 
2 
4 
20 
: 10.46 
0 
4 
0 
98 
67 
33 
22 
4 
4 
76 
0 
30 
0 
2 
36 
16 
69 
24 
24 
0 
16 
0 
7 
7 
9 
14 
7 
11 
0 
0 
7 
18 
0 
2 
7 
17. Presence of: - eosinophilic granulocytes. 
- plasma cells. 
18. Presence of Barr bodies. 
19. Vascular invasion: - lymph vessels. 
- blood vessels. 
20. Capsule: - presence of capsule in histology section. 
- tumor infiltration into the capsule. 
- tumor infiltration into capsular vessels 
- lymph vessels. 
- blood vessels. 
21. Calcification: - focal. 
- diffuse. 
22. Admixture with other type of newqrowth: 
- relation to dysgerminoma (yes/no). 
23. Presence of normal ovarian structures (yes/no). 
24. Presence of cystic structures (yes/no). 
25. Indication of ovarian dysgenesis (yes/no). 
0 1 2 3 4 
7 
4 
100 
18 
59 
4 
4 
54 
51 
70 
83 
100 
no 
100» 
31S 
S9% 
100ÍS 
27 
33 
0 
39 
14 
4 
4 
17 
16 
11 
11 
0 
38 
16 
0 
16 
14 
2 
4 
12 
8 
8 
2 
0 
11 
27 
0 
7 
0 
0 
0 
0 
3 
0 
0 
0 
18 
20 
0 
20 
14 
90 
88 
17 
22 
14 
2 
0 
yes 
OS 
69« 
U S 
0!S 
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Addendu* 4. 
Nuclear measurements. 
A microphotographie slide, showing nuclear cross-sections, is pro­
jected (magnification 26450x) onto a graphic tablet connected to a POP 
11/40 computer. All positions on the graphic tablet are electronically 
uniguely defined by a pair of coordinates (X,Y). Using a penlike sty­
lus connected to the graphic tablet the membrane of a projected nu­
clear cross-section is traced. The graphic tablet sends the correspon­
ding (X,Y) coordinates to the computer, which stores these on disk as 
contour-points (Fig. Add. 4.1=Fig. 6.1.). The contour is the represen­
tation of the cross-sectional nuclear membrane, that results from 
interconnecting the contour-points by straight lines. 
Figure Add· 4.1. Illustration of the measuring system. 
:c ρ 
Ρ - orojeclor 
C3T - graohic laiNcl 
S - sty i js 
XY- eoordirviles 
С - COTlDutf"-
D = d s* 
Τ - len rninal 
/щ 
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From the stored contour-points a number of morphometric parameters 
is calculated. For each parameter the name, abbreviation, description 
and definition is given in terms of the representation of the contour. 
A. Size factors: dependent on size of the traced object (nucleus) 
1. AREA: the area of the nuclear cross-section (cm2). 
Definition: The area of the region within the contour. 
2. PERIM: Perimeter (rcircumference): The length of the cross-sec-
tional nuclear membrane (cm). 
Definition: The total length of the contour. 
3. MD: Maximal diameter: The maximal diameter available of the 
nuclear cross-section (cm). 
Definition: The length of the longest axis (LA), where LA is the 
line between the two most distant points of the contour. 
(Fig. Add.1.2). 
Figure Add. 4.2. Illustration of the contour (C), longest axis (LA), 
maximal diameter (MD), shortest axis (5A), and non-
overlapping areas (shaded) after mirroring. 
( -
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ü. AXMOM: Axial moment: Reflects the degree of extension of the 
nuclear cross-section with respect to the longest axis (cm^). 
Definition: For the regions on both sides of the LA the respec-
tive areas and mean distance to the LA of that region are multi-
plied. AXMOM is the sum of these two values. 
This parameter is also used to make parameter 7 (Asymmetry) size 
independent. 
B. Shape factors: Independent of size of the traced object (Nucleus). 
5. AXRAT: Axis ratio: Degree of flatness of the nuclear cross-sec-
tion 
Definition; The length of the shortest axis (SA) divided by the 
LA, where the SA of the object is the longest intercept perpen-
dicular to the LA (Fig. Add. 4.2). 
Range: 0< AXRAT < 1. 
6. CIRC: Circularity: A measure of the degree to which the shape of 
the cross-sectional nuclear membrane relates to a circle. This 
parameter might be considered a measure of roundness of the nu-
clear cross-section. 
Definition: CIRC=4.7rAREA/PERIM2. 
Range: 0<CIRC<1. For a line the CIRC is 0, whereas for a circle 
the CIRC is 1. 
7. ASYM; Asymmetry; The degree to which regions at one side of the 
LA of the nuclear cross-section do not have counterparts at the 
other side. 
Definition: to calculate ASYM the contour at one side of the LA 
is mirrored onto the other side rendering non-overlapping regions 
(Fig. Add. 4.2). The area of each non-overlapping region is mul-
tiplied by its mean distance to the LA and these values are 
summed. The multiplication is motivated by the assumption that a 
non-overlapping protrusion should contribute more to the ASYM 
than a non-overlapping smooth layer of egua] area does. (Fig. 
Add. 4.3). The result of this calculation is divided by the para-
meter 4 (AXMOM) to avoid size dependency of ASYM. 
Range: 0<ASYM< 1. 
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Figure Add. 4.3. Illustration of 2 different non overLappinq regions of 
equal area contributing to the asymmetry. 
I II 
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Addendua 5 
Univariate analysis. 
Student t-tests. P-values. 
Table Add. 5.1. Patients with short duration (<5 wks) versus long 
duration of symptoms (>5 wks) 
Mean values 
AREA 
PEHIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vc 
eosinoph. 
plasma ce 
mitoses 
il. 
of 
ratio 
gran. 
ills 
lymphocytes 
Short duration 
η 
19 
19 
19 
19 
19 
19 
19 
17 
20 
20 
20 
20 
mean 
5.42 
9.02 
0.82 
3.04 
2.9Θ 
0.25 
0.72 
17.91 
0.17 
0.14 
0.33 
13.97 
std 
0.95 
0.83 
0.02 
0.28 
0.76 
0.03 
0.03 
9.65 
0.23 
0.14 
0.24 
7.44 
Long duration 
η 
20 
20 
20 
20 
20 
20 
20 
20 
22 
22 
22 
22 
mean 
5.35 
9.03 
0.81 
3.01 
2.91 
Π.24 
0.72 
23.97 
0.40 
0.56 
0.24 
18.56 
std 
0.52 
0.48 
0.04 
0.17 
0.43 
0.03 
0.03 
13.58 
0.40 
0.84 
0.12 
11.90 
Ρ 
0.77 
0.96 
0.68 
0.72 
0.72 
0.24 
0.39 
0.13 
0.03 
0.04 
0.14 
0.13 
Table Add. 5.1a. Patients with short duration (<5 wks) versus long du­
ration of symptoms (>5 wks) 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
Sh. 
η 
19 
19 
19 
19 
19 
19 
19 
17 
20 
20 
20 
20 
art dur« 
mean 
1.16 
1.06 
0.23 
0.65 
1.07 
0.40 
0.36 
2.85 
0.52 
0.53 
0.76 
2.97 
ition 
std 
0.18 
0.14 
0.03 
0.08 
0.21 
0.05 
0.09 
0.70 
0.33 
0.36 
0.16 
0.85 
Long dura 
η 
20 
20 
20 
20 
20 
20 
20 
20 
22 
22 
22 
22 
mean 
1.14 
1.07 
0.23 
0.63 
1.07 
0.38 
0.36 
2.98 
0.73 
0.94 
0.68 
3.34 
tion 
std 
0.15 
П.12 
0.04 
0.07 
0.17 
0.03 
0.10 
0.67 
0.39 
0.66 
0.19 
1.16 
Ρ 
0.79 
0.86 
0.67 
0.40 
0.93 
0.18 
0.87 
0.57 
0.07 
0.02 
0.15 
0.25 
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Table Add.5. 
Mean values 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. 
.2. 
of 
Pregnant 
ratio 
eoslnoph. gran. 
plasma cells 
mitoses 
lymphocytes 
patients versus non 
η 
5 
5 
5 
5 
5 
5 
5 
4 
4 
4 
4 
4 
Pregnai 
mean 
5.19 
8.80 
0.82 
2.93 
2.80 
0.23 
0.72 
18.43 
0.22 
0.12 
0.39 
20.84 
лі 
std 
0.32 
0.33 
0.03 
0.12 
0.24 
0.03 
0.04 
7.06 
0.22 
0.16 
0.25 
16.62 
pregnant pa tients. 
Non-pregnant 
η 
42 
42 
42 
42 
42 
42 
42 
41 
46 
46 
46 
46 
mean 
5.38 
9.02 
0.82 
3.03 
2.94 
0.25 
0.72 
22.83 
0.30 
0.37 
0.27 
17.33 
std 
0.81 
0.71 
0.03 
0.24 
0.64 
0.03 
0.03 
13.12 
0.36 
0.62 
0.18 
14.29 
Ρ 
0.61 
0.51 
0.Θ4 
0.40 
0.63 
0.25 
0.90 
0.51 
0.67 
0.46 
0.24 
0.64 
Tabi· Add.5.2е. Pregnant patients versus non-pregnant patients 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
η 
5 
5 
5 
5 
5 
5 
5 
4 
4 
4 
4 
4 
Pregnant 
mean 
1.19 
1.09 
0.23 
0.65 
1.10 
0.38 
0.32 
2.68 
0.59 
0.38 
0.81 
3.46 
std 
0.32 
0.28 
0.04 
0.15 
0.30 
0.03 
0.03 
0.50 
0.44 
0.45 
0.15 
1.39 
Non-pregnant 
η 
42 
42 
42 
42 
42 
42 
42 
41 
46 
46 
46 
46 
mean 
1.14 
1.06 
0.23 
0.63 
1.06 
0.39 
0.37 
3.12 
0.64 
0.76 
0.70 
3.26 
std 
0.12 
0.10 
0.03 
0.06 
0.15 
0.04 
0.10 
0.81 
0.37 
0.57 
0.20 
1.38 
Ρ 
0.48 
0.57 
0.97 
0.75 
0.62 
0.46 
0.31 
0.29 
0.79 
0.20 
0.31 
0.79 
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Table Add. 5.3. Patients with a small primary tumor «15 cm) versus 
patients with a large primary tumor (>15 cm) 
Mean values of 
AREA 
PERIM 
CIRC 
MO 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
Small tumors 
η 
1Θ 
18 
18 
18 
18 
18 
18 
16 
18 
18 
IB 
18 
mean 
5.14 
8.81 
0.82 
2.94 
2.76 
0.24 
0.72 
26.38 
0.36 
0.50 
0.27 
16.70 
std 
0.83 
0.76 
0.04 
0.23 
0.64 
0.03 
0.03 
15.55 
0.40 
0.90 
0.19 
11.48 
Large tumors 
η 
27 
27 
27 
27 
27 
27 
27 
27 
30 
30 
30 
30 
mean 
5.47 
9.09 
0.82 
3.05 
3.01 
0.25 
0.73 
19.07 
0.25 
0.26 
0.30 
17.05 
std 
0.72 
0.62 
0.02 
0.22 
0.59 
0.03 
0.03 
8.68 
0.27 
0.34 
0.19 
15.05 
Ρ 
0.16 
0.17 
0.68 
0.13 
0.18 
0.62 
0.40 
0.05 
0.27 
0.20 
0.59 
0.93 
Table Add« 5.3a. Patients with a small primary timor (<:15 cm) versus 
patients with a large primary tumor (>15 cm) 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
Small tumors 
η 
18 
18 
18 
18 
18 
18 
18 
16 
18 
18 
18 
18 
mean 
1.14 
1.07 
0.23 
0.65 
1.04 
0.40 
0.33 
3.36 
0.70 
0.84 
0.70 
3.32 
std 
0.18 
0.16 
0.04 
0.08 
0.20 
0.02 
0.03 
0.74 
0.44 
0.78 
0.22 
1.26 
Large tumors 
η 
27 
27 
27 
27 
27 
27 
27 
27 
30 
30 
30 
30 
mean 
1.14 
1.06 
0.23 
0.63 
1.08 
0.39 
0.38 
2.89 
0.63 
0.64 
0.74 
3.27 
std 
0.13 
0.10 
0.03 
0.06 
0.16 
0.05 
0.12 
0.76 
0.29 
0.42 
0.13 
1.49 
Ρ 
0.96 
0.73 
0.97 
0.45 
0.55 
0.56 
0.11 
0.05 
0.49 
0.26 
0.37 
0.90 
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Table Add. 5.4. Patients with clinical stage laj, versus all patients 
in other clinical stages. 
Mean values 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. 
of 
ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
η 
23 
23 
23 
23 
23 
23 
23 
22 
24 
24 
24 
24 
Stage 
mean 
5.4Θ 
9.14 
0.81 
3.05 
3.03 
0.26 
0.72 
24.35 
0.27 
0.34 
0.29 
15.3B 
la 
std 
0.7Θ 
0.69 
0.03 
0.26 
0.62 
0.03 
0.03 
12.14 
0.36 
0.42 
0.21 
9.91 
Other stages 
η 
24 
24 
24 
24 
24 
24 
24 
23 
27 
27 
27 
27 
mean 
5.24 
Θ.85 
0.82 
2.98 
2.83 
0.24 
0.73 
20.61 
0.32 
0.37 
0.27 
19.58 
std 
0.76 
0.66 
0.02 
0.20 
0.60 
0.03 
0.03 
13.23 
0.35 
0.73 
0.17 
17.31 
Ρ 
0.29 
0.16 
0.08 
0.29 
0.27 
0.04 
0.36 
0.33 
0.65 
0.87 
0.79 
0.30 
Table Add. 5.4a. Patients with clinical stage lai, versus all patients 
in other clinical stages. 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
η 
23 
23 
23 
23 
23 
23 
23 
22 
24 
24 
24 
24 
Stage 
mean 
1.17 
1.09 
0.24 
0.65 
1.11 
0.39 
0.36 
3.16 
0.59 
0.74 
0.72 
3.04 
la 
std 
0.17 
0.13 
0.04 
0.08 
0.20 
0.02 
0.10 
0.79 
0.34 
0.44 
0.22 
0.70 
Other stages 
η 
24 
24 
24 
24 
24 
24 
24 
23 
27 
27 
27 
27 
mean 
1.12 
1.04 
0.22 
0.63 
1.02 
0.39 
0.36 
3.00 
0.68 
0.71 
0.70 
3.49 
std 
0.12 
0.11 
0.02 
0.07 
0.13 
0.05 
0.10 
0.80 
0.40 
0.66 
0.19 
1.75 
Ρ 
0.20 
0.17 
0.02 
0.32 
0.08 
0.93 
0.84 
0.49 
0.38 
0.84 
0.72 
0.24 
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Table Add. 5.5. Patients with unilateral salpingo-oophorectomy (USO) 
without adjuvant therapy versus patients with USO with 
adjuvant therapy 
Mean values 
AREA 
PER IM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. 
оГ 
ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
ι 
Non adjuvant 
η 
24 
2Α 
24 
24 
24 
24 
24 
23 
23 
23 
23 
23 
mean 
5.48 
9.12 
0.Θ1 
3.04 
3.02 
0.25 
0.72 
24.00 
0.31 
0.31 
0.31 
15.25 
std 
0.71 
0.64 
0.03 
0.24 
0.56 
0.03 
0.03 
11.02 
0.39 
0.35 
0.21 
10.12 
η 
14 
14 
14 
14 
14 
14 
14 
13 
16 
16 
16 
16 
Adjuvant 
mean 
5.13 
β.79 
0.82 
2.95 
2.75 
0.25 
0.72 
17.21 
0.34 
0.26 
0.29 
14.04 
std 
0.93 
0.Θ0 
0.02 
0.26 
0.73 
0.03 
0.04 
9.94 
0.40 
0.37 
0.20 
6.06 
Ρ 
0.21 
0.17 
0.62 
0.29 
0.19 
0.77 
0.96 
0.07 
0.81 
0.72 
0.77 
0.67 
Tabi· Add· 5.M. Patients with unilateral salpingo-oophorectomy (USO) 
without adjuvant therapy versus patients with USO 
with adjuvant therapy 
VC of mean values of 
AREA 
PERIM 
CIRC 
M0 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
Non adjut 
η 
24 
24 
24 
24 
24 
24 
24 
23 
23 
23 
23 
23 
mean 
1.17 
1.08 
0.23 
0.64 
1.10 
0.39 
0.36 
3.12 
0.60 
0.74 
0.74 
2.97 
'ant 
std 
0.17 
0.13 
0.04 
0.08 
0.19 
0.02 
0.10 
0.70 
0.37 
0.38 
0.22 
0.68 
η 
14 
14 
14 
14 
14 
14 
14 
13 
16 
16 
16 
16 
Adjuvant 
mean 
1.09 
1.03 
0.22 
0.62 
0.99 
0.40 
0.36 
2.84 
0.70 
0.63 
0.72 
2.96 
atd 
0.11 
0.08 
0.03 
0.06 
0.14 
0.06 
0.11 
0.78 
0.39 
0.47 
0.14 
0.74 
Ρ 
0.16 
0.24 
0.57 
0.49 
0.06 
0.58 
0.96 
0.28 
0.45 
0.42 
0.74 
0.99 
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Table Add 5.6. Patients without recurrent disease versus patients with 
recurrent disease· 
Mean values 
AREA 
PERIM 
CIRC 
MO 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. 
eosinoph. gr 
plasma cells 
mitoses 
lymphocytes 
of 
ratio 
an. 
1 
No 
η 
28 
28 
28 
28 
28 
28 
28 
27 
30 
30 
30 
30 
recurrence 
mean 
5.33 
9.00 
0.82 
3.00 
2.90 
0.25 
0.72 
21.33 
0.34 
0.32 
0.30 
13.85 
std 
0.83 
0.72 
0.03 
0.24 
0.66 
0.03 
0.03 
9.32 
0.38 
0.39 
0.20 
5.89 
η 
9 
9 
9 
9 
9 
9 
9 
8 
8 
8 
8 
8 
Recurrence 
mean 
5.42 
9.00 
0.82 
3.05 
3.01 
0.26 
0.72 
21.83 
0.27 
0.19 
0.31 
18.57 
std 
0.78 
0.77 
0.02 
0.28 
0.60 
0.03 
0.03 
16.77 
0.44 
0.18 
0.23 
15.39 
Ρ 
0.80 
0.98 
0.78 
0.63 
0.66 
0.11 
0.55 
0.91 
0.67 
0.34 
0.87 
0.18 
Table Add. 5.6a. Patients without recurrent disease versus patients 
with recurrent disease. 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eosinoph. gran. 
plasma cells 
mitoses 
lymphocytes 
No 
η 
28 
28 
28 
28 
28 
28 
28 
27 
30 
30 
30 
30 
recurrence 
mean 
1.10 
1.04 
0.23 
0.62 
1.01 
0.39 
0.34 
3.05 
0.68 
0.71 
0.74 
2.93 
std 
0.11 
0.09 
0.04 
0.06 
0.14 
0.04 
0.08 
0.63 
0.38 
0.46 
0.14 
0.67 
η 
9 
9 
9 
9 
9 
9 
9 
8 
8 
8 
8 
8 
Recurrence 
mean 
1.24 
1.13 
0.23 
0.67 
1.21 
0.40 
0.43 
2.86 
0,57 
0.64 
0.69 
3.08 
std 
0.22 
0.17 
0.03 
0.09 
0.23 
0.02 
0.13 
1.07 
0.34 
0.23 
0.32 
0.85 
Ρ 
0.02 
0.05 
0.97 
0.04 
0.00 
0.47 
0.01 
0.53 
0.44 
0.70 
0.59 
0.60 
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Table Add. 5.7. Surviving patients and patients who died of disease. 
Mean values 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. 
of 
ratio 
eoslnoph. gran. 
plasma cells 
mitoses 
lymphocytes 
I 
Survivors 
η 
41 
41 
41 
41 
41 
41 
41 
39 
44 
44 
44 
44 
mean 
5.38 
9.02 
0.82 
3.02 
2.95 
0.25 
0.72 
21.82 
0.29 
0.29 
0.28 
16.76 
std 
0.80 
0.70 
0.03 
0.24 
0.63 
0.03 
0.03 
12.26 
0.34 
0.34 
0.20 
13.27 
Non-survivors 
η 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
mean 
4.93 
8.53 
0.83 
2.90 
2.59 
0.25 
0.73 
20.13 
0.19 
0.97 
0.30 
19.24 
std 
0.72 
0.13 
0.01 
0.09 
0.20 
0.02 
0.03 
11.50 
0.21 
1.63 
0.04 
18.72 
Ρ 
0.27 
0.18 
0.37 
0.33 
0.27 
0.89 
0.80 
0.79 
0.53 
0.02 
0.84 
0.71 
Tabi· Add. 5.7e- Surviving patients and patients who died of disease 
VC of mean values of 
AREA 
PERIM 
CIRC 
MD 
AXMOM 
ASYM 
AXRAT 
Stroma/vol. ratio 
eoslnoph. gran. 
plasma cells 
mitoses 
lymphocytes 
Survivors 
η 
41 
41 
41 
41 
41 
41 
41 
39 
44 
44 
44 
44 
mean 
1.13 
1.05 
0.23 
0.63 
1.05 
0.39 
0.36 
3.03 
0.65 
0.68 
0.72 
3.21 
std 
0.15 
0.12 
0.03 
0.07 
0.18 
0.04 
0.09 
0.78 
0.36 
0.44 
0.18 
1.31 
Non-survi 
η 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
mean 
1.24 
1.15 
0.21 
0.69 
1.13 
0.39 
0.43 
3.16 
0.60 
1.13 
0.77 
3.75 
vors 
std 
0.14 
0.12 
0.01 
0.07 
0.13 
0.04 
0.13 
0.87 
0.43 
1.29 
0.04 
2.03 
Ρ 
0.19 
0.15 
0.48 
0.13 
0.43 
0.95 
0.13 
0.76 
0.77 
0.10 
0.51 
0.41 
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Addendun 6. 
Multivariate analysis. 
Stepwise regression analysis. 
Table Add.6.1. Nuclear measurements in tumor sections from patients 
without recurrent disease, without adjuvant therapy 
(Group 1), with recurrent disease, without adjuvant 
therapy (Group 2) and without recurrent disease, with 
adjuvant therapy (Group 3). 
GROUP 
group 1 group 2 group 3 
MEAN STD MEAN STD MEAN STD 
n=15 n=8 n=13 
mean AREA 
mean PERIM 
mean CIRC 
mean MD 
mean AXMOM 
mean ASYM 
mean AXRAT 
VC AREA 
VC PERIM 
VC CIRC 
VC MD 
VC AXMOM 
VC ASYM 
VC AXRAT 
5.47 
9.14 
0.Θ1 
3.03 
3.00 
0.24 
0.73 
1.11 
1.04 
0.23 
0.62 
1.03 
О.З 
0.32 
0.73 
0.62 
0.04 
0.23 
0.58 
0.02 
0.03 
0.11 
0.1 
0.04 
0.05 
0.14 
0.02 
0.02 
5.53 
9.11 
0.82 
3.08 
3.11 
0.27 
0.72 
1.26 
1.13 
0.23 
0.68 
1.24 
0.40 
0.43 
0.76 
0.75 
0.02 
0.29 
0.57 
0.03 
0.04 
0.22 
0.18 
0.03 
0.10 
0.22 
0.02 
0.14 
5.18 
8.83 
0.82 
2.97 
2.79 
0.25 
0.72 
1.09 
1.03 
0.22 
0.62 
0.99 
0.40 
0.36 
0.95 
0.82 
0.02 
0.26 
0.75 
0.03 
0.04 
0.11 
0.08 
0.03 
0.06 
0.15 
0.06 
0.11 
Table Add.6.2. Mean stroma-volume rate (S-V ratio) in tumor sections 
from patients without recurrent disease, without adju­
vant therapy (Group 1), with recurrent disease, with­
out adjuvant therapy (Group 2) and without recurrent 
disease with adjuvant therapy (Group 3). 
GROUP 
group 1 group 2 group 3 
MEAN STD MEAN STD MEAN STD 
mean S-V ratio 23.70 8.86 24.50 16.18 18.38 9.39 
VC S-V ratio 3.13 0.60 3.06 0.98 2.95 0.69 
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Table Add.6.3. Cell quantitative parameters in tumor sections from 
patients without recurrent disease, without adjuvant 
therapy (Group 1), with recurrent disease, without 
adju vant therapy (Group 2) and without recurrent 
disease, with adjuvant therapy (Group 3). 
GROUP 
group 1 group 2 group 3 
MEAN STD MEAN STD MEAN STD 
n=15 n=7 n=15 
mean No eosinoph. gran. 
mean No plasma cells 
mean No mitoses 
mean No lymphocytes 
VC eosinoph. gran. 
VC plasma cells 
VC mitoses 
VC lymphocytes 
0.33 
0.36 
0.33 
13.01 
0.65 
0.78 
0.77 
2.82 
0.37 
0.41 
0.23 
6.17 
0.37 
0.44 
0.16 
0.68 
0.31 
0.21 
0.26 
20.59 
0.59 
0.68 
0.65 
3.29 
0.46 
0.19 
0.19 
15.43 
0.37 
0.24 
0.31 
0.6Θ 
0.36 
0.28 
0.26 
14.68 
0.72 
0.64 
0.70 
3.05 
0.40 
0.38 
0.17 
5.69 
0.40 
0.48 
0.12 
0.67 
Table Add.6.4. Clinical parameters from patients without recurrent 
disease, without adjuvant therapy (Group 1), with 
recurrent disease, without adjuvant therapy (Group 2) 
and without recurrent disease, with adjuvant therapy 
(Group 3). 
GROUP 
group 1 group 2 group 3 
MEAN STD MEAN STD MEAN STD 
n=15 n=7 n=13 
pregnancy 2.80 0.77 2.33 1.32 2.80 0.77 
age 18.20 4.80 19.33 5.68 20.13 5.38 
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Table Add. 6.3. P-values (Student t-test) with a comparison of morpho-
metric parameters of tumor sections from patients 
without recurrrent disease (group 1), with recurrent 
disease, without postoperative therapy (group 2) and 
without recurrent disease, with postoperative therapy 
(group 3). 
parameter 
mean No eos 
mean No plascell 
mean No mitoses 
mean No lymphoc 
mean AREA 
mean PERIM 
mean CIRC 
mean MO 
mean AXMOM 
mean ASYM 
mean AXRAT 
mean stroma-volume ratio 
VC AREA 
VC PERIM 
VC CIRC 
VC HD 
VC AXMOM 
VC ASYM 
VC AXRAT 
VC stroma-volume ratio 
VC eosinophil, gran. 
VC plasma cells 
VC mitoses 
VC lymphocytes 
pregnancy 
age 
gr.l-gr.2 -
0.93 
0.34 
0.45 
0.25 
0.87 
0.92 
0.87 
0.67 
0.68 
0.02 
0.53 
0.Θ8 
0.12 
0.22 
0.91 
0.15 
0.01 
0.02 
0.07 
0.83 
0.72 
0.58 
0.36 
0.15 
0.28 
0.61 
- gr.l-gr.3 -
0.83 
0.56 
0.35 
0.45 
0.36 
0.27 
0.78 
0.49 
0.39 
0.44 
0.85 
0.14 
0.24 
0.68 
0.73 
0.83 
0.44 
0.37 
0.27 
0.47 
0.64 
0.43 
0.18 
0.35 
1.00 
0.31 
- gr.2-gr.3 
0.81 
0.63 
0.94 
0.36 
0.39 
0.45 
0.93 
0.37 
0.31 
0.21 
0.73 
0.31 
0.08 
0.16 
0.81 
0.13 
0.01 
0.80 
0.20 
0.78 
0.48 
0.87 
0.63 
0.45 
0.28 
0.73 
168 
Table Add.6.6. Multiple correlation coefficient (R) between recurrent 
disease and parameters 
collection of parameters R Ρ η 
morphometry: 0.83 0.00 37 
mean AREA 
mean PERIM 
mean CIRC 
mean MD 
mean AXMOM 
mean ASYM 
mean AXRAT 
VC AREA 
VC PERIM 
VC CIRC 
VC MD 
VC AXMOM 
VC ASYM 
VC AXRAT 
voline quantitation: 0.24 0.39 35 
mean stroma-volume ratio 
VC stroma-volume ratio 
cell quantitation: 0.43 0.60 38 
mean No eos 
mean No plasmcell 
mean No mitoses 
meen No lymphoc 
VC eosinophil, gran. 
VC plasma cells 
VC mitoses 
VC lymphocytes 
Table Add. 6.6.(Continued) 
clinical parameters: 
pregnancy 
age 
5 selected parameters: 
VC AREA 
VC PERIM 
VC MD 
VC АХМОМ 
VC AXRAT 
4 selected parameters: 
VC АХМОМ 
VC AXRAT 
age 
pregnancy 
2 selected parameters: 
VC АХМОМ 
VC AXRAT 
0.19 0.49 40 
0.59 0.02 37 
0.56 0.01 37 
0.55 0.00 37 
170 
Addendua 7. 
Analysis of morphometric data using alternative sunmarizing statis-
tics. 
In order to Investigate whether the results of the analysis could 
be influenced by an alternative choice of the summarizing statistics 
rather than using mean values and VC's of the morphometric data the 
following alternative values could be proposed: 
1. Minimum 
2. 5th percentile 
3. 10th percentile 
4. 50th percentile (median) 
5. 90th percentile 
6. 95th percentile 
7. Maximum. 
The pth percentile of a sample is a number Qp such that at least p% 
of the sample values are smaller than or equal tp Qp and at least 
(100-p)% of those values are larger or equal to Qp. 
In statistics the Interquartile range, meaning the range between 
the 25th and 75th percentile, is sometimes used as an alternative for 
the standard deviation. 
Concerning the use of minimum, maximum and other percentiles it 
should be noted that: 
1. The minimum value Is dependent from the nunber of measurements. 
When this number Is not exactly the same for all patients this in-
troduces sytemic errors. Therefore it should be disregarded for 
this very reason. 
2. The 5th percentile is not very accurate in samples of moderate num-
bers. 
3. The 10th percentile is not very powerful to discriminate when a 
scale effect on the distribution of the parameters within a pa-
tient seems likely. 
4. The 50th percentile (median) will not give different results com-
pared to the mean. 
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5. The 90th percentile might be a reasonable alternative to 
investigate as compared to the mean. 
6. The 95th percentile is like the 5th percentile not very accurate in 
samples of moderate size. 
7. The maximum value should be disregarded, since it is like the 
minimum value dependent from the number of measurements. 
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STELLINGEN 
behorend bij het proefschrift 
ASPECTS OF PURE DYSGERHINOMA OF THE OVARY 
R.P.SOETERS 
I 
De benaming zuiver dysgerminoom van het ovarium dient vervangen te worden 
door dysgerminoom van het ovarium. De benaming gemengd dysgerminoom van 
het ovarium dient vervangen te worden door gemengde kiemcel tumor van het 
ovarium. 
II 
Kwantitatief morfometrisch onderzoek dient een rol te spelen bij de diag-
nostiek van patiënten met een dysgerminoom van het ovarium, 
III 
Een uitgesproken kern polymorÏie bij patiënten met een dysgerminoom van 
het ovarium lijkt de prognose in negatieve zin te beïnvloeden, 
IV 
Een goede stagering bij patiënten met een eenzijdig afgekapseld dysgermi-
noom van het ovarium bepaalt de prognose in verband met een wezenlijk an-
dere therapie bij de hogere stadia. 
V 
Een lymfografisch onderzoek is bij patiënten met een stadium lai dysger-
minoom van het ovarium obligaat, 
VI 
De mate van lymfocyten infiltratie bij patiënten met een dysgerminoom van 
het ovarium lijkt in tegenstelling tot literatuur gegevens geen invloed 
te hebben op de prognose. 
VII 
Bij de microscopische beoordeling van de flora vaginalis is de fase-con-
trast microscopie superieur ten opzichte van de heldere veld microscopie, 
VIII 
Bij ongecementeerd Ingebrachte femorale endoprothesen dient de laag tus-
sen prothese en bot zacht en poreus te zijn, 
С, Bomsey et al., 1972. 
IX 
De productie van neurohypofyse hormonen vindt ook extra-cerebraal plaats. 
X 
De mate waarin moeders over het eetgedrag van hun 2-jarige peuter klagen 
lijkt niet gerelateerd te zijn aan het gewicht van de peuter. 
XI 
Ook bij consumptief krediet wordt een grote mate van evenwichtige en ra-
tionele besluitvorming vereist van geldgever èn geldnemer. 
XII 
Indien men de vroeg neonatale conditie van een pasgeborene accuraat wil 
vastleggen door middel van de pH van het navelstrengbloed, dient men de 
pH van de barende daarbij te betrekken, 
XIII 
Toepassing van korte golf therapie bij sinusitis heeft een positief ef-
fect, aangezien in de meeste gevallen sprake Is van een bacterieie in-
fectie. 
XIV 
Parenteral nutrition Is a major tool In the management of cancert not a 
weapon for anti-cancer warfare. 
Brennen, 1981. 
XV 
Het behulp van echografie zijn cerebrale bloedingen bij kinderen met 
een zeer laag geboorte gewicht en voortijdig geboren goed vast te stel-
len. Binnen een gegeven populatie geeft de frequentie van voorkomen en 
de uitgebreidheid van cerebrale bloedingen informatie over de kwaliteit 
van perinatologische zorg. 
XVI 
De krlterla voor Intensieve klinische zorg omschreven In het 2 e interim 
rapport van de commissie neonatologie van de Nederlandse Vereniging voor 
Kindergeneeskunde (1978) en gehanteerd in het advies inzake "INTENSIVE 
CARE NEONATOLOGIE" van de Gezondheidsraad (1982) zijn 6 Jaar nadien aan 
een herziening toe. 
XVII 
Het grote aantal medewerkende auteurs vermeld bij Nederlandse artikelen 
doet vermoeden, dat dit meer te maken heeft met sensitiviteit dan met 
specifieke activiteit. 
XVIII 
De leden van de nationale ziekenfondsraad zijn particulier verzekerd, 

"Anyone could have done that. The great and the difficult thing was 
what I achieved - to make the world believe that I had done it. " 
Oscar Wilde 

